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Chapter 1 General introduction 
1.1 Self-interaction of monoclonal antibodies 
Attractive self-interaction of proteins, also referred to as self-association, reflects a process, 
in which native, monomeric proteins of the same species form dimers and oligomers. If 
oligomers are the functional entity of these proteins, attractive self-interaction will lead to 
activation of components as shown for enzymes and enzymatic cascades.1, 2 For 
monoclonal antibodies, self-interaction can be linked to unwanted phenomena such as 
protein aggregation and particle formation as well as exceptional increase in viscosity.3–10 
This introduction will give an overview of the mechanism underlying the self-interaction 
process as well as a description of the commonly used analytical techniques to characterize 
mAb self-interaction. Additionally, influencing factors are presented and discussed. 
1.1.1 The driving forces of mAb self-interaction 
Protein interaction processes are driven either by repulsive or attractive forces. If antibodies 
are regarded as colloids, the interaction can be described by the DLVO theory.11 
Accordingly, the net interaction forces depend on the distance between the surface layers 
of the molecules. At low protein concentration, large distances between molecules can lead 
to repulsive interactions dominated by the electric double layers that surround each colloid. 
Upon increase in concentration, distances between molecules become smaller leading to 
prevalence of attractive Van der Waals forces. The theory of proximity energies provides 
an energetic framework to these high concentration environments, where not only proteins 
but also the whole solution composition as a mixture of differently charged components is 
considered.12, 13 Non-specific charge-charge, charge-dipole and dipole-dipole interactions 
contribute to the overall long distance electrostatic forces whereas attractive hydrophobic 
forces are present at short distances.13, 14 Crowding at high protein concentration leads to 
very short distances, which favor the presence of hydrophobic, attractive forces. Therefore, 
close proximity of the molecules will raise the probability to attractive interaction and thus, 
to the formation of protein oligomers.3  
Monoclonal antibodies are multi-domain proteins consisting of two Fab and one Fc 
domains. All domains can be involved in the self-interaction mechanism. Under low ionic 
strength conditions, Fc-Fc interaction were observed which led to liquid-liquid phase 
separation.15 Fab-Fc interactions were also identified in a formulation dependent manner, 
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with enhanced oligomerization at higher pH and elevated sodium chloride concentration.16 
Fab-Fab interactions were also described for mAbs and they also depend on ionic strength 
and pH, which underlines the heterogeneity of this type of non-specific protein-protein 
interaction.17 So far, it is not possible to clearly predict distinct self-interaction sites based 
on primary sequence and structural modeling. Work and cost extensive studies are 
necessary to investigate this kind of weak protein-protein interaction in order to enhance 
the molecule specificity, manufacturability and overall developability. 
1.1.2 A brief overview of suitable analytical techniques 
The analysis of protein-protein interactions is well established in various fields of scientific 
research. High affine interactions such as antibody-antigen binding can be easily assessed 
by ELISA or SPR measurements. For the detection of weak interaction processes such as 
mAb self-interaction, other techniques with different sensitivity and assay principle are 
used. Analytical Ultracentrifugation (AUC) is regarded as the gold-standard to analyze 
weak protein-protein interaction processes enabling to calculate the second virial 
coefficient B22 as interaction parameter.
18 It was used in several studies to investigate the 
extent of self-interaction9, 19–21 Whereas AUC provides high quality data and characteristic 
physical numbers, its throughput is very limited. Light scattering techniques such as 
Dynamic Light Scattering (DLS) can be applied in high throughput to determine the 
diffusion interaction parameter kD.
21–23 Emerging techniques such as Affinity Capture Self-
Interaction Nanoparticle Spectroscopy (AC-SINS), Bio-Layer-Interferometry (BLI) and 
Hydrogen-Deuterium Exchange Mass Spectrometry (HDX-MS) have been used recently 
to characterize mAb self-interaction processes and to rank mAbs by their self-interaction 
propensity.24–27 In particular, HDX-MS was used to identify key residues contributing to 
the self-interaction of mAbs.16, 24, 28–30 The published work is limited to either a comparison 
of different mAbs in one formulation or of various formulations of one mAb. Because self-
interaction is formulation dependent, the combination of both would be highly useful to 
characterize mAb candidates in early stages of discovery. Further advantages and 
disadvantages of the abovementioned methods are discussed in detail in chapter 2 of this 
thesis. The methods described here differ in their assay and detection principle, which 
makes it challenging to compare data sets and studies. To this end, the multi method 
characterization of one particular model system may disclose new correlations and 
understandings of the results from the various analytical methods providing more 
comprehensive insights into the self-interaction process. 
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1.1.3 Factors affecting self-interaction of mAbs 
 
Figure 1  Formulation and rational engineering as two approaches to influence factors that impact mAb self-
interaction. 
MAb self-interaction processes are driven by electrostatic and hydrophobic forces 
depending on the molecules proximity.31 Various factors influence the self-interaction 
propensity, which are related to i) the formulation composition or b) intrinsic properties of 
the mAb, which can be affected by engineering (Figure 1). During discovery phase and 
lead candidate optimization, intrinsic properties of a protein can be adjusted by engineering, 
whereas in later stages of development, when a lead candidate has already been defined, 
formulation development can affect the self-interaction and its consequences. 
1.1.4 Formulation of mAbs 
A biopharmaceutical formulation typically consists of a buffer at a specific pH and ionic 
and non-ionic excipients that should protect the biotherapeutic from chemical, 
conformational and colloidal degradation. The latter is strongly affected by mAb self-
interaction. Thus, the selection of formulation components to prevent strong attractive self-
interaction of mAbs is important to reduce aggregation and viscosity. Various examples 
can be found in literature and a few are highlighted in the following. Sodium chloride as 
ionic excipient effectively lowers the viscosity of a mAb at high protein concentration and 
both, different cations and anions affect the solution properties reducing the self-interaction 
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propensity.9 32 In addition to sodium chloride, arginine hydrochloride was described as 
viscosity reducing agent by lowering the attractive self-interaction propensity. 32, 33 
Recently, dipicolinic acid was shown to reduce viscosity by lowering intermolecular 
attractions.34 Specifically the pH significantly influences the self-interaction behavior of 
mAbs.35–38 The pH dictates the surface charge distribution of the protein molecules which 
are key for the interactions. Thus, a formulations pH far away from the pI might reduce 
self-interaction by increasing overall electrostatic repulsion, but may not necessarily reduce 
the viscosity at high protein concentration if charge heterogeneity on the surface acts as the 
main driver.18  
1.1.5 Engineering of mAbs 
As depicted in figure 1, engineering approaches can be used to change the surface charge 
distribution, the overall surface hydrophobicity and aggregation prone regions. These 
properties were shown to be associated with mAb self-interaction. Yadav et al. 
demonstrated the effect of the proteins charge on the rheological characteristics of two 
mAbs, which differed mainly in their CDR regions, and one of which showed high self-
interaction propensity and high viscosity at elevated concentration whereas the other did 
not.4, 14, 18 39 They generated “charge-swap” mutants and the resulting variants showed 
decreased viscosity and pronounced repulsive intermolecular interaction.39 Apgar et al. 
generated 40 variants of a mAb, which exhibited high viscosity at 80 mg/ml and a strong 
self-interaction propensity in AC-SINS.40 They identified a high net negative charge within 
the variable region as most promising engineering area. Only some variants showed 
decreased viscosity although the mutations were of the similar nature indicating that the 
interplay between structure, viscosity and self-interaction is not clearly understood. 
For another mAb, three hydrophobic residues were identified by HDX-MS to be 
responsible for its aberrant self-interaction behavior which could be resolved by mutation.29 
Wu et al. identified a hydrophobic triad consisting of phenylalanine, histidine and 
tryptophan within the HCDR3 of the mAb CNTO607 as a key driver for its low solubility 
and high self-interaction propensity.41 The exchange of these residues against more 
hydrophilic residues such as alanine improved the solubility but diminished target 
binding.41, 42 The precursor molecule of CNTO607 was included in this thesis and is 
referred to as mAb1 in Chapter VI. 
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Calculations for predicting aggregation prone regions (APR) were developed to understand 
the effect of hydrophobicity, β-sheet propensity and on the probability for polypeptides and 
small proteins mainly consisting of secondary structure elements to build amyloidic 
fibrils.43 The approach to predict the APRs was transferred to large antibodies by 
Chennamsetty et al. using the “spatial-aggregation propensity (SAP)” based on a three 
dimensional simulation of a full IgG1 molecule.44 The SAP depends on the surface 
accessible area of a residue and its hydrophobicity. The authors selected sites for rational 
engineering and generated variants with reduced SAP score in the CH2 domain which 
showed less turbidity upon shaking and a higher apparent unfolding temperature.44 Nichols 
et al. designed variants by disrupting the APR of a model mAb.45 Introducing a single 
mutation in this region led to destabilization and a loss of antigen binding. In contrast, 
variants with a mutation in spatial proximity retained their target binding properties and 
showed slightly improved physicochemical properties although kD, as a measure for 
attractive self-interaction, was not significantly influenced.45 
Thus, rational engineering can improve the physicochemical properties of mAbs but 
antigen binding was impaired in most cases, indicating that the link between structure, self-
interaction behavior and target binding is not clearly understood. Thus, application of 
different predictive tools for APRs or surface hydrophobicity for rational mutagenesis and 
detailed analytical characterization of resulting variants would by highly valuable. 
1.2 Developability of mAbs 
Developability assessments of monoclonal antibodies are the investigation of properties of 
a therapeutic compound that are linked to an overall low risk of failure during chemistry, 
manufacturing, control (CMC), preclinical and clinical development.  
The term developability of a mAb includes different aspects which are important for 
success along the road to a market product. To this end, an “ideal” drug candidate can be 
produced with high yields and high quality, if possible using a platform bioprocess.46 High 
quality includes low heterogeneity and high storage stability. Moreover, a candidate should 
enable the use of high concentration solutions, which simplifies processing and 
administration. 
The very early evaluation during discovery and candidate selection based on in silico 
approaches and experimental data from extended characterization and forced degradation 
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studies can be used to decide for a candidate with the most favorable properties for 
subsequent development. 46, 47 
In general, an early developability assessment of a mAb consists of at least three major 
parts, depending of the project progress and availability of material. First, computational 
tools are applied to predict various properties of a protein including pI, presence of free 
cysteine residues and N-glycosylation sites in CDRs.46 If homology modeling is 
appropriate, common chemical degradation sites such as surface exposed deamidation and 
oxidation sites can be predicted.46–48 
Computational predictions of the colloidal stability and the aggregation propensity can be 
based on physics or statistics.49 Physics based predictions do not require prior experimental 
data. In contrast, the statistical methods, implemented as machine learning approaches and 
the generation of artificial intelligence, rely on previously obtained experimental data and 
the accuracy depends on the data quality used to train the prediction method.49, 50 
Aggregation prone regions of mAbs can be predicted by a variety of algorithms such as 
AggreScan3D 2.0 and AggScore, which are based on homology modeling of the variable 
region of a mAb on available 3D models of Fab fragments.51, 52 A “developability index” 
based on spatial aggregation propensity and net charge was correlated with long-term 
stability and successfully applied to unknown mAb candidates.53 The limitation to a certain 
segment was overcome by Jain et al. who published a database of 12 biophysical properties 
of 137 clinical stage or approved mAbs.54 This dataset includes various properties 
commonly connected to “good” developability characteristics such as drug-like 
specificity55, high conformational as well as high colloidal stability. Based on machine 
learning approaches and subsequent analysis of homology models of 56 antibodies, 
developability guidelines for mAbs considering five metrics were proposed: 1) total length 
of CDRs, 2) surface hydrophobicity, 3) abundance of positive and 4) negative charges in 
CDR and 5) asymmetric distribution of surface charges.56 Protein-sol is another tool based 
on the publication of Jain et al. to model clusters according to charge and hydrophobicity 
and to predict biophysical properties of mAbs based on the primary sequence of the variable 
fragment.57  
The second step is the small-scale production of promising candidates. Expression and 
purification titer can be used to tell whether a mAb should be well producible or bears a 
higher risk for extended optimization effort. After production of typically less than 100 
candidates, biophysical characterization is performed with high-throughput assays which 
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require only little sample, which includes e.g. analysis of thermal stability and monomer 
content. At this stage, assessment of the self-interaction propensity could be included. 
Clone Self-Interaction Bio-Layer-Interferometry (CSI-BLI) as well as Affinity-Capture 
Self-Interaction Nanoparticle Spectroscopy (AC-SINS) are assays which only require small 
amounts of material and can be run in high-throughput.25, 26, 58 However, neither of these 
assays is suitable to assess the impact of formulation on self-interaction. Thus, the risk of 
excluding promising candidates due to challenges, which could be easily covered by 
formulation development, is high. Because the developability assessments typically do not 
include formulation screenings or considerations, implementation of preformulation 
studies in the second step of the assessment might be useful. 
In the third step of a developability assessment, forced degradation studies are performed 
to explore degradation pathways and to rank the remaining candidates based on their 
stability profiles.47 Due to the low number of candidates, production processes can be 
scaled up to provide material for further in-depth characterization of the candidates. For the 
analysis of self-interaction, assays can be used that require medium to high sample amounts 
like SLS and DLS and even viscosity measurements.59–61 These physico-chemical results 
can be combined with data from pharmacokinetics and pharmacodynamics as well as 
manufacturability experiments to get the full picture of the potential candidates for decision 
making.46, 47  
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Aim and outline of this thesis 
MAbs play a major role in the treatment of various severe diseases. To increase patient 
comfort and compliance, high concentration liquid formulations are developed which 
enable subcutaneous applications. Several challenges are associated with the high 
concentration approach including increased protein aggregation and a viscosity which is 
not suited for injection through fine needles and some steps in manufacturing. These 
challenges can be partially explained by the intrinsic propensity of a protein to self-interact, 
depending on the protein structure itself and on the formulation conditions. 
This thesis should give insights into the self-interaction behavior of mAbs. The investigated 
set of model proteins comprised three mAbs derived from the phage display HuCAL library 
of the MorphoSys AG, four derived from the phage display Ylanthia library of the 
MorphoSys AG and two commercially available mAbs. The goal was to investigate and 
understand the connection between molecule structure, formulation composition, target 
binding and self-interaction propensity. The topic was approached in three steps. First, 
orthogonal techniques were established to characterize the self-interaction propensity of 
the mAbs. Subsequently, the self-interaction behavior of the mAbs was studied in detail. 
Lastly, self-interaction hot spots identified for three model mAbs were modified by rational 
mutagenesis and the mAb variants were characterized regarding their self-interaction 
propensity and target binding properties. 
Chapter 2 describes the establishment of an analytical technique to determine the self-
interaction propensity of mAbs in a formulation dependent manner (SI-BLI), which can be 
applied in high throughput. In this context, the newly established method is compared to 
other, well-known techniques such as dynamic light scattering. 
In Chapter 3, the SI-BLI assay is applied in a developability assessment combined with 
preformulation screening for mAbs derived from the Ylanthia library. The assay can predict 
rankings of formulations regarding the increase in viscosity at higher protein concentration. 
In Chapter 4, self-interaction of the model mAb Infliximab is characterized under 
pharmaceutically relevant formulation conditions using a multi-method approach 
comprising AUC, DLS, viscosimetry, HDX-MS, SI-BLI and small angle X-ray scattering. 
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Chapter 5 describes the detailed analysis of the formulation dependent self-interaction and 
the identification of hot spots by both, in silico and in vitro approaches for one mAb from 
the HuCAL library. Based on these results, variants were generated and characterized. 
In Chapter 6, an engineering approach for two mAbs from the HuCAL library is presented, 
which is based on computational methods. Results from the experimental characterization 
of these variants is compared to predictions of protein-sol. 
Chapter 7 is a summary and conclusion of this thesis, which contains suggestion for future 
analysis of mAb self-interaction and guidance for next-generation mAb design. 
  
Assessment of antibody self-interaction by bio-layer-interferometry as a tool for early stage 
formulation development 
15 
 
Chapter 2 Assessment of antibody self-interaction by 
bio-layer-interferometry as a tool for early stage 
formulation development 
This chapter is published as: 
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2.1 Abstract 
Purpose: 
To speed up the drug development process in the biopharmaceutical industry, high 
throughput methods are indispensable for assessing drug candidates and potential lead 
formulations, in particular during late stages of discovery and early phases of development. 
This study aimed to establish a bio-layer-interferometry based high throughput assay for 
assessing formulation dependent mAb self-interaction (SI-BLI) and to compare the results 
with kD values obtained by dynamic light scattering (DLS). 
Methods: 
Self-interaction of proprietary and commercially available mAbs was analyzed by SI-BLI 
and dynamic light scattering (DLS).  
Results: 
We found significant correlations of the SI-BLI results and kD-values obtained by DLS for 
both, different mAbs in one platform formulation and for mAbs formulated in several 
buffer compositions. In total, we assessed self-interaction propensity of different mAbs in 
58 formulations and found significant Pearson correlation (p<0.05) between kD and results 
of SI-BLI. 
Conclusions: 
The SI-BLI results correlate with kD and enable fast ranking of both different drug 
candidates and potential lead formulations. Thus, SI-BLI might decrease the risk to lose 
potent mAb candidates during transition from discovery to development, and help to 
accelerate the development of high concentration liquid formulations. 
2.2 Introduction 
By 2020, 70 monoclonal antibodies products will be available on the market and the world-
wide sales will be nearly $125 billion.1 These delicate biomolecules are prone to various 
forms of instabilities which have to be kept minimal in the course of manufacturing, storage 
and delivery to the patient. In particular, mAb molecules as colloids exhibit attractive and 
repulsive forces amongst each other. Pronounced attractive self-interaction is linked to 
protein oligomerization or aggregation as well as drastically increased solution viscosity at 
elevated protein concentration.2, 3 High mAb concentrations may be essential to enable 
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subcutaneous administration. High viscosities can lead to problems during purification, 
formulation, filtration or injection of mAb solutions. 
Self-interaction at high mAb concentrations can be triggered by charge-charge interactions, 
charge-dipole and dipole-dipole interactions. Additionally, short range forces such as 
hydrophobic or van der Waals interactions are present at high protein concentrations where 
the distance between the mAb molecules is low.3, 4 Attractive forces between mAb 
molecules might lead to cluster formation of up to nine mAb molecules, and the size of the 
cluster correlates with solution viscosity at high protein concentrations.5 
Development of high concentration formulations is mostly initiated in advanced stages of 
antibody development when more protein material is available and one or two lead 
candidates have been selected. Several studies show the influence of buffer composition, 
pH and presence of excipients on the self-interaction propensity of a mAb.3, 6–10 
To find suitable antibody candidates for development, various assessments are performed 
during early stages of the development phase. This includes developability assessment to 
reduce the risk of costly failure during later stages due to physico-chemical deficiencies of 
the mAb molecule. Such evaluation often includes evaluation of production performance 
like yield and protein titer as well as colloidal, conformational and chemical stability. As 
these assessments are performed during early stages, the number of mAbs to be screened 
is high and material availability is limited. Computational tools are available to link primary 
structure to the proteins behavior at high concentration but cannot advise how to change 
the formulation composition in order to solve self-interaction related problems.11 Thus, 
decisions based on these computational tools may erroneously exclude highly potent mAbs 
in early phase. Therefore, predictive methods with minimal protein consumption suitable 
for high throughput are sought after. 
The colloidal stability of mAbs is an important parameter to be assessed in early 
development, which is typically evaluated via the diffusion interaction parameter kD and 
the second virial coefficient.8, 12 Using a well-plate based light scattering device, the 
required volume of sample is reduced. A mAb dilution series is required to assess protein 
self-interaction. Consequently, the material requirements increase and insufficient mAb 
quantities may be available during early stages of development, especially to evaluate the 
mAb behavior in different formulations. Another method to assess mAb self-interaction is 
self-interaction chromatography based on the retention of a mAb on a column with a 
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stationary phase to which the mAb of interest is covalently coupled.13 Column preparation 
as well as the chromatography itself requires several milligrams of protein material making 
the self-interaction chromatography hardly available for a single assessment during early 
development stages. Affinity-capture self-interaction nanoparticle spectroscopy is a very 
recent method for assessing mAb self-interaction in a high throughput manner.14, 15 This 
technique requires low sample amounts and is dedicated for developability screenings but 
includes labor intensive steps such as conjugation of capture antibodies to gold 
nanoparticles. 
Additionally, analytical ultracentrifugation (AUC) is used to describe the self-interactions 
of mAbs via the second virial osmotic coefficient.16, 17 Major disadvantages of this 
technique are its low throughput and enormous material consumption. On the other hand, 
this method provides the possibility to investigate the formulation dependency of the 
oligomerization in detail. A bio-layer interferometry (BLI) -based technique was 
introduced by Sun et al. to describe self-interaction processes of mAbs.18 The method can 
be run in high throughput with low sample consumption. Commercial anti-human-Fc 
biosensors, a capture level of 0.8 nm and a mAb concentration of 1 µM during the assessed 
self-interaction event were found to result in the best assay condition for the screening. By 
analyzing nine different mAbs in PBS, they found a good correlation of the assay results 
obtained from self-interaction chromatography and cross-interaction chromatography.18 
To our knowledge, there is no analytical methodology published that combines ranking of 
mAbs and formulations by self-interaction propensity in high throughput fashion. We 
therefore tried to establish BLI on a 96 biosensor system, improving loading, quenching 
and baseline steps in order to enhance reproducibility. Our goal was to show a correlation 
between kD and responses from the SI-BLI assay. We therefore analyzed a larger set of 
mAbs formulated in PBS and a selection of mAbs formulated in different commonly used 
buffers. We chose proprietary mAbs, which showed problematic behavior during 
downstream processing and functional assays. Additionally we included adalimumab into 
our sample set as it is marketed in a high concentration liquid formulation. To verify the 
applicability of formulation dependent SI-BLI we used Omalizumab, because of its known 
self-interaction propensity, influenced by formulation composition.18, 19 
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2.3  Materials and methods 
2.3.1 Materials 
Phosphate buffered saline (Thermo Fisher Scientific, MA), L-histidine (Merck KGaA, 
Germany), sodium chloride (Carl Roth GmbH + Co. KG, Germany), hydrochloric acid 
(Merck KGaA, Germany), citric acid monohydrate (Merck KGaA, Germany), sodium 
phosphate monobasic (Merck KGaA, Germany), L-Arginine (Merck KGaA, Germany), L-
tryptophan (Merck KGaA, Germany), L-phenylalanine (Merck KGaA, Germany) were all 
of analytical grade. 
Adalimumab (Humira®) and Omalizumab (Xolair®) were purchased and buffer 
exchanged into PBS including polysorbate 20 removal by protein A chromatography using 
Äkta Avant (GE Healthcare, Chicago, IL). mAb stock solutions were concentrated using 
30 kDa Amicon Ultra-15 centrifugal devices (Merck KGaA, Germany) to 10 mg/ml.  
MorphoSys mAb1 to mAb8 were expressed in HKB11 cells and purified via Protein A 
chromatography. Antibodies were formulated by dialysis overnight. mAb stock solutions 
were concentrated using 30 kDa Amicon Ultra-15 centrifugal devices (Merck KGaA, 
Germany) to 5 mg/ml.  
The mAb concentration was determined by UV absorbance at 280 nm using a Nanodrop 
device (Thermo Fisher Scientific, MA) by applying the theoretical extinction coefficient of 
the individual mAb. Molar extinction coefficients were calculated based on primary 
structure only and without further consideration of higher order structure or glycan content. 
Extinction coefficients vary between 206000 and 237000 M-1/cm. After downstream 
processing, mAbs were analyzed by UHPLC-SEC. All mAbs showed a monomer content 
of >90%. 
Disulfide-linked human Fc protein was expressed in HKB11 cells and purified via Protein 
A chromatography and buffer exchanged into PBS using PD10 columns and gravity flow 
(GE Healthcare, Chicago, IL). The protein was concentrated using 30 kDa Amicon Ultra-
15 centrifugal devices (Merck KGaA, Germany) to 5 mg/ml.  
2.3.2 Determination of the diffusion interaction parameter kD by DLS 
DLS experiments were performed using a DynaPro plate reader (Wyatt Technologies, 
Santa Barbara, CA). Samples were 0.22 µm filtrated and measured at 25°C as triplicates in 
384 well plates with 12 acquisitions for 5 s. The mutual diffusion coefficient D of the 
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antibodies was calculated for at least 5 different protein concentrations by applying 
cumulant fit analysis. kD was calculated as described by Connolly et al..
8 The 
concentrations used for determining the kD were in the range of 0.5 mg/ml to 10 mg/ml 
depending on the available sample amount. Exemplary raw data of kD determination are 
presented in the supplemental material (Figure S1) 
2.3.3 Detection of mAb self-interaction by SI-BLI 
The method described by Sun et al. was adapted for high throughput on an Octet HTX 
system (FortéBio, CA), which is able to address up to 96 samples in parallel.18 Anti-hIgG 
Fc capture (AHC) biosensors (FortèBio, CA) were used. In the first assay step, a baseline 
was established in PBS for at least 60 s, followed by capture of the mAb of interest at 25 nM 
in PBS until the BLI signal increased by approximately 1 nm (Fig. 1). Remaining binding 
capacity of the capture sensors was saturated for 600 s with 1 µM of human Fc in PBS. 
Subsequently, a second baseline was acquired in the formulation composition of interest 
for 60 s, followed by incubation with 2 µM mAb in the respective formulation for at least 
1200 s. Preliminary experiments demonstrated that this time span was sufficient to reach 
equilibrium binding. As shown by Sun et al., the mAb concentration during association can 
affect the signal to noise ratio (BLI response difference between capture level and 
association equilibrium) in BLI measurements. They chose an IgG concentration of 1 µM 
for the screening condition.18 We performed experiments indicating that with 2 µM IgG 
concentration the largest assay window could be achieved (data are shown in the 
supplemental material, Figure S2). The response at equilibrium was used for further 
calculations. To compensate for differences in the amount of captured mAb, the self-
interaction signal normalized to the amount of captured mAb (Rrel), was calculated 
according to Equation 1. 
𝑅𝑟𝑒𝑙 =
𝑅𝑒𝑠𝑝𝑜𝑛𝑠𝑒𝐴𝑠𝑠𝑜𝑐𝑖𝑎𝑡𝑖𝑜𝑛 𝑒𝑞𝑢𝑖𝑙𝑖𝑏𝑟𝑖𝑢𝑚 [𝑛𝑚]
𝑅𝑒𝑠𝑝𝑜𝑛𝑠𝑒𝑐𝑎𝑝𝑡𝑢𝑟𝑒 𝑠𝑡𝑒𝑝[𝑛𝑚]
 
(1) 
As negative controls, sensors were used without captured IgG, i.e. which were only 
saturated with human Fc protein. Even if the protein of interest showed an association 
behavior to the human Fc-protein, this was also regarded as potential self-association, 
which could have been caused by Fab-Fc or Fc-Fc interactions. Further, unspecific binding 
to the biosensor surface itself cannot be excluded by using only this negative control. 
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Figure 1  Schematic overview of the BLI-based self-interaction assay (a – Capture of mAb, b – Saturation of 
remaining binding sites of the biosensor, c – Baseline acquisition in the formulation of interest, d – 
Association reaction in formulation of interest until equilibrium) 
2.3.4 Preparation of mAb3 formulations 
The mAb was formulated by dialysis and concentrated to 10 mg/ml using Amicon Ultra-
15 centrifugal devices (Merck KGaA, Germany).  
Table 1   Formulations of mAb3 
Formulation Buffer system pH Excipient 
F1 25 mM Na-phosphate 7.0 --- 
F2 25 mM Na-phosphate 7.0 25 mM NaCl 
F3 25 mM Na-phosphate 7.0 25 mM Trp 
F4 25 mM Na-phosphate 7.0 25 mM Phe 
F5 25 mM Na-phosphate 7.0 25 mM Arg-HCl 
F6 25 mM His-HCl 6.0 --- 
F7 25 mM His-HCl 6.0 25 mM NaCl 
F8 25 mM His-HCl 6.0 25 mM Trp 
F9 25 mM His-HCl 6.0 25 mM Phe 
F10 25 mM His-HCl 6.0 25 mM Arg-HCl 
F11 25 mM Na-citrate 5.0 --- 
F12 25 mM Na-citrate 5.0 25 mM NaCl 
F13 25 mM Na-citrate 5.0 25 mM Trp 
F14 25 mM Na-citrate 5.0 25 mM Phe 
F15 25 mM Na-citrate 5.0 25 mM Arg-HCl 
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2.3.5 Calculation of statistical significance 
In order to evaluate the suitability of the BLI-based self-interaction assay, Pearson 
correlation as well as Spearman correlation analysis of results obtained by DLS and BLI 
was performed using the software PRISM 5.04. A significance level of p = 0.05 was 
applied. 
2.4 Results and discussion 
2.4.1 kD and SI-BLI of different mAbs in PBS 
The diffusion interaction parameter kD is widely used to describe intermolecular 
interactions of proteins.8, 16 It can be calculated based on a first-order approximation of the 
concentration dependence of the apparent diffusion coefficient. We analyzed nine different 
antibodies formulated in PBS.  
Table 2   Rrel ± SD and kD ± SD of different mAbs in PBS. 
mAb Rrel kD [ml/g] 
Adalimumab 0.19 ± 0.02 -6.8 ± 1.83 
mAb1 0.16 ± 0.17 -1.4 ± 0.66 
mAb2 0.38 ± 0.02 -56.4 ± 10.31 
mAb3 0.04 ± 0.02 -26.8 ± 3.49 
mAb4 0.99 ± 0.06 -114.4 ± 8.82 
mAb5 0.68 ± 0.06 -44.8 ± 5.80 
mAb6 0.32 ± 0.00 -6.5 ± 0.82 
mAb7 0.32 ± 0.02 -9.6 ± 1.28 
mAb8 2.21 ± 0.20 -80.9 ± 3.00 
 
For mAb1, mAb6 and mAb7 as well as adalimumab, kD values were slightly negative, 
whereas we observed strongly negative kD values for mAb8 and mAb4 (Table 2). mAbs2, 
3 and 5 also exhibit net attractive protein-protein interaction in PBS but to a different extent. 
mAb1 showed no significant attractive interactions in PBS. These results indicate a wide 
spectrum of attractive self-association behavior of our chosen model proteins in PBS. 
The same sample set was characterized by SI-BLI (Table 2). The results indicate strong 
self-interaction propensity of mAb8 and mAb4, followed by mAb5. Adalimumab, as well 
as mAb1 and mAb3 showed low signals in the SI-BLI assay. As the standard deviation of 
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the triplicates was low, a ranking of the mAbs regarding the self-interaction propensity was 
possible. mAbs with prominent behavior like mAb4 and mAb8 which showed strongly 
negative kD values also gave high signals in the SI-BLI assay. In contrast, adalimumab 
showed rather low interaction propensity as determined by DLS as well as by SI-BLI. 
However, we observed differences between the results e.g. for mAb4 and mAb8. Whereas 
mAb4 showed the most negative kD, mAb8 showed the highest in SI-BLI signal. In the SI-
BLI assay, one binding partner is attached to the sensor surface and the other one is free in 
solution. If oligomerization takes place as a consequence of mAb self-interaction, the 
oligomers can be large in size. If such large oligomers either bind to the attached mAb at 
the BLI sensor surface, the signal is increased compared to binding signals based on 
dimerization. In DLS, the formation of only few large oligomers will not affect the 
measurements especially, if these oligomers are present over the whole concentration range 
analyzed. This effect might explain this deviation between DLS and SI-BLI observed but 
we do not have any information on the nature of interactions for these mAbs. A Pearson 
correlation analysis of the results obtained by both methods showed a non-significant 
correlation (p > 0.05). We then analyzed the data based on self-interaction ranking of the 
different mAbs in PBS and found significant Spearman correlation (p < 0.05). We therefore 
conclude that ranking of different mAbs in a platform formulation like phosphate buffered 
saline is possible by using SI-BLI.  
2.4.2 Assay variability of SI-BLI 
According to the assay setup, each experiment is performed on one AHC biosensor. To 
study the assay variability of the proposed setup, we analyzed the self-interaction 
propensity of mAb3, mAb4 and adalimumab in PBS with 6 different biosensors for each 
antibody (Fig. 2). Overall, the standard deviations are low and the results are reproducible. 
Adalimumab showed the highest relative standard deviation (7.5 %) compared to mAb3 
(4.0 %) and mAb4 (2.2 %). For mAbs with a high tendency for self-interaction, the absolute 
standard deviation is higher, indicating that these interactions include unspecific 
interactions as well as oligomerization processes. In case of low self-interaction propensity, 
the absolute standard deviations are smaller but relative standard deviations are higher due 
to very low Rrel values. Comparing different mAbs in different formulations, ranking of 
formulations seems to be more difficult for formulations showing low mAb self-interaction 
propensity. 
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Figure 2  Assay variability of SI-BLI for mAb3, mAb4 and adalimumab in PBS. Error bars represent the relative 
standard deviation. 
2.4.3 Characterization of formulation dependent self-interaction 
behavior of mAbs using kD and SI-BLI 
In addition to screening different mAbs in the same formulation, in our case PBS, we 
evaluated SI-BLI for screening the formulation dependency of self-interaction exemplarily 
for mAb3 and compared the obtained Rrel with the kD values from DLS. We varied pH 
values, buffer type and added sodium chloride, arginine hydrochloride, tryptophan or 
phenylalanine, excipients known for affecting self-interaction of mAbs.6 We ranked the 
formulations based on the measured self-interaction propensity of mAb3. A strong negative 
kD value was ranked with a high number, whereby a slightly negative kD was ranked with 
a low number (Raw data are listed in the supplemental material in table S1). The most 
negative kD-value of mAb3 and therefore the highest ranking was observed in 25 mM 
histidine hydrochloride pH 6.0 without further excipients (F6) (Fig. 3). An increase in ionic 
strength, (F7 – 25 mM sodium chloride; F10 – 25 mM arginine hydrochloride) led to charge 
shielding and reduced electrostatic repulsion. Correspondingly, kD was reduced. In general, 
mAb3 showed stronger attractive interactions in histidine hydrochloride based 
formulations compared to sodium citrate formulations (F11-F15). kD in sodium phosphate 
pH 7.0 (F1) without excipients was higher than in histidine hydrochloride at pH 6.0, 
indicating that attractive self-interaction was more pronounced at pH 6.0. Contrary to the 
results for F7 and F10, adding 25 mM sodium chloride (F2) or 25 mM arginine 
hydrochloride (F5) did not influence the kD of mAb3 in sodium phosphate buffer. But kD 
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was decreased by addition of hydrophobic amino acids like L-tryptophan (25 mM, F3) and 
L-phenylalanine (25 mM, F4). 
 
Figure 3   Spearman correlation plot of Rrel and kD for mAb3 in 15 different formulations. 
We ranked the formulations based on the Rrel obtained by SI-BLI. A high response 
correspond to a high ranking. Similar to the kD results, the sodium citrate based 
formulations showed low Rrel compared to the histidine hydrochloride based formulations. 
Furthermore, the self-interaction propensity as observed by SI-BLI was reduced by addition 
of sodium chloride and arginine hydrochloride to histidine formulations (F7, F10). Rrel was 
not significantly affected by adding charged excipients to sodium phosphate based 
formulation (F2, F5) but was increased by adding L-tryptophan to the formulation (F4).  
Overall, the kD and SI-BLI results correlated well. Formulations that triggered self-
interaction of mAb3 as indicated by strongly negative kD –values also showed increased 
Rrel in SI-BLI. mAb3 showed attractive interactions in all formulations. A correlation 
analysis of the results obtained by DLS and SI-BLI showed significant Spearman 
correlations (p < 0.05), whereas a Pearson correlation remained non-significant (p > 0.05). 
Additionally, mAb2 and mAb3 were formulated at different pH values and buffer 
concentrations. Figure 4A depicts a high in self-interaction propensity of mAb2 at pH of 
5.5 to 6.0. At a buffer concentration of 7 mM, this strong attractive interaction is also found 
at higher pH, whereas the SI-BLI signal decreases at higher buffer concentrations. We 
hypothesize that self-interaction of this mAb is reduced at higher buffer concentration due 
to charge shielding of protonated amino acids at pH 7.0. mAb2 and mAb3 have a similar 
framework region and only differ in their complementary determining regions. At pH 4.5, 
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self-interaction of the two mAbs is similar, but at higher pH mAb2 showed significantly 
higher response (Fig. 4B). mAb3 contains an N-glycosylation site within its CDR which 
could decrease the self-interaction propensity. Thus, the BLI-based self-interaction assay 
was able to differentiate self-interaction propensity between different mAbs in dependence 
of formulation conditions. 
 
Figure 4 Rrel of mAb2 in sodium phosphate/sodium citrate buffer at different pH and buffer concentration (A) 
and mAb2 and mAb3 as a function of pH in 25 mM sodium phosphate/sodium citrate buffer (B). 
2.4.4 Characterization of self-interaction propensity of Omalizumab by 
SI-BLI 
Omalizumab has been shown to exhibit a marked increase in viscosity with increasing 
concentration triggered by self-interaction.20 The kinematic viscosity of a formulation 
containing 16 mM Histidine pH 6.0, 266 mM sucrose, 0.03 % PS20 and 125 mg/ml mAb 
was 80 cSt. The addition of 100 mM sodium chloride to a 125 mg/ml Omalizumab solution 
reduced the viscosity by a factor of 4 from 80 cSt to 20 cSt.20 Therefore, we challenged the 
SI-BLI assay with this extreme, studying the effect of salt, pH and buffer strength on the 
self-interaction of Omalizumab. 
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Figure 5  Formulation dependent self-interaction behavior of Omalizumab determined by SI-BLI in dependence 
of formulation pH-value in 20 mM histidine buffer (A), of histidine buffer concentration at pH 6.0 (B), 
of sodium chloride concentration in 20mM histidine buffer pH 6.0 (C) and of magnesium chloride 
concentration in 20 mM histidine buffer pH 6.0 (D). 
The formulation pH had tremendous impact on the self-interaction propensity of 
Omalizumab (Fig. 5A). At pH 7.0, the theoretical isoelectric point of Omalizumab20, the 
BLI signal was 40-fold higher compared to pH 5.0. Increasing the net surface charge of the 
antibody by lowering the pH below the pI resulted in stronger electrostatic repulsion and 
in a lower Rrel. Although addition of salt caused a strong decrease in Rrel, the self-interaction 
propensity of Omalizumab was not significantly affected by the concentration of the 
histidine buffer at pH 6.0 in a range from 2 to 20 mM (Fig. 5B). The Rrel of 3.7 in 20 mM 
histidine hydrochloride pH 6.0 substantially decreased with addition of sodium chloride 
(Fig. 5C). The decrease was more pronounced with magnesium chloride (Fig. 5D). This 
reduction of attractive self-interaction with higher ionic strength is in line with findings 
reported in literature.20 The addition of salt results in a disruption of attractive electrostatic 
interactions. 
2.4.5 Correlation of kD obtained by DLS and Rrel obtained by SI-BLI 
During this study, in total 58 mAb formulations were analyzed by DLS and SI-BLI 
regarding the self-interaction propensity. Overall, a more negative kD-value is associated 
with a higher response of the SI-BLI assay. We found significant Spearman correlation 
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coefficients for smaller sample sets of both different antibodies formulated in PBS and for 
one mAb formulated in different buffer compositions. In order to assess, if the SI-BLI assay 
can be used as a high throughput alternative to kD determination by DLS, we used all 
corresponding DLS and SI-BLI results and looked for Spearman and Pearson correlation. 
First we analyzed our complete data set for Gaussian distribution and found non-significant 
differences for our data set (p > 0.05). For the 58 samples we found significant Spearman 
correlation between Rrel and kD (ρ = - 0.77, p < 0.0001) as well as statistically significantly 
correlation (p < 0.0001) with a Pearson correlation coefficient of -0.72 (Fig. 6). Thus, 
ranking of the self-interaction propensity of different mAb formulations by SI-BLI is 
possible. In addition, Rrel can be used as a predictor for kD. 
 
Figure 6   Correlation of Rrel obtained by SI-BLI- and kD obtained by DLS for different mAbs in different 
formulations. 
2.4.6 Using the SI-BLI assay for developability assessments and 
preformulation 
Various studies show the correspondence of net attractive mAb self-interaction as indicated 
by negative kD with the viscosity increase of antibody formulations at high protein 
concentration.8,21,22 In order to predict the self-interaction propensity at early stages of 
development, promising in silico tools are available.23 But these tools do not consider 
excipient and formulation effects. The formulation dependent self-interaction behavior can 
be studied by DLS techniques in a high throughput manner. However, sample preparation 
including dialysis and preparation of a dilution series are labor intensive. Furthermore, 
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excipients such as sucrose and trehalose can affect the results obtained by DLS.24 The SI-
BLI assay setup was described by Sun et al.18 They used this method to screen for suitable 
antibody clones in discovery. It was proposed that mAbs which showed higher self-
interaction response as adalimumab should be considered as potentially problematic for 
later development steps. They used PBS as platform formulation only. We transferred the 
assay to a 96 well setup which enables interaction assessment with only 21 µg of mAb 
material per formulation at a single concentration of 0.3 mg/ml (2 µM). This setup was 
applied to screen the self-interaction of various mAbs in different formulations. The 58 
samples rendered a significant correlation of the Rrel from SI-BLI and the kD from DLS. 
At early development stage either mAbs which show low viscosity at high concentration 
have to be selected or mAb candidates require optimization by mutagenesis or the 
formulation composition needs to be adapted. This can be supported by analysis of protein-
protein interaction in high throughput with minimal sample consumption and preparation 
effort. All these attributes are combined in the SI-BLI assay which makes it suitable for use 
already during transition from discovery to development stage. This early assessment of 
protein-protein interactions is of high value for candidate selection and for formulation 
selection in the discovery phase. It cannot replace detailed analysis of the protein behavior, 
specifically at high concentration at later stages of development. 
2.4.7 Limitations of the SI-BLI assay 
The SI-BLI assay setup included the essential mAb capture step. The utilized anti-hIgG Fc 
capture sensors have a high affinity to human Fc and this binding was shown to be stable 
for the whole assay duration.18 Nevertheless, we observed loss of binding capacity of the 
biosensor in acetate buffers below pH 4.0. Furthermore, by losing the captured IgG and Fc 
protein, the association reaction will be overestimated. Further, a possible association 
reaction cannot be safely attributed to self-interaction, as this association curve can also be 
caused by binding of IgG to the biosensor itself, which at least lost part of the captured IgG 
and blocking Fc. 
Self-interaction processes of mAbs can be triggered by Fab-Fc domain interactions or by 
Fab-Fab domain interactions.25–27 Also Fc-Fc domain interactions are possible as well. 
Especially in the latter case, association of the free mAb molecules with the Fc-protein used 
for saturation after the capture step might interfere. To avoid this, other biosensors like anti-
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hFab-CH1 capture sensors or sensors based on covalent binding of analyte (amino reactive 
biosensors) can be used. 
The optical thickness of the layer on the sensor surface is a result of association of protein 
molecules. Net repulsive interactions can therefore not be analyzed. Thus, the SI-BLI assay 
cannot discriminate between molecules and conditions which show weak attractive 
interaction and repulsive interaction. But it can cover the range of critical substantial 
attractive interactions.  
During kD analysis, diffusion coefficients of the mAb molecules are determined with the 
analyte in solution. Similar to self-interaction chromatography, the SI-BLI method studies 
the interaction of mAb molecules bound to the sensor surface with molecules in solution, 
which potentially restricts their movement, flexibility and accessibility sterically. We 
therefore suggest using SI-BLI as a rapid screening method for suitable formulations, and 
kD analysis for in-depth characterization of self-interaction for selected final formulations.  
2.4.8 Comparison to other SI analyzing techniques 
As discussed, SI-BLI seems to be a powerful tool for early stage formulation development 
or developability assessments, when only small amounts of protein material are available 
and the number of candidates and possible formulations is high. SI-BLI is a relatively new 
technique for analyzing mAb self-interaction behavior compared to other techniques such 
as AUC, DLS and SIC. AUC provides the second virial coefficient, but consumes 
substantial amounts of material and offers low throughput. Methods of medium throughput 
are DLS and SLS. Both are also based on molecular interactions present in solution. As it 
was mentioned for AUC, DLS and SLS can provide information on the second virial 
coefficient and kD. But to assess self-interaction propensity by these techniques, a dilution 
series of the mAb formulation is necessary starting at concentrations of several g/L. 
Upconcentration and dilution make these methods more labor intensive and can lead to 
material loss, which increases material consumption. Both SIC and AC-SINS require 
several preparation steps including conjugation to either suitable chromatographic beads or 
via a capture antibody conjugated to gold nanoparticles. Both methods study interactions 
of immobilized mAb with mAb molecules in solution. A very recent technique for 
analyzing mAb self-association is HDX-MS. It enables to detect the mAb structures 
involved on peptide level or potentially even higher resolution. If mutagenesis is an option 
to reduce the self-interaction propensity of a lead candidate, HDX-MS can give important 
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advice. It is specifically of use at later stages of development when more protein material 
is available. We summarize a comparison of the techniques for analyzing mAb self-
interaction in Figure 7 and Table 2. 
 
Figure 7   Comparison of different techniques to assess mAb self-interactions. 
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Table 3   Overview of methods to analyzed mAb self-interaction. 
Method SI-BLI AC-SINS SIC DLS/SLS AUC HDX-MS 
Interaction partners Immobilized /  
in solution 
Immobilized / immobilized 
Immobilized /  
in solution 
in solution in solution in solution 
Assay read out 
Binding normalized to 
amount of captured 
sample, Rrel 
Wavelength shift caused 
by binding Δλ 28 
Retention factor 29 
Diffusion interaction 
parameter kD 
Sedimentation coefficient, 
second virial coefficient, 
hydrodynamic non-ideality 
coefficient19, 30 
Differences in deuterium 
uptake 26 
Required protein 
amount 
Very low, approx. 24 µg 
per antibody and 
formulation 
Very low, approx. 0.5 µg 
per antibody solution 28 
High (column preparation); 
low for analysis (5-10 µg 
sample) 29 
Moderate, approx. 500 µg 
per antibody and 
formulation8 
High, 15 mg per antibody 
and formulation16 
High, 30 mg per antibody 
and formulation 26 
Sample preparation 
Dilution or buffer 
exchange. 
Working concentration: 
0.3 mg/ml 
Preparation of gold 
nanoparticles with capture 
antibody. 
Working concentration: 
0.05 mg/ml 
Immobilization of mAbs to 
stationary phase at a 
concentration of 15 mg/ml; 
Injection of protein 
solutions of 2.5 mg/ml to 
10 mg/ml 
Buffer exchange, 
upconcentration, 
preparation of dilution 
series from 0.5 mg/ml to 
10 mg/ml 
Buffer exchange, 
upconcentration and 
preparation of dilution 
series to high protein 
concentrations (up to 
150 mg/ml) 
Lyophilization or dialysis 
and reconstitution in D2O 
containing reconstitution 
buffer 25. No technical 
limitations in protein 
concentration. 
Application for early 
development 
Yes Yes No Yes No No 
Advantages 
Very low sample 
consumption; high 
throughput; 
Low sample consumption; 
High–throughput, no 
interference with 
compounds from 
supernatants 
Moderate throughput , 
automated sampling, 
standard LC equipment 
required 
 
Moderate sample 
consumption & 
throughput; 
Assessment in solution 
Interaction parameter are 
directly accessible. Direct 
measurement of 
oligomerisation possible. 
High resolution of self-
interaction sites 
Disadvantages 
Unspecific binding needs 
to be excluded, buffers 
must be compatible with 
capture (pH above 4.0), 
only rank order of mAbs 
and formulations possible, 
weak attractive or 
repulsive interactions 
cannot be measured 
 
only ranking of mAbs 
relative to each other, no 
formulation dependent SI 
measurements published 14 
High sample consumption 
(SIC), 
Moderate throughput 
(sequential sampling) 
 
Low - moderate sample 
consumption & 
throughput, limitations at 
low-ionic strength and 
sugar containing 
formulations24 
 
Low throughput, high 
sample consumption, 
expensive AUC devices 
required 
Very low throughput, 
expensive HDX-MS 
devices required complex 
evaluation, time-
consuming method 
development 
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2.5 Conclusion 
We were able to differentiate the self-interaction behavior of different mAbs in PBS as a 
platform formulation both by kD analysis via DLS as well as by SI-BLI. The self-interaction 
rankings of the mAbs obtained from the two methods correlated significantly. Additionally, 
we analyzed the self-interaction behavior of one mAb in different formulations using both 
methods. Again, we found a significant correlation between the results from both 
methodologies, kD and Rrel, based on a sample set of 58 different conditions. Thus, SI-BLI 
is suitable to rank the self-interaction propensity of mAbs in a formulation dependent 
manner. Over and above our proprietary mAbs, we analyzed the self-interaction behavior 
of Omalizumab, which is commercially available and well described in the literature. Our 
SI-BLI and DLS data corroborated the reduction of attractive self-interaction with 
increasing ionic strength and decreasing pH value from pH 7.0 to 5.0, as described in 
literature. Whereas the SI-BLI assay allows to characterize the self-interaction behavior of 
mAbs for ranking purpose, this assay cannot provide a physico-chemical interaction 
parameter like kD. Furthermore, the SI-BLI assay provides information based on the 
interaction of mAb molecules in solution with non-covalently surface attached mAb 
molecules and cannot replace interaction assays where both interaction partners are free in 
solution. These aspects have to be weighed against the clear benefits of the SI-BLI assay, 
low material requirements and working at one diluted concentration only, which enables 
analysis of the formulation effect already at very early stages. 
In summary, SI-BLI appears to be a powerful tool for early stage formulation development 
when only limited amount of protein is available and the number of antibody candidates is 
high. By implementing this approach in developability assessments of mAbs, the risk to 
lose potential lead candidates based on highly attractive self-interaction propensity can be 
decreased. 
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Supplementary data 
Table S1  kD and Rrel of different formulations of mAb3. Mean and standard deviation (SD) were calculated 
based on n=3. 
 kD [ml/g] Rrel 
mean±SD Rank mean±SD Rank 
Formulation 1 -24.3±2.4 2 1.2±0.1 1 
Formulation 2 -33.2±1.3 9 1.4±0.1 4 
Formulation 3 -55.9±4.5 13 1.5±0.2 7 
Formulation 4 -57.5±2.6 14 2.4±0.0 12 
Formulation 5 -33.0±0.7 8 1.9±0.1 9 
Formulation 6 -93.9±8.1 15 3.1±0.4 15 
Formulation 7 -34.9±1.6 10 2.2±0.2 10 
Formulation 8 -40.8±2.8 11 2.7±0.1 14 
Formulation 9 -53.6±3.4 12 2.6±0.6 13 
Formulation 10 -28.7±0.9 7 2.4±0.1 11 
Formulation 11 -26.1±0.6 6 1.5±0.0 8 
Formulation 12 -24.6±0.6 3 1.4±0.1 5 
Formulation 13 -24.6±1.5 4 1.4±0.1 3 
Formulation 14 -25.1±0.7 5 1.4±0.1 6 
Formulation 15 -23.5±0.5 1 1.3±0.0 2 
 
 
Figure S1  Exemplary data of kD determination for adalimumab, mAb2 and mAb4. 
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Figure S2  Linearity check of Rrel in dependence on used mAb concentration for association. 
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3.1 Abstract 
Developability assessment of therapeutic mAb candidates before entering CMC 
development mitigates the risk of later failure because of manufacturing and stability 
issues. For mAbs derived from library based screenings, such evaluation starts with the first 
panning and ends with the selection of a lead candidate. This candidate should show, 
amongst others, high affine target binding and beneficial conformational as well as 
chemical stability. In addition, colloidal stability, reflected by the self-interaction 
propensity, should be superior in order to reduce aggregate formation and unacceptably 
high viscosity at elevated protein concentrations. Here, we present a study demonstrating 
the application of self-interaction bio-layer interferometry (SI-BLI) in a developability 
assessment, including the evaluation of preformulations. We reveal that the formulation 
rankings based on SI-BLI, DLS and viscosity measurements correlate. SI-BLI provides a 
deeper understanding of influencing factors on mAb self-interaction such as ionic strength 
or cation species. The attractive mAb self-interaction propensity was significantly more 
suppressed by Mg2+ compared to Na+. SI-BLI can be performed in high throughput with 
minimal material and sample preparation needs. Therefore, it can be applied in early stages 
of developability assessment going beyond the use of a platform formulation and a small 
number of analysis, to screen more parameters before proceeding with candidate selection 
and further extensive development. 
 
Graphical abstract Analysis of antibody self-interaction by bio-layer interferometry as tool to support lead 
candidate selection during preformulation and developability assessments 
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3.2 Introduction 
A major challenge in early stages of development of therapeutic monoclonal antibodies 
(mAbs) is the efficient and rational selection of the best candidate for moving forward into 
CMC and clinical development. The lead candidate should provide functionality and 
sufficient stability during manufacturing, filling and storage. Thus, analytical tools have to 
be applied to evaluate the chemical, conformational and colloidal stability of the potential 
candidates. This developability assessment starts in an early phase when hundreds to 
thousands of molecules have to be screened. To this end, methodologies capable of high 
throughput and low sample consumption, as well as in silico tools have to be employed.1 
In an intermediate phase, tens to hundreds of molecules can be tested to obtain a better 
mechanistic understanding of processes. Finally, few candidates are characterized in-depth 
to decide for a lead and a backup candidate.2, 3 This decision path should mitigate the risk 
of failure in subsequent CMC development. 
The colloidal stability in terms of protein-protein self-interaction can be described by the 
second virial coefficient B22 or the related diffusion interaction parameter kD.
4–6 Both 
parameters are typically assessed by light scattering techniques 7, 8 since other analytical 
methods come with throughput limitations or require extensive amounts of sample like 
AUC and self-interaction chromatography.9–11 Although SIC analyses can be performed in 
high throughput on HPLC systems requiring only small injection amounts, the preparation 
of the stationary phase requires several milligrams. The light scattering based 
methodologies can be used in a high throughput manner if corresponding instruments are 
available. But sample preparation steps including concentration and preparation of a 
dilution series still requires 500 µg of sample.12 The self-interaction can be assessed with 
even less material in high throughput manner by using bio-layer interferometry (SI-BLI). 
Sun et al. applied this technique to distinguish between different antibodies based on their 
self-interaction propensity in a platform formulation.13 Because self-interaction processes 
are dependent on the formulations composition 14–20, we developed the assay further and 
showed its correlation with kD.
12 
Here we present the applicability of this assay for the final stage of mAb assessment when 
the decision for a lead and backup candidate has to be taken. We used SI-BLI for a 
preformulation study to determine the effect of buffer, ionic strength, pH and excipients on 
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the self-interaction propensity of four different mAbs. These mAbs, derived from phage 
display library 21, target the same epitope of the antigen and were matured based on one 
common parental mAb. They were produced by comparable upstream and downstream 
processes and have theoretical isoelectric points between 9.3 and 9.4. We screened 19 
different formulations for each mAb by SI-BLI and found remarkable effects on self-
interaction propensity. The findings could be confirmed by dynamic light scattering and 
viscosimetry for selected formulations. Additionally, we differentiated between a general 
effect of ionic strength and a more specific metal ion modality for one dedicated mAb. 
Thus, we successfully applied the SI-BLI assay as a high-throughput approach for 
preformulation and for follow-up studies, which demonstrated its usefulness for fast and 
reliable screening of the formulation dependent self-interaction propensity of mAbs. 
3.3 Materials and methods 
3.3.1 MAb production and formulation 
Four mAbs were expressed in HKB11 stable cell pools and purified via affinity Protein A 
chromatography. To reach at least 95 % monomeric content, preparative size exclusion 
chromatography was performed followed by buffer exchange to 150 mM histidine 
hydrochloride pH 6.0. The protein concentration was adjusted to 10 mg/ml. For 
preformulation assessment, samples were diluted to 1 mg/ml with the respective 
formulation buffer. For the follow up studies, the 10 mg/ml protein solution was dialyzed 
over night against the formulations F1-F4 (Table 1) by using Slide-A-Lyzer dialysis 
cassettes with a MWCO of 30 kDa (Thermo Fisher Scientific, MA). Formulations F5 to 
F11 were prepared by dilution to the SI-BLI assay concentration (0.3 mg/ml) after dialysis 
to water over night (Table 1). 
A D-Optimal Design approach was applied for preformulation screening (MODDE, 
Sartorius Stedim, Sweden). As formulation factors, histidine hydrochloride at pH 5.0, 6.0 
and 7.0, sodium chloride, magnesium chloride, arginine hydrochloride and surfactant were 
used. These factors were combined to reach a theoretical osmolarity of 300 mOsm in each 
formulation. A detailed overview of the compositions of the preformulations can be found 
in the supplemental material (Table S1). Results were statistically analyzed by applying 
multivariate data analysis, which is implemented in the DoE software. After model 
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refinement by excluding combination factors, statistically estimated effects were calculated 
for the linear terms pH, sodium chloride, arginine hydrochloride, magnesium chloride and 
surfactant. 
Table 1   Overview of the formulations used. 
 Buffer pH NaCl [mM] MgCl2 [mM] Ionic strength 
F1 15 mM Histidine-HCl 6.0 - -  
F2 15 mM Histidine-HCl 6.0 130   
F3 15 mM Histidine-HCl 6.0 130 0.5  
F4 15 mM Histidine-HCl 6.0 - 90  
F5 50 mM Na-Acetate 5.5  100 0.342 
F6 50 mM Na-Acetate 5.5 100  0.142 
F7 50 mM Na-Acetate 5.5  50 0.192 
F8 50 mM Na-Acetate 5.5 200  0.242 
F9 50 mM Na-Acetate 5.5 - - 0.042 
F10 25 mM Na-Acetate 5.5 - - 0.021 
F11 10 mM Na-Acetate 5.5 - - 0.008 
3.3.2 Self-Interaction Bio-Layer Interferometry 
The SI-BLI method was performed as previously described.12 Briefly, anti-hIgG Fc capture 
(AHC) biosensors were used on an Octet HTX system (Sartorius AG, FortéBio, CA) in a 
384 well plate format. A baseline was established in PBS, followed by capture of the mAb 
of interest at 25 nM in PBS until the BLI signal increased by approximately 1 nm followed 
by saturation of the sensor with 1 μM of human Fc in PBS. Subsequently, a second baseline 
was acquired in the formulation composition, followed by an association step with 2 μM 
mAb in the same formulation. The response at equilibrium normalized to the amount of 
captured mAb (Rrel) was used for further calculations:  
𝑅𝑟𝑒𝑙 =
𝑅𝑒𝑠𝑝𝑜𝑛𝑠𝑒𝐴𝑠𝑠𝑜𝑐𝑖𝑎𝑡𝑖𝑜𝑛 𝑒𝑞𝑢𝑖𝑙𝑖𝑏𝑟𝑖𝑢𝑚 [𝑛𝑚]
𝑅𝑒𝑠𝑝𝑜𝑛𝑠𝑒𝑐𝑎𝑝𝑡𝑢𝑟𝑒 𝑠𝑡𝑒𝑝[𝑛𝑚]
 
(1) 
As control, sensors saturated with human Fc without IgG capture were used. 
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3.3.3 Dynamic Light Scattering 
Dynamic light scattering was conducted on a DynaPro® Plate Reader (Wyatt Technology, 
CA). 80 µl of sample were filtrated using 96 well filter plates (0.22 µm, Merck Millipore, 
Germany). Afterwards, 20 µl of sample were transferred to a 384 well plate (Corning INC, 
NY) in triplicates. Wells were sealed with silicone oil and then centrifuged at 400xg for 
2 min. Diffusivity was measured with 5 acquisitions à 10 s at 25 °C. Data were processed 
using Dynamics 7.8 (Wyatt Technology, CA). Five different protein concentrations 
between 0.5 and 10 mg/ml were analyzed to determine the diffusion interaction parameter 
kD via linear regression using PRISM 5 (GraphPad Software Inc., CA) 
22. 
3.3.4 Viscosimetry 
Viscosity of mAb solutions was analyzed using a Viscosizer TD capillary system (Malvern, 
UK) at mAb concentrations between 1.5 and 80 mg/ml. A constant pressure of 1000 mbar 
was applied at a capillary temperature of 20 °C with UV detection at 280 nm. The relative 
values were referenced to 1 mg/ml caffeine solution in H2O. The concentration dependent 
increase in viscosity was characterized by the slope B1 of logarithmized viscosity values 
based on ln η= ln η0 + B1  c. 
3.3.5 nano Dynamic Scanning Fluorimetry 
1 mg/ml mAb samples were filled in standard nanoDSF glass capillaries and measurements 
were performed using a Prometheus NT.48 (NanoTemper Technologies, Germany). 
Intrinsic fluorescence at 330 nm and 350 nm was evaluated during a temperature ramp from 
20 °C to 90 °C at 1 K/min. Transition onset and inflection points were determined from the 
first derivative using the PR.Control software (NanoTemper, Germany). 
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3.4 Results 
3.4.1 SI-BLI preformulation screening as part of a developability 
assessment 
We evaluated the effect of pH and excipients on the self-interaction of the four candidate 
mAbs by SI-BLI as a preformulation screening before initiation of subsequent extensive 
stability studies. This enables the evaluation of the colloidal stability under formulation 
conditions with low self-interaction propensity. We varied pH, buffer concentration as well 
as the concentration of different excipients based on a DoE approach according to Table 
S1 (Supplemental material). MAb self-interaction was remarkably decreased if ionic 
excipients were included in the formulation. The addition of magnesium chloride 
minimized the BLI response (exemplarily shown for mAbA in Figure 1).  
 
Figure 1 SI-BLI association reaction of mAbA in 15 mM His pH 7.0, 0.05% PS20 (His-HCl; PF13), 15 mM 
His pH 7.0, 0.05% PS20, 135 mM NaCl (+NaCl; PF16), 15 mM His pH 7.0, 0.05% PS20, 135 mM 
Arg-HCl (Arg-HCl; PF15), 15 mM His pH 7.0, 0.05% PS20, 90 mM MgCl2 (+MgCl2; PF14). 
The results of the preformulation study were statistically analyzed and effects were 
calculated. The effect plot showed comparable results for all mAbs (Figure 2 shows the 
effects exemplarily for mAbA). We determined a significant, negative effect on attractive 
self-interaction for magnesium chloride (p<0.001). In addition, a higher pH increased 
attraction of the mAb molecules significantly (p<0.001), whereas surfactant concentration 
as well as addition of NaCl and Arg-HCl did not show a significant effects. These results 
suggest, that a formulation comprising magnesium chloride at slightly acidic pH would 
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reduce the self-interaction propensity of the mAb und thus, the response of the SI-BLI 
assay. 
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Figure 2  Effect plot of the DoE-based SI-BLI preformulation screening of mAbA. Error bars represent the 95 % 
confidence interval. 
3.4.2 Assessment of self-interaction propensity by DLS for selected 
formulations 
The effects of pH and MgCl2, although not all salts, point to electrostatics as an important 
trigger for self-interaction of the mAbs. Therefore, we conducted a more detailed 
investigation of all four mAbs in four formulations, 15 mM His pH 6.0 containing either 
no salt, 130 mM NaCl, 130 mM NaCl + 0.5 mM MgCl2 or 90 mM MgCl2 (F1 – F4, 
Table 1). We analyzed kD by DLS, Rrel as indicator of attractive self-interaction by SI-BLI 
and the viscosity as a function of protein concentration. 
The concentration dependent diffusivity of mAbB is exemplarily shown in Figure 3A. We 
observed negative slopes for all mAbs in all formulations with the most negative for the 
His buffer without additional salt (F1) and the least negative with addition of 90 mM MgCl2 
(F4). Thus, the most negative kD values indicating strong attractive self-interaction was 
observed in absence of salts (Figure 3B). With addition of salt, kD increased and at the high 
MgCl2 concentration the only slightly negative kD values reflect diminished self-
interaction. Comparing NaCl (F2) and NaCl + MgCl2 (F3), the addition of only 0.5 mM 
MgCl2 did not have a significant impact on a formulation already containing 130 mM NaCl. 
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Figure 3  kD analysis of the four mAbs in 15 mM His pH 6.0 without salt (F1), 15 mM His pH 6.0 + 130 mM 
NaCl (F2),15 mM His pH 6.0 + 130 mM NaCl + 0.5 mM MgCl2 (F3) and 15 mM His pH 6.0 + 90 
mM MgCl2 (F4) by DLS. A) concentration dependent diffusivity of mAbB (for mAbA, mAbC and mAbD 
see Figure S1); B) kD values (± SD). 
 
3.4.3 Assessment of self-interaction propensity by SI-BLI for selected 
formulations 
The self-Interaction propensity of the mAbs was additionally assessed by SI-BLI. 
Association curves of mAbC are exemplarily shown in Figure 4A. The highest Rrel values 
for all mAbs and formulations indicating strong attractive self-interaction resulted from His 
buffer without additional salt (F1) (Figure 4B). Rrel decreased in salt containing 
formulations. Formulation F4, containing a high MgCl2 concentration, resulted in low Rrel 
values, indicating that self-interaction was diminished in these formulations. The addition 
of a low amount of MgCl2 to a 130 mM NaCl formulation only slightly influenced the 
attractive self-interaction (F2 vs. F3).  
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Figure 4  SI-BLI results of the four mAbs in in 15 mM His pH 6.0 without salt (F1), 15 mM His pH 6.0 + 
130 mM NaCl (F2),15 mM His pH 6.0 + 130 mM NaCl + 0.5 mM MgCl2 (F3) and 15 mM His pH 6.0 
+ 90 mM MgCl2 (F4). A) Association curve of the self-interaction of mAbC (for mAbA, mAbB and 
mAbD see Figure S2); B) Overview of calculated Rrel values (± SD). 
 
3.4.4 Analysis of mAb concentration dependent viscosity for selected 
formulations 
All mAbs showed a formulation dependent increase of viscosity with increased 
concentration (Figure 5). The dynamic viscosity of mAbD formulations increased 
exponentially from 1.0 mPa*s at 2.7 mg/ml to 1.5 mPa*s at 43 mg/ml in F1 without salt. 
The addition of MgCl2 (F4) led to a reduced increase from 1.0 mPa*s (4.9 mg/ml) to 
1.1mPa*s (39 mg/ml). For formulations 2 and 3, the viscosity increased from 1.0 mPa*s to 
1.2 mPa*s at 27 mg/ml and 35 mg/ml, respectively. We linearized the data for 
determination of the slope of the increased dynamic viscosity (Figure 5A). The slope was 
used to compare the formulations and mAbs. As shown in figure 5B, the strongest increase 
in viscosity was observed for F1 containing only histidine. The addition of NaCl in F2, as 
well as NaCl + 0.5 mM MgCl2 in F3 significantly reduced the slope for all mAbs except 
for mAbC, which showed the same trend, which was not significant though. The slope of 
the increased viscosity was the lowest for all mAbs in formulation F4 containing a high 
amount of MgCl2. 
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Figure 5  Viscosity of the four mAbs in in 15 mM His pH 6.0 without salt (F1), 15 mM His pH 6.0 + 130 mM 
NaCl (F2),15 mM His pH 6.0 + 130 mM NaCl + 0.5 mM MgCl2 (F3) and 15 mM His pH 6.0 + 90 mM 
MgCl2 (F4). A) Concentration dependent viscosity of mAbD (natural log of the dynamic viscosity in 
mPa*s) (for mAbA, mAbB and mAbC see Figure S3); B) Overview of calculated slopes of the 
concentration dependent dynamic viscosity (B1). 
3.4.5 Correlation of results obtained by SI-BLI, DLS and Viscosimetry 
SI-BLI, DLS and Viscosimetry were performed to analyze the self-interaction propensity 
of the four model mAbs in four different formulations differing in ionic strength and the 
cation type. Comparable rankings of the formulations for all mAbs were observed by all 
methods. We calculated significant Pearson correlation coefficients for results of Rrel and 
kD (r = 0.82, p < 0.001) (Fig S4) as also reported previously 
12. Additionally, the correlation 
of Rrel and B1, reflecting the concentration dependent viscosity increase, was also 
significant (r = 0.68, p < 0.01). 
3.4.6 The Mg2+ effect on mAb self-interaction propensity 
Since the self-interaction propensity was decreased in high ionic strength formulation and 
was further reduced by MgCl2 at higher concentration, we performed additional SI-BLI and 
nanoDSF experiments. To differentiate between the effect of ionic strength and a specific 
or non-specific effect of the divalent ion Mg2+, we formulated mAbC exemplarily in 
formulations based on sodium acetate buffer pH 5.5 with NaCl and MgCl2 concentrations 
(F5-F8) and with different buffer strength (F9-F11). 
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The self-interaction propensity of mAbC decreased with an increase in ionic strength of the 
buffer only formulations (Figure 6). The supplement of salt reduced attractive self-
interaction generally. In addition, the Rrel was lower in solutions containing the same 
concentration of chloride, but Mg2+ instead of Na+. Further, Rrel was lower in the 
formulation containing 50 mM MgCl2 compared to 200 mM NaCl although the ionic 
strength of the latter was higher. 
 
Figure 6  SI-BLI results for mAbC in formulations containing different buffer concentrations and low and high 
concentration of ionic excipients. 
To determine if the effect of MgCl2 on self-interaction arises from specific Mg
2+ binding 
to the mAb, we performed nanoDSF for mAbC in 10 mM sodium acetate, 50 mM sodium 
acetate without salt, 50 mM sodium acetate + 100 mM NaCl and 50 mM sodium acetate + 
50 mM MgCl2. A specific interaction should alter the conformational stability of the 
protein.23 The apparent unfolding temperature varied between 64.9°C as the lowest 
temperature in the formulation containing NaCl and 66.0°C in 10 mM sodium acetate as 
the highest temperature (See Table S2). We did not observe significant differences in Tm 
comparing formulations with NaCl or MgCl2 and therefore consider the interaction of Mg
2+ 
and the mAbs as unspecific and not targeted to specific interaction sites of the protein 
molecules. 
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3.5 Discussion 
To minimize cost and time, platform approaches are widely used in the development of 
biopharmaceutical products.24, 25 This includes the use of platform formulations 
considering a narrow pH range and standard excipients derived from commercially 
available products especially in early phases of development.26–28 In addition to surfactants 
like polysorbate 20 or 80, ionic modifiers and sugars are used to stabilize the product. For 
the development of high concentration mAb formulations, the assessment of protein self-
interaction is of utmost importance as this propensity drives viscosity and colloidal 
instability. 9,18,29,30 Limiting this analysis to platform formulations bears the risk of 
dismissing high potential candidate molecules in early stages due to inadequately high 
viscosity or colloidal instability. We established a workflow, which makes use of SI-BLI 
during candidate screening to analyze candidates in a high number of formulations with 
minimal effort and material requirements. This enables the combination of both candidate 
assessment and preformulation in the development of high concentration mAb 
formulations. Recent studies applied kD to train artificial neural networks to predict the 
formulation behavior of therapeutic protein candidates.31 The SI-BLI datasets obtained in 
high throughput could be included to improve model accuracy and precision by including 
the formulation dependent attractive self-interaction propensity. 
In addition to the assessment of colloidal stability and viscosity, the evaluation of 
conformational properties can be included both in developability assessments and 
preformulation work.31 As the apparent unfolding temperature of a mAb can be easily 
analyzed in high throughput by DSF, mAbs with lower stability can be excluded prior to 
subsequent lab extensive parts of developability assessments. 
With regard to developability, computational tools such as Therapeutic Antibody Profiler 
(TAP) and Developability Index (DI) have been generated to predict developability 
challenges based on the structural properties of the variable domains of a mAb.32, 33 In case 
of TAP, these structural properties include CDR length, surface hydrophobicity, surface 
exposed positive and negative charged properties as well as charge symmetry at 
pH 7.4.32.The DI is based on spatial aggregation propensity and net charge.33 Thus, DI can 
reflect pH dependence of surface charge and the probability of electrostatic interactions. 
Because SI-BLI can be performed in high-throughput at different pH values, the 
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combination of data from in silico tools such as DI and experimental data from SI-BLI may 
support the assessment at early stages of discovery. Thus, the development of mAb 
candidates, which are suitable for high concentration formulations can be initiated earlier 
which can save time and effort at later stages of development. 
We analyzed four mAbs in four different formulations containing different NaCl or MgCl2 
levels. Rrel from SI-BLI was increased for formulations without salt and was remarkably 
reduced by the addition of ionic excipients. Ions potentially influence the self-interaction 
process by shielding electrostatically driven interactions. Thus, attractive self-interaction 
was decreased in formulations containing NaCl and was further minimized by MgCl2. 
Based on kD we identified strong attractive interactions in formulations without salt and 
less attractive interaction in formulations containing salt. With both methods, we observed 
comparable rankings of the formulations which confirmed the correlation of SI-BLI and 
DLS results12. We further evaluated the effect of protein concentration on the dynamic 
viscosity of the formulations. Viscosity increased exponentially with protein concentration 
which was consistently described for other mAbs. 9,14,17,18,30,34,35 However, the increase was 
overall small but we were able to rank the formulation based on the slope of this increase. 
We observed a stronger increase in formulations without salt for all mAbs. The addition of 
90 mM MgCl2 minimized the viscosity. To this end, the ion effect on the attractive self-
interaction of the mAbs was confirmed by all methodologies used. The results of SI-BLI, 
DLS and viscosimetry correlate significantly and confirm previous findings.4,22,36 In this 
context, rankings based on Rrel values may reflect a new approach to predict the solution 
behavior at high protein concentration and to generate developability rankings. A limitation 
which has to be kept in mind is the fact that net repulsive interactions cannot be assessed 
by SI-BLI.4 
Since the attractive self-interaction of the investigated mAb samples could be significantly 
reduced by salts, we tested different facets of this factor with SI-BLI: the effect of different 
Cl-concentration, of mono- or divalent cations and of overall ionic strength. As depicted in 
figure 6, attractive self-interaction was less pronounced in formulations containing 50 mM 
MgCl2 compared to 200 mM NaCl, although the ionic strength as well as the Cl
- 
concentration of the 200 mM NaCl containing formulation was higher. Thus the divalent 
cation Mg2+ reduces attractive self-interaction distinctively more than Na+ or a general 
increase in ionic strength. This may indicate the salting-in effect of Mg2+, which has been 
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described before 37, although different proteins were studied and higher MgCl2 
concentrations were required to observe significant effects. In addition, we could not 
confirm specific binding of cations to the protein by nanoDSF and therefore hypothesize 
that the observed behavior is caused by the combination of two effects: a preferential, 
although rather unspecific, interaction of Mg2+ with the mAbs, and the effect of increasing 
ionic strength of the solution. A special attractive interaction and viscosity decreasing effect 
of cations on mAbs has been demonstrated for cationic amino acids 34 and we observed a 
decrease in Rrel for mAbA upon addition of Arg-HCl. Screening of different ionic species, 
e.g. by SI-BLI can improve the chances of successfully developing high concentration 
formulations by minimizing electrostatically driven self-interaction processes. 
3.6 Conclusion 
We described the application of SI-BLI in a preformulation screening as part of the 
developability assessment of mAbs. We analyzed four mAbs in 19 different formulations 
and identified significant effects on mAb self-interaction. After formulation selection, self-
interaction propensity was analyzed by DLS and SI-BLI. Additionally, the viscosity at 
elevated protein concentration was determined. We observed a significant correlation of 
rankings based on kD obtained by DLS, Rrel obtained by SI-BLI and the increase in 
viscosity. Additionally, SI-BLI enabled us to understand the influence of different ions on 
the self-interaction behavior. Based on our findings, SI-BLI could be helpful to predict the 
solutions behavior at high protein concentration and thus to mitigate risks in CMC 
development of high concentration protein formulations. As this assay only requires a 
single, low concentration of protein for determination of attractive self-interaction, it can 
be applied in very early stages of development where the number of potential candidates is 
high and the available amount of protein material is limited. This could accelerate the 
design of high concentration liquid formulations for subcutaneous administration and thus 
decrease effort and shorten timelines for late stage CMC development. 
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Supplementary data 
 
Figure S1  Diffusivity of mAbA, mAbC and mAbD in Formulations F1 to F4. 
 
 
Figure S2  Association curves of SI-BLI of mAbA, mAbB and mAbD in Formulations F1 to F4. 
 
 
Figure S3  Viscosity profiles (ln) of mAbA, mAbB and mAbC in Formulations F1 to F4. 
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Figure S4  Correlation plot of Rrel and A) kD and B) B1. 
 
Table S1   Overview of preformulations tested and the results of SI-BLI. 
Preformulation matrix Rrel 
# Buffer pH NaCl Arg-HCl MgCl2 PS20 mAbA mAbB mAbC mAbD 
PF1 
1
5
m
M
 H
is
-H
C
l 
5 --- --- --- --- 0.8 0.8 1.5 0.7 
PF2 5 --- --- 90 --- 0.5 1.5 0.6 0.4 
PF3 5 --- 135 --- --- 0.8 3.0 2.0 0.7 
PF4 5 135 --- --- --- 1.3 0.5 3.6 1.4 
PF5 7 --- --- --- --- 9.0 12.6 16.1 10.4 
PF6 7 --- --- 90 --- 0.6 2.2 0.5 0.6 
PF7 7 --- 135 --- --- 1.1 1.2 1.7 0.9 
PF8 7 135 --- --- --- 2.0 1.5 4.0 1.7 
PF9 5 --- --- --- 0.05 0.9 1.0 1.5 0.7 
PF10 5 --- --- 90 0.05 0.4 0.5 0.4 0.6 
PF11 5 --- 135 --- 0.05 0.8 0.7 1.1 0.8 
PF12 5 135 --- --- 0.05 1.1 1.2 1.7 1.7 
PF13 7 --- --- --- 0.05 8.1 7.0 10.7 7.7 
PF14 7 --- --- 90 0.05 0.5 0.6 0.5 0.3 
PF15 7 --- 135 --- 0.05 1.0 0.9 1.3 0.8 
PF16 7 135 --- --- 0.05 1.9 1.8 2.3 1.5 
PF17 6 27 54 54 0.025 1.1 0.9 1.3 1.7 
PF18 6 27 54 54 0.025 1.0 1.0 1.5 0.8 
PF19 6 27 54 54 0.025 1.1 1.2 1.4 0.8 
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Table S2   NanoDSF results of mAbC. 
Formulations of mAbC Tm [°C] ± SD Tm onset [°C] ± SD 
10mM Na-Acetate pH 5.5 66.0 ± 0.1 53.0 ± 0.4 
50mM Na-Acetate pH 5.5 65.4 ± 0.1 56.4 ± 0.3 
50mM Na-Acetate pH 5.5 + 100 mM NaCl 64.9 ± 0.2 55.2 ± 0.2 
50mM Na-Acetate pH 5.5 + 50 mM MgCl2 65.4 ± 0.3 55.0 ± 0.2 
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Chapter 4 A multi-method approach to assess the 
self-interaction behavior of Infliximab 
 
M. Domnowski1,2; T. Maruno3; K. Enomoto3; F. Kummer2;  
A. Kulakova4; P. Harris4; S. Uchiyama3; J. Jaehrling2; W. Frieß1 
 
1 Department of Pharmacy: Pharmaceutical Technology and Biopharmaceutics; Ludwig-
Maximilians-Universitaet Muenchen, Butenandtstrasse 5, 81377 Munich, Germany   
2 MorphoSys AG, Semmelweisstraße 7, 82152 Planegg  
3 Osaka University, Department of Biotechnology, Graduate School of Bioengineering, 
Osaka 565-0871, Japan 
4 Technical University of Denmark, Department of Chemistry, 2800 Kongens Lyngby, 
Denmark 
Author contributions: 
M.D., S.U. J.J. and W.F. conceived and designed the study. M.D. conducted and analyzed 
lyophilization, SEC-MALS, CD, DLS, SI-BLI, HDX-MS and viscosimetry experiments. 
T.M. conducted and analyzed AUC. K.E. conducted and analyzed HDX-MS. F.K. 
performed mAb digestion. A.K. conducted and analyzed SAXS experiments. M.D., T.M., 
F.K., A.K., J.J. and W.F. contributed to the writing of the manuscript. P.H, S.U., J.J. and 
W.F. reviewed the paper. 
Keywords: Infliximab, Self-interaction, Self-association, AUC, SAXS, BLI, HDX-MS 
Abbreviations: AUC SV/SE – Analytical Ultracentrifugation Sedimentation 
Velocity/Sedimentation Equilibrium; CDR – Complementarity determining region; CH – 
constant heavy chain; CL – constant light chain; DLS – Dynamic Light Scattering; Fab – 
Antigen binding Fragment; Fc – crystallizable Fragment; HDX-MS – Hydrogen Deuterium 
Exchange Mass Spectrometry; MALS – Multi Angle Laser Light Scattering; SAXS – Small 
Angle X-Ray Scattering; VH – variable heavy chain; VL – variable light chain 
A multi-method approach to assess the self-interaction behavior of Infliximab 
 
 
61 
 
 
4.1 Abstract 
Attractive self-interaction processes in antibody formulations increase the risk of 
aggregation and extraordinarily elevated viscosity at high protein concentrations. These 
challenges affect manufacturing and application. This study aimed to understand the self-
interaction process of Infliximab as a model system with pronounced attractive self-
interaction. The association mechanism was studied by a multi method approach 
comprising analytical ultracentrifugation, dynamic light scattering, small angle X-ray 
scattering, self-interaction bio-layer interferometry and hydrogen-deuterium exchange 
mass spectrometry. Based on our results, both Fab and Fc regions of Infliximab are 
involved in self-interaction. We hypothesize a mechanism based on electrostatic 
interactions of polar and charged residues within the identified areas of the heavy and the 
light chain of the mAb. The combination of fast and reliable screening methods and low 
throughput but high resolution methods can contribute to detailed characterization and 
deeper understanding of specific self-interaction processes. 
4.2 Introduction 
By 2020, 70 monoclonal antibody (mAb) products will be available on the market and the 
world-wide sales will be nearly $125 billion.1 These biomolecules are susceptible to various 
forms of instability during manufacturing, storage and delivery to the patient. In particular, 
as colloids mAb molecules exhibit attractive and repulsive interactions with each other.2 
This reversible self-interaction is linked to protein oligomerization or aggregation as well 
as drastically increased solution viscosity at elevated protein concentration.3, 4  
mAb self-interaction can either be driven by Fc-Fc interaction, Fab-Fab-interactions or 
Fab-Fc-interactions5–9 and the identification of self-interaction sites on an IgG domain level 
can be highly useful. Analytical ultracentrifugation (AUC)10, dynamic light scattering 
(DLS)11, small-angle X-ray scattering (SAXS)11 and self-interaction bio-layer 
interferometry (SI-BLI)12, 13 have been described for this purpose. The identification 
requires either digestion of the IgG into Fab and Fc domain or separate expression of the 
fragments as single proteins. In addition, lab extensive purification is necessary to achieve 
high sample quality. An even deeper structural understanding of interaction hot spots on a 
peptide or residue level would be highly beneficial to engineer mAbs and to avoid 
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unfavorable amino acids and sequences in the primary structure. Results of hydrogen-
deuterium-exchange mass spectrometry could provide such high resolution data. In general, 
this method is used for analyzing highly specific interaction processes during the in-depth 
characterization process of biopharmaceutical drug development.14 In addition, this method 
allows the analysis of weaker protein-protein interactions like in the case of mAb self-
interaction processes.7, 15 
In 2017, Lerch et al. published the self-interaction site of Infliximab based on studies by 
X-ray crystallography, SEC, SV-AUC and SE-AUC. Based on X-ray crystallography of 
the Fab fragment, a “head-to-tail orientation” was proposed. The VL of one Fab builds an 
interaction interface with the CL of another Fab. Patches, which indicate hydrophobic 
interactions have been identified within these chains e.g. Leu3 of the CL was shown to stack 
into a pocket created by Thr197, Lys145 and Glu143 of VL. In addition, they identified other 
interaction sites in other crystal forms indicating that multiple arrangements are possible.16 
But the question arises whether these findings are relevant for pharmaceutical formulations 
of the protein, in this case Infliximab. High ionic strength buffers and crystallization agents 
have to be used for crystallization. Furthermore, only the Fab fragment was crystallized, 
not the full mAb. In addition, the identified interaction sites were present in solid crystals 
of Infliximab Fab fragments. But do they also play a role in solution, specifically a 
pharmaceutically relevant formulation? 
In our study, we used Infliximab as a model system to generate and challenge a multi-
method approach for identifying self-interaction sites based on approaches alternative to 
X-ray crystallography working in solutions reflecting pharmaceutically relevant 
formulations and for the whole mAb. DLS, SI-BLI, SAXS and AUC were used to assess 
the overall propensity for reversible self-interaction on protein level. We further 
investigated the interaction process after fragmentation of the IgG into Fab and Fc domain 
by SI-BLI and AUC. Finally, we performed HDX-MS as a high resolution method to 
identify residues that are involved in the self-interaction process of Infliximab. In our study, 
we identified that residues in both the Fc and the Fab region trigger the self-interaction of 
Infliximab. This finding, mostly driven by HDX-MS and AUC results, indicate that 
interaction hot-spots of mAbs found in solution can differ markedly from the hot-spots 
identified by crystallography. 
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4.3 Experimental section 
4.3.1 Materials 
Phosphate buffered saline (Thermo Fisher Scientific), sodium phosphate monobasic 
(Merck KGaA), trehalose dihydrate (Merck KGaA) were all of analytical grade. Deuterium 
oxide (99.96%) was purchased from Eurisotop GmbH. 
Infliximab (Flixabi®) was purchased, reconstituted according to the manufacturer’s 
protocol and buffer exchanged into 10 mM sodium phosphate pH 7.2 including polysorbate 
20 removal by protein A chromatography using an Äkta Avant (Cytiva). mAb stock 
solutions were concentrated using Amicon Ultra-15 centrifugal devices (Merck KGaA) to 
10 mg/ml. 
4.3.2 Digestion 
Infliximab (Flixabi®) was reconstituted according to the manufacturer’s protocol and 
buffer exchanged into 150 mM sodium phosphate pH 7.0 using PD10 columns (Cytiva). 
Digestion was performed using FabALACTICA Fab Kit (Genovis) according to the manual 
overnight. Purification of Fc fragments was performed using a HiTrap MabSelect SuRe 5 
mL pre-packed column (Cytiva) on an Äkta Avant system loading the eluate from the 
FabALACTICA Fab Kit. Purification of Fab fragments was performed using CaptureSelect 
IgG-CH1 5 mL pre-packed column (Thermo Fischer Scientific) on an Äkta Avant system 
loading the flow through of the Fc fragment purification. Fc fragments and Fab fragments 
were formulated in PBS after purification. Sterile filtration was performed and the 
fragments were subjected to SEC analysis. 
4.3.3 Lyophilization 
Lyophilization stoppers (B2 TR coating, West) and DIN 2R Vials (Fiolax®, Schott) were 
cleaned with ddH2O and dried at 60 °C for 8 h. The vials were filled with 300 µl and semi-
stoppered subsequently. A thermocouple was used for temperature recording throughout 
the freeze drying process. Both placebo and protein formulations were freeze-dried using a 
FTS LyostarTM 3 freeze dryer (SP Scientific) by 1) freezing to -50 °C, ramp: 0.5 K/min; 
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2) primary drying at 0.1 mbar and -25 °C shelf temperature for 20 h followed by a 
0.15 K/min ramp to 10 °C; 3) secondary drying at 0.1 mbar and 10 °C for 10 h. The vials 
were stoppered at 800 mbar after secondary drying and crimped with flip-off seals. 
4.3.4 Size-Exclusion-Chromatography combined with Multi Angle Laser 
Light Scattering 
SEC analysis was performed using a Vanquish UHPLC system (Thermo Fisher Scientific,). 
A Waters BEH200 column (1.7 µm, 4.6 x 150 mm) was used with a flowrate of the mobile 
phase (50 mM sodium phosphate, 400 mM sodium perchlorate, pH 6.0) of 0.4 ml/min. 
Routine UV-detection was at 210 nm. All samples were diluted to 5 mg/ml in formulation 
buffer prior to injection of 0.75 µg. For MALS measurements, samples were directed to a 
µDAWN MALS detector and a µREX RI detector (both Wyatt Technologies). 
4.3.5 Circular Dichroism spectroscopy (CD) 
Near-UV spectra of Infliximab were recorded on a Chirascan instrument (Applied 
Photophysics). Samples were diluted in 6 mM sodium phosphate pH 6.2, 90 mM trehalose 
to 2 mg/ml and pipetted to quartz cuvettes with a path length of 1 mm. The CD spectra 
were acquired from 260 nm to 350 nm at 1 nm step size, 0.5 s-1 sampling time and 20 °C. 
Collected spectra (n=6) were blank corrected. The absorbance at 280 nm was used for 
concentration and MRME calculation. 
4.3.6 Dynamic Light Scattering 
DLS experiments were performed using a DynaPro plate reader III (Wyatt Technologies). 
Samples were filtrated through 0.22 µm filters to remove larger particulate impurities and 
measured at 25 °C as triplicates in 384 well plates with 12 acquisitions for 5 s. Six protein 
concentrations between 0.5 and 20 mg/ml were measured. Data were processed by the 
software DYNAMICS V7.8 (Wyatt Technologies). Cumulant fit analysis was applied for 
determination of the apparent diffusion coefficient and polydispersity, followed by 
calculation of hydrodynamic radii based on Stokes-Einstein relation.  
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4.3.7 Self-Interaction Bio-Layer-Interferometry (SI-BLI) 
SI-BLI was performed on an Octet HTX device (Sartorius AG, FortéBio) as previously 
described.13 Full-length IgG or Fc domain were captured (Anti-hIgG Fc capture (AHC) 
biosensors) and the association of IgG, Fc and Fab domain analyzed. To capture equal 
amounts, we captured 1 nm of the full-length IgG or 0.3 nm of the Fc domain which is 
approximately a third in size. 
4.3.8 Hydrogen-Deuterium-Exchange Mass Spectrometry 
HDX-MS Experiments using Waters HDX with LEAP system (Waters) were conducted in 
two independent laboratories 1 and 2. In both laboratories, lyophilized Infliximab was 
reconstituted to a protein concentration of 60 mg/ml. For the high concentration condition, 
the reconstituted product was diluted to 20 mg/ml in D2O containing formulation buffer. 
For the low concentration condition, the reconstituted product was first diluted to 1.5 mg/ml 
in formulation buffer and subsequently diluted to the assay concentration of 0.5 mg/ml in 
D2O containing formulation buffer. After incubation at 20 °C, the labeling reaction was 
quenched by 1:1 dilution in quenching buffer followed by online digestion at 15 °C using 
a Enzymate Pepsin column (300 Å, 5 µm, 2.1x30 mm, Waters) at a flowrate of 80 µl/min 
(0.1 % Formic acid). Peptides were trapped for 3 minutes at 0 °C using an Acquity UPLC 
BEH C18 VanGuard column (1.7 µm, 2.1x5 mm, Waters, MA). After trapping, C18 
separation was performed on an Acquity UPLC BEH C18 column (1.7 µm, 1.0x100 mm, 
Waters) at 0 °C and a flowrate of 40 µl/min. A 9 min linear gradient from 8 % to 40 % 
Acetonitrile was applied and eluting peptides were directed to MS detection. Protein Lynx 
Global Server (PLGS) version 2.5.3 and DynamX version 3.0 (both Waters) were used to 
identify peptides and analyze H/D exchange. Statistical analysis was performed using 
Hybrid Significance Testing.17 In Lab1, samples were incubated in D2O containing buffer 
for 1, 3 and 10 min at 20 °C before quenching 1:1 with 0.1 M potassium phosphate, 4 M 
guanidine hydrochloride, 0.2 M TCEP at pH 2.6 at 2 °C. The eluate was directed into a 
Waters Synapt G2Si mass spectrometer for MS/MS-IMS detection.  
In Lab2 protein solutions were incubated for 1, 3, 10, 60 and 240 min and quenched with 
0.1 M potassium phosphate, 2 M guanidine hydrochloride, 75 mM TCEP pH 2.6 at 4 °C. 
MS/MS detection was performed on a Waters Synapt G2S mass spectrometer. 
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4.3.9 Analytical Ultracentrifugation 
Experiments were conducted at 20 ℃ using an Optima XL-I or Optima AUC (Beckman 
Coulter) equipped with a UV-VIS detection system. Sedimentation velocity experiments 
were performed with 0.5, 5.0, and 20 mg/mL protein solutions at 42,000 rpm. For 0.5 and 
5.0 mg/mL, 390 µL sample was loaded into the sample sector of 12 mm double-sector 
charcoal-filled epon centerpiece, and 400 µL buffer (6 mM sodium phosphate pH 6.2, 
90 mM trehalose) was loaded into the reference sector of centerpiece. For 20 mg/mL 
sample, 97.5 µL sample was loaded into sample sector of 3 mm double-sector charcoal-
filled epon centerpiece, and 100 µL buffer was loaded into the reference sector of 
centerpiece. The collected data were analyzed using continuous c(s) distribution model of 
Program SEDFIT ver. 16.2b fitting for the frictional ratio, meniscus, and time-invariant 
noise and using regularization level of 0.68 for 0.5 and 5.0 mg/mL samples. For the 20 
mg/mL sample, the non-ideal distribution model implemented in SEDFIT was used as 
described previously.18 
Sedimentation equilibrium experiments were performed at 20 °C with 0.1, 0.5, 1.0, 2.5, 
5.0, 10, and 20 mg/mL protein solutions at 5,000, 9,000 and 13,000 rpm. For 0.1, 0.5, 1.0, 
2.5, and 5.0 mg/mL, 100 µL sample was loaded into sample sector of the 12 mm 6-channel 
charcoal-filled epon centerpiece, and 110 µL buffer was loaded into the reference sector of 
the centerpiece. For 10 and 20 mg/mL sample, 25 µL sample was loaded into sample sector 
of the 3 mm double-sector charcoal-filled epon centerpiece, and 27.5 µL buffer was loaded 
into the reference sector of the centerpiece. Data were collected at sedimentation 
equilibrium at each rotor speed. The average data from eight scans were analyzed using 
Program SEDPHAT ver. 15.2c. 19, 20 
4.3.10 Small Angle X-ray Scattering 
SAXS data collection was performed at the EMBL beamline P12 at the Petra III storage 
ring (DESY, Hamburg). Data were collected at 0.5, 0.9, 2.5, 5.8, 7.1, 10.3, and 18.7 mg/mL 
in 6 mM sodium phosphate pH 6.2, 90 mM trehalose. A buffer was measured before and 
after each sample. The experimental details are shown in Table S2 in supplementary 
material. Pair-distance distribution function (p(r)) and all molecular parameters, including 
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radius of gyration (Rg), maximum dimension (Dmax), molecular weight (MW), were derived 
from the experimental data with the graphical data analysis program PRIMUSQT.21, 22 
4.3.11 Viscosimetry 
Viscosity measurements were performed on a ViscoSizerTD system (Malvern) at 20 °C. 
The capillary was flushed with water before applying the sample at a constant pressure of 
1500 mbar. Caffeine in water (1 mg/ml) was used as reference.  
 
4.4 Results 
4.4.1 Formulation development for self-interaction analysis of 
Infliximab 
At first, we performed a screening of Infliximab for self-interaction to identify formulations 
which are i) suitable for pharmaceutical application, ii) suitable for freeze-drying in order 
to expand the pharmaceutical application, use the process for simple water removal to 
initiate HDX-MS and iii) provide highly attractive interaction for detailed analysis and 
method evaluation. We observed an increased binding signal at low pH and low buffer 
concentration (Figure 1). In addition, trehalose up to a concentration of 90 mM did not 
influence the interaction, whereas the BLI signal was reduced at 120 mM trehalose. As the 
protein concentration should be higher in the reconstituted product to enable the dilution to 
the HDX assay concentration with D2O containing buffers, we performed lyophilization 
with a diluted formulation containing 20 mg/ml Infliximab in 2 mM sodium phosphate pH 
6.2, 30 mM trehalose. The lyophilized product was intended to be reconstituted in a third 
of the initial volume to a solution ending up in 60 mg/ml Infliximab in 6 mM sodium 
phosphate pH 6.2, 90 mM trehalose. The integrity of the mAb after lyophilization and 
reconstitution was confirmed by HPLC-SEC which indicates only 0.3% monomer loss and 
by CD spectroscopy which indicated structural integrity (Figure S1). 
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Figure 1 SI-BLI results of Infliximab to identify formulation conditions suitable for assessing SI behavior and 
lyophilization in 20 mM sodium phosphate at different pH values, in sodium phosphate buffer pH 7.2 
of different concentration, and in 5 mM sodium phosphate pH 6.2 at different trehalose 
concentrations. 
4.4.2 Characterization of self-interaction of Infliximab by DLS 
The apparent diffusion coefficient (Dapp) of Infliximab in the target formulation of 6 mM 
sodium phosphate pH 6.2, 90 mM trehalose was analyzed by DLS as a function of protein 
concentration in order to characterize the self-interaction processes (Figure 2). We 
observed a non-linear dependence with a strong decrease of the diffusion coefficient at 
protein concentrations below 2.5 mg/ml. 
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Figure 2  DLS results (apparent diffusion coefficient Dapp and polydispersity index PDI) of Infliximab from 1 to 
20 mg/ml in 6 mM sodium phosphate pH 6.2, 90 mM trehalose. 
4.4.3 Analysis of self-interaction and oligomerization of Infliximab by 
SAXS 
Subsequently we performed SAXS measurements of Infliximab in the target formulation 
at different concentrations. The intensity at low q-values increased with increasing 
concentration, pointing towards oligomerization (Figure 3A and B). Additionally, the shape 
of the p(r) function changed with concentration and an additional third peak at around 20-
25 nm was observed at higher concentrations flagging the formation of larger oligomeric 
species (Figure 3C). Furthermore the Rg, Dmax, and MW increased with increasing 
Infliximab concentration (Figures 3D, E, and F). At 18.3 mg/ml Dmax reached 60 nm which 
did not correspond to a monomer with approximately 15 nm23 or a dimer with 20 to 30 nm24 
Dmax and indicated the formation of large oligomeric species. 
As the first two peaks at approximately 5 and 9 nm of the p(r) profile, which are 
characteristic for an IgG23, 24, were preserved at higher Infliximab concentration, we 
hypothesize that the increasing in Rg, Dmax, and MW is related to the presence of distinct 
oligomers and not to unspecific aggregation. 
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Figure 3 SAXS data of Infliximab at different concentrations in 6 mM sodium phosphate pH 6.2, 90 mM 
trehalose. A) SAXS curves, B) zoomed view at low q values C) p(r) functions, D) Rg, E) Dmax, F) MW 
calculated from porod volume. 
4.4.4 Analysis of self-interaction and dimerization of Infliximab by AUC 
In a subsequent step, SV-AUC was performed to determine the size distribution of 
Infliximab species in solution (Figure 4). At low concentration of 0.5 mg/ml, Infliximab 
was monodisperse with a sedimentation coefficient (s20,w) of 6.6 S which is a typical value 
of an antibody monomer.25 At higher concentration of 5 mg/ml we observed two peaks with 
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6.6 S and 8.3 S which confirmed the observations reported by Lerch et al.16 The authors 
described a peak resolution between 6.6 S and 8.2 S at 0.6 mg/ml. However, 8.2 S and, in 
our case, 8.3 S do not represent a stable and fully dimerized antibody species, which would 
be expected to sediment at a higher sedimentation coefficient.25 These results indicate fast 
kinetics of the weak self-association process of Infliximab. The distribution of the solution 
at 20 mg/ml obtained by C(s) incorporating non-ideality was monodisperse with 8.3 S, 
which corresponds to Infliximab dimer. SE-AUC was performed to generate an equilibrium 
concentration gradient from which the apparent molecular weight reflecting the 
intermolecular interactions of Infliximab in solution can be deduced. The apparent 
molecular weight of Infliximab increased with concentration > 1 mg/ml which corresponds 
to the data acquired by DLS, SAXS and SV-AUC (Table 1). The apparent molecular weight 
increased to 272 kDa indicating the presence of dimeric species. With increasing the 
Infliximab concentration from 10 to 20 mg/ml the apparent molecular weight decreased 
from 272.0 kDa to 224.8 kDa which is consistent with the decrease in S observed in SV-
AUC. Additionally, at higher rotor speed of 9,000 and 13,000 rpm, the apparent molecular 
weight could not be determined at concentrations of 2.5 mg/ml and higher due to a strong 
increase in turbidity from the entire solution in the cell. This is reflected in decrease in light 
intensity at 350 nm at the cell bottom (supplemental material figure S2 and S3) suggesting 
formation of a highly concentrated Infliximab layer at the cell bottom. This layer may arise 
from a concentration dependent formation of higher order structures which we also 
observed by DLS and SAXS at protein concentrations of 20 mg/ml. Thus, AUC of full-
length Infliximab indicates dimerization of Infliximab in solution, which can be further 
oligomerize to fast dissociating higher order structures. The inverse of the apparent 
molecular weight was plotted against the protein concentration (Figure S4). This plot 
indicated differences in B22 below and above 2.5 mg/ml. Below this concentration 
threshold, a negative B22 was observed which indicated attractive interactions between 
Infliximab molecules. B22 was increased at concentrations above 2.5 mg/ml. 
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Table 1  Concentration dependent apparent molecular weight of Infliximab in 6 mM sodium phosphate pH 
6.2, 90 mM trehalose obtained by SE-AUC at different rotor speeds. 
Rotor Speed [rpm] 
Infliximab Concentration [mg/ml] 
0.1 0.5 1 2.5 5 10 20 
5,000 166.6 150.0 160.3 237.1 238.6 272.0 224.8 
9,000 146.4 154.4 164.2 n.d. n.d. n.d. n.d. 
13,000 143.7 154.0 n.d. n.d. n.d. n.d. n.d. 
Unit: kDa; n.d.: Not determined due to the turbidity at cell bottom 
 
 
Figure 4 Distribution of the sedimentation coefficient of Infliximab in 6 mM sodium phosphate pH 6.2, 90 mM 
trehalose obtained by SV-AUC. Non-ideal c(s) model was used for the analysis of the sedimentation 
profile obtained at 20 mg/ml Infliximab. 
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4.4.5 Viscosity as an indicator for attractive self-interaction of Infliximab 
A high self-interaction propensity of mAb molecules frequently correlates with increased 
viscosity at high protein concentrations.26–29 We observed an exponential increase in 
viscosity with increasing Infliximab concentration in 6 mM sodium phosphate pH 6.2, 
90 mM trehalose from 1.1 mPa*s at 1.0 mg/ml, which corresponds to the viscosity of the 
formulation buffer, to 10 mPa*s at 90 mg/ml (supplemental material figure S5). This 
increase in viscosity indicated the presence of higher order structures due to network 
formation. These results correspond to our observations from DLS, SAXS and SE-AUC, 
which also indicated large oligomeric species at elevated protein concentrations.  
4.4.6 Analysis of intermolecular interactions of Infliximab fragments by 
SI-BLI 
We wanted to understand, which of the three potential interactions, Fab-Fab, Fc-Fc or Fab-
Fc, is or are relevant. We therefore digested the IgG and performed experiments on the two 
fragments. After purification, SEC-MALS indicated 83.6 % purity of the 53 kDa Fc 
fragment which contains approx. 8% of a 110 and a 151 kDa species each as impurities and 
more than 98 % purity of the 51 kDa Fab-fragment. 
First, we captured the Fc fragment by using the anti-hFc capture biosensor. Thus, the Fc 
part was presented on the sensor surface. We did not observe further binding of Fc 
fragments during the association reaction (Figure 5). In contrast, binding of Fab fragment 
and the whole IgG was detected. Using the same biosensors, we captured the whole IgG 
and thus, presented the Fab region. We observed binding of Fc fragment and whole IgG. If 
we applied the Fab fragment as analyte, no association was seen. In summary, binding 
processes were identified in BLI assay set ups, where the Fc part was presented on the 
sensor surface and the Fab fragment was in solution or the Fab fragment was presented on 
the surface and the Fc part was in solution. In addition, we characterized the self-interaction 
in the SEC mobile phase used by Lerch et al. for SEC and AUC experiments.16 Self-
interaction was suppressed at pH 7.2 and the high ionic strength conditions and we only 
detected net attraction between captured IgG and Fc fragment or IgG in solution.  
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Figure 5  SI-BLI results for Infliximab fragments with either Fc or whole IgG as capture molecule in 6 mM 
sodium phosphate pH 6.2, 90 mM trehalose (□) and in 20 mM sodium phosphate, 400 mM sodium 
chloride (■). The association signals of Fab and Fc only reached a third of the binding signal of an 
IgG which reflects the difference in molecular size. 
We further performed experiments which involved a capture setup of the Fab fragment. We 
identified unspecific interactions of Fab, Fc and IgG with the anti-hFab biosensors in these 
experiments. Thus we could not distinguish clearly between non-specific binding to the 
underlying sensor, and Fab-Fab interactions in the absence of Fc or whole IgG. 
4.4.7 Analysis of intermolecular interactions of Infliximab fragments by 
AUC 
Additional AUC analyses were performed using the Infliximab Fab and Fc fragments to 
understand the interactions of Infliximab in solution. The maximum concentrations of 
34.3 M Fc (1.7 mg/mL) and 68.7 M Fab (3.3 mg/mL) tested correspond to 34.3 M 
Infliximab (5.0 mg/ml). At lower concentration of 0.33 mg/ml the Fab fragment was 
monodisperse with a sedimentation coefficient of 3.7 S (Figure 6A). At higher 
concentration of 3.3 mg/ml two peaks with 3.8 S and 4.7 S corresponding to monomer and 
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dimer were observed. Also Lerch et al. observed the shift in monomer dimer equilibrium 
of the Fab fragment at higher concentrations.16 We did not see an indication for attractive 
self-interaction of the Fc fragment (Figure 6B), which showed concentration independently 
3.9 S. In mixtures of Fab and Fc fragment, a slight shift of the 3.8 S peak to 4.0 S was 
observed. Additionally, the peak at 4.7 S was shifted to 4.9 S which points towards weak 
hetero association of Fab and Fc fragment (Figure 6C). We hypothesize that the 
dissociation of Fab and Fc fragments is fast, and therefore the Fab-Fc complex could not 
be observed as a distinct and well separated peak by SV-AUC.19 Additionally we conducted 
SE-AUC and did not observed the enrichment at the bottom of the cell, unlike for the full-
length Infliximab (Figure S2 A-F) Based on these AUC results, we can hypothesize that 
the self-interaction of infliximab occurs through association of Fab domains, and further 
oligomerization requires complete IgG molecules containing both, Fab and Fc domains. 
 
Figure 6  SV-AUC experiments of Infliximab-Fab and Infliximab-Fc fragment and mixtures thereof. A) Fab 
fragment at 6.87 μM and 68.7 μM (0.33 mg/ml and 3.3 mg/ml), B) Fc fragment at 3.43 μM and 34.3 
μM (0.17 mg/ml and 1.7 mg/ml). C) Fab, Fc and mixture of both at 68.7 and 34.3 μM respectively 
which corresponds to 5.0 mg/ml whole IgG molecule. 
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4.4.8 Identification of peptides involved in self-interaction of Infliximab 
by HDX-MS 
To identify amino acids or peptide sequences involved in the pronounced attractive self-
interaction of Infliximab in solution we compared the deuterium uptake incubation in D2O 
containing formulation buffer at low (0.5 mg/ml) and high protein concentration 
(20 mg/ml). As Infliximab tends to form larger structures at 20 mg/ml, we expected that 
peptides involved in the interaction should show a decreased deuterium uptake at high 
concentration. To challenge our data for reproducibility, we performed HDX-MS 
experiments at two different laboratories utilizing two different HDX-MS device settings 
regarding the MS setup, labeling and quenching conditions as described above. Comparing 
laboratory 1 and 2, we identified 615 and 1092 data points of peptides / corresponding 
labeling times respectively, reflecting approx. 90% sequence coverage in both setups. 
Statistical analysis of the data sets demonstrated comparable findings (Figure 7). We 
observed a significant decrease in deuterium uptake at 20 mg/ml Infliximab compared to 
0.5 mg/ml in the VH domain region (E50IRSKSINSATHYAESVKGRF70) and two regions 
of the CH domain of the Fc fragment (K329ALPAPIEKTISKAKGQPREPQV351 and 
V430MHEALHNHYTQKSLSLSPG449). In addition, we identified a region in the CL 
domain, (K149VDNALQSGNSQESVTEQDSKDSTYSLSSTL179). A list of peptides with 
significant differences in H/D uptake can be found as supplemental material (Table S1). 
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Figure 7  Overview of HDX-MS results. Infliximab was incubated in 6 mM sodium phosphate pH 6.2, 90 mM 
trehalose at 0.5 mg/ml and 20 mg/ml for various time frames. A) Volcano plot of results from 
laboratory 1; B) Volcano plot of results from laboratory 2; C) Annotation of regions with significant 
differences in H/D exchange on a homology model of Infliximab (pdb: 1HZH) 
 
4.5 Discussion 
4.5.1 Analysis of Infliximab self-interaction on protein resolution level 
We chose Infliximab as a model system because the self-interaction process of this protein 
was described for in-solution conditions and in a solid crystalline state.16 But the 
formulations used in literature were not of pharmaceutical relevance as they were either 
SEC mobile phases or crystallization inducing buffers. Thus we searched for a 
pharmaceutical formulation which enabled the analysis of the self-interaction behavior and 
which was capable of lyophilization. SI-BLI revealed insights into the pH dependence of 
A multi-method approach to assess the self-interaction behavior of Infliximab 
 
 
78 
 
 
the self-interaction process of Infliximab and indicated the effect of buffer and trehalose 
concentration. Based on that, we developed a formulation that displayed the wanted 
features.  
Light scattering techniques such as DLS and SAXS8, 30, 31 are established methods for 
analyzing protein-protein interactions and were used in this study to determine self-
interaction behavior of Infliximab on a protein level. DLS provides the apparent diffusion 
coefficient of a scattering agent whereas SAXS can provide the radius of gyration. By 
analyzing both physical parameters in a concentration dependent manner, attractive 
protein-protein interactions are indicated by an increase in size with concentration. 
Our results indicated attractive interactions between mAb molecules in solution. Usually, 
reversible self-interaction processes analyzed by DLS include the calculation of the 
diffusion interaction parameter kD. This parameter contains both, a thermodynamic as well 
as a hydrodynamic term.32 At low protein concentration and in our case at low ionic strength 
the hydrodynamic effects may cause the non-linearity. Additionally, the SV-AUC (Figure 
4) and SAXS results (Figure 3) indicated that Infliximab tends to specifically dimerize at 
protein concentration above 2.5 mg/ml, which results in a heterogeneous solution at higher 
protein concentration. Due to this association as a function of concentration, it was not 
possible to differentiate between unspecific self-interaction, which is represented by kD and 
dimerization of Infliximab by the light scattering signal.33, 8 To this end, we refrained from 
including quantitative values.. With SAXS, we observed an increase of the radius of 
gyration and of the molecular weight at a protein concentration of 20 mg/ml indicating 
oligomerization of Infliximab at higher concentration. Furthermore, the characteristic 
features from antibodies were still present in the p(r) function suggesting conserved 
structure and no unspecific aggregation. The increase in Rg and Dmax pointed into the 
direction of very large, oligomeric species. The presence of such oligomers may explain 
the increase in turbidity observed in SE-AUC experiments. 
In addition to DLS and SAXS, we performed AUC as a powerful method to assess the 
intermolecular interaction of macromolecules.34–36 A weak reversible self-association of 
Infliximab IgG was confirmed by SV-AUC and SE-AUC at a protein concentration above 
2 mg/ml, where the results indicated an apparent molecular weight corresponding to a 
dimeric species. This dimeric species is predominant at concentrations between 2 and 
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20 mg/ml. It should be noted that at 20 mg/mL a single species was observed at 6.8S by 
C(s) for non-interacting systems while this species takes 8.3S by non-ideal C(s) analysis, 
corresponding to dimer of Infliximab IgG. At higher rotor speeds, we observed a decrease 
in light transmission towards the cell bottom in SE-AUC which can be explained by further 
intermolecular interactions.  
In fact, the apparent molecular weight in SE-AUC becomes higher than that of a monomer 
when the initial concentration is above 1 mg/mL, indicating the formation of oligomers. At 
higher concentrations like 5 mg/ml, the apparent molecular weight reached at a value close 
to dimer, while light scattering (turbidity) which is a sign of the formation of large 
oligomers was detected at the bottom of the cell. The volume of the region where light 
scattering is confirmed increases as the initial concentration and/or the speed of rotation 
increases. Thus SV-AUC demonstrated Infliximab dimerization while didn’t form further 
large oligomers. B22 reflects these observation as was negative below 2.5-5 mg/ml and 
slightly positive over 5 mg/ml. 
Also Nishi et al. reported the property of liquid-liquid phase separation (LLPS) for a mAb 
.37 
MAbs with LLPS tendency exist as monomer and small oligomers at low concentration at 
which LLPS does not occur. Above a certain concentration LLPS can be noted, as in 
addition to monomer and small oligomers, higher oligomers emerge. These higher 
oligomers form a phase that has slightly higher density than a phase composed from 
monomer and small oligomers. Under gravity force, formation of LLPS takes long time. It 
can be accelerated by centrifugation because higher oligomers sediment faster to the 
bottom, leading to the formation of a heavy lower phase, and higher oligomers are depleted 
in the upper phase solution corresponding (Figure 8). These higher order structures were 
also observed by SAXS reflected by the increase in Dmax and Rg. Additionally, these 
oligomeric interactions trigger the formation of networks, which cause the increase in 
viscosity. Our data show, that the dimerization of Infliximab is not the final state of the 
self-interaction process. Whereas SV-AUC showed that the dimer is stable at 20 mg/ml, a 
further increase in concentration confirmed the additional oligomerization and also lead to 
the increase in the viscosity (Figure S5). 
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Figure 8  Schematic overview of phase separation behavior of Infliximab IgG under centrifugal force for the 
solution below 20 mg/ml. 
4.5.2 Analysis of Infliximab self-interaction on fragment resolution level 
For a more detailed understanding of the self-interactions processes, the characterization of 
the Infliximab Fab and Fc fragments was performed after digestion of the native protein. 
Several studies showed results based on analysis of self-interaction mechanisms of 
fragments.5, 6, 8  Kanai et al demonstrated that the increase in viscosity of a Fab only 
containing solution was comparable to the solution of the corresponding full length IgG.5 
Nishi et al. showed that a liquid liquid phase separation of a mAb was mainly driven by 
attractive electrostatic interactions of Fc fragments.6 Fab-Fc interactions were identified as 
self-interaction mechanism by Arora et al., demonstrated by HDX-MS experiments.7 For 
Infliximab, Lerch et al proposed a Fab-Fab based self-interaction process based on their 
crystallization, AUC and SEC data.16 All these references differed in their solution 
conditions. To this end, we aimed to understand how the formulation affects Infliximab 
self-interaction and what are the processes occurring in solutions. We used SI-BLI with 
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captured IgG or Fc fragment on the sensor, and Fab, Fc or native IgG as analyte in solution. 
A marked attractive interaction of captured Fc with Fab or IgG in solution, as well as of 
captured IgG with IgG or Fc in solution was observed. Thus, Fab and Fc fragments are 
involved in the self-interaction process of Infliximab. For further elucidation, we performed 
SV-AUC experiments. The Fab fragment dimerized at higher protein concentration, 
whereas the Fc fragment was in its monomeric form at both concentrations. In a Fab Fc 
mixture, we observed a small shift of the Fc and Fab as well as the Fab-Dimer peak to 
higher S-values indicating a weak reversible association of Fab-Fc that may coexist with 
Fab homodimers. Upon concentration during the centrifugation process, only the IgG 
preparation showed turbidity indicating that the IgG format itself provided interaction sites 
responsible for larger network formation. 
Thus, Fab fragments tended to form concentration dependent dimers in AUC, but IgG-Fab 
interaction was not observed by SI-BLI. Fab-Fab interaction could not be studied with SI-
BLI for technical reasons. Both methods demonstrated Fab-Fc interaction. Additionally, 
pronounced oligomerization resulting in the marked accumulation of large protein 
structures at the cell bottom did occur with Infliximab but not in the Fab-Fc mixture. Thus, 
AUC demonstrated that attractive interactions may not occur in mixtures of Fab and Fc 
fragments to the same extent and by the very same mechanism as for the full-length mAb. 
On the same account, we did not find IgG-Fab interactions in SI-BLI. As identified by X-
ray crystallography, the Fab tends to form dimers via head-to-tail orientation.16 Potentially 
this head-to-tail interaction process cannot proceed after capturing the IgG on a biosensor, 
or the “tail”-epitope is not accessible in the complete IgG molecule. Overall, we 
demonstrated that Fab-Fc interactions substantially contribute to the Infliximab self-
interaction in solution, on top of the Fab-Fab interactions previously identified. 
4.5.3 Analysis of Infliximab self-interaction on peptide resolution level 
Lerch et al. identified distinct regions within the Fab fragment by X-ray crystallography 
that are involved in the self-interaction process of Infliximab. We aimed to identify the 
sequences, which trigger the self-interaction in solution in particular after the detection of 
Fc involvement by AUC and BLI measurements. In addition, we targeted for a method, 
which overcomes the challenge of having results obtained by methods performed under 
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artificial conditions and the interactions in the pharmaceutically relevant formulation 
applied to the patient. To this end, we chose HDX-MS as a high resolution technique which 
can be operated under native circumstances. HDX-MS is an emerging techniques to 
understand higher order structures of proteins, targeted mutations or chemical 
modifications.7, 38, 39 This technique is also used in epitope mapping, where the binding 
affinity is usually high.40, 14 In addition, HDX-MS can be used to examine low affine mAb 
self-interaction.7, 41, 15 Correspondingly, we compared the H/D exchange of Infliximab in 
the monomeric state at 0.5 mg/ml and in the oligomerized state at 20 mg/ml. 
By analyzing overlapping peptides for the identified heavy chain region, we identified the 
four residues H61YAE64 as present in all peptides that showed significant differences in 
deuterium uptake. By SI-BLI we showed that the attractive interaction of Infliximab was 
more pronounced at pH 6.2 compared to pH 7.2 and pH 8.2. Thus, H61 may play an 
important role in the self-interaction process as this residue gets deprotonated at pH 7.2 
then becoming a surface exposed neutral residue. E64 is deprotonated at pH 6.2. We 
therefore hypothesize that the protonated state of H61, together with deprotonated E64 can 
interact with other domains via electrostatic interactions or hydrogen bonding. We further 
identified a region in the CH2 domain of Infliximab Fc fragment 
(K329ALPAPIEKTISKAKGQPREPQV351) which showed less deuterium uptake at higher 
protein concentration. This area contains several electron-rich residues like proline and 
glutamic acid. These residues might interact with H61 and E64 at pH 6.2 until H61 gets 
deprotonated at pH 7.2 and hydrogen bonds are destabilized. In addition, the C-terminus of 
the IgG heavy chain (V430MHEALHNHYTQKSLSLSPG449) showed significant 
concentration dependent differences in H/D exchange, confirming that the Fc region is 
involved in self-interaction as well. As this area contains several histidine residues, the state 
of protonation might be the trigger for the self-interaction processes of Infliximab. Within 
the light chain of Infliximab Fab fragment we identified a region consisting of 30 residues 
(K149VDNALQSGNSQESVTEQDSKDSTYSLSSTL179) that showed differences in 
deuterium uptake at high protein concentration. This region contains several polar amino 
acids like serine and threonine that are accessible for hydrogen bonding. Because the 
identified peptides of this region were not well overlapping, a more detailed differentiation 
might be too speculative.  
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The regions identified by HDX-MS differ from the sites identified by X-ray 
crystallography. Thus, the identified self-interactions sites differ between processes present 
in solution and in a crystal. This indicates the importance of analysis interaction processes 
by a multi-method approach where various results contribute to the overall picture of a self-
interaction mechanism. 
In summary, our results indicate that Infliximab self-interaction in solution is driven by a 
combination of Fab-Fab and Fab-Fc interactions under conditions which are relevant for 
pharmaceutical formulations. A possible self-interaction process may start with Fab-Fab 
interactions leading to dimerization. These dimers can further oligomerize by weak Fab-Fc 
interactions at higher protein concentration. This higher order oligomerization was only 
observed in the presence of complete IgG molecules which may indicate conformational, 
sterical and avidity effects contributing to the self-interaction mechanism. Our results 
complement published data which showed Fab-Fab interaction of Infliximab only. Lerch 
et al. performed the analysis at high ionic strength for crystallization of Fab fragments 
followed by X-ray structure determination. The protein crystals are 1) a solid state and 2) 
did not contain the whole IgG molecule. Here, we present a study in a pharmaceutically 
relevant formulation considering the whole IgG molecule. We assume that the use of a 
multi-method approach containing analyses of intact IgG, fragments and peptides led to a 
clearer picture of the self-interaction process. We found that mAb self-interaction is not 
only dependent on the protein structure, but that the formulation buffer itself can influence 
the self-interaction mechanism. Depending on the environment of the molecule, different 
sites can be involved in self-interaction which may explain the differences between findings 
of crystallography and in-solution methods. We assume that the ionic strength and the pH 
impact the nature of the interaction sites. By increasing the ionic strength of the 
formulation, charge shielding might reduce the ability to form hydrogen or electrostatic 
bonds between Infliximab molecules. For crystallization, the ionic strength is higher and 
the protein concentration might further increase during the process of crystal growth. This 
might increase the probability for hydrophobic interactions because the distance between 
the molecules becomes smaller. In solution, where the protein concentration is lower, 
electrostatic interactions are more pronounced than hydrophobic forces.2 The interplay 
between the solution parameters and specific residues of the protein also may explain why 
even for proteins which are prone to self-interact, formulation development or rational 
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engineering can both be successful strategies for developing stable high concentration 
liquid formulations.  
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Figure S1  CD spectra of Infliximab formulations before lyophilization in 2 mM sodium phosphate pH 6.2, 
30 mM trehalose and after reconstitution in 6 mM sodium phosphate pH 6.2, 90 mM trehalose. 
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Figure S2:  Observation of turbidity in sedimentation equilibrium by A350 measurement;  
(A-F) Infliximab Fab, Fc and Fab-Fc mixture (sedimentation equilibrium at 5,000 rpm).  
(A) Fab (6.87 µM)-Fc (3.43 µM) mixture, (B) Fab (6.87 µM), (C) Fc (3.43 µM), (D) Fab (68.7 µM)-
Fc (34.3 µM) mixture, (E) Fab (68.7 µM), (F) Fc (34.3 µM).   
(G-J) Full-length Infliximab (sedimentation equilibrium at 9,000 rpm). 
(G) 2.5 mg/mL, (H) 5 mg/mL, (I) 10 mg/mL, and (J) 20 mg/ml. 
(K-O) Full-length Infliximab (sedimentation equilibrium at 13,000 rpm). 
(K) 1 mg/mL, (L) 2.5 mg/mL, (M) 5 mg/mL, (N) 10 mg/mL, and (O) 20 mg/ml. 
Data for (I), (J), (O) and (N) were obtained in 3mm path centerpiece, and the rest were obtained in 
12 mm path centerpiece. 
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Figure S3  Sedimentation equilibrium profiles of Infliximab with non-linear fitting analysis and residual plots. 
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Figure S4  Inverse plot of molecular weight at each sample concentration  
 
 
Figure S5  Viscosity as a function of protein concentration. Infliximab was analyzed in 6 mM sodium phosphate 
pH 6.2, 90 mM trehalose.  
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Table S1  List of peptides with significant decrease in H/D uptake at 20 mg/ml compared to 0.5 mg/ml 
Infliximab 
  Protein Star
t 
End Sequence Exposur
e time 
[min] 
ΔHX 
[Da] 
p-value 
L
a
b
o
ra
to
ry
 1
 Heavy 
chain 
48 64 VAEIRSKSINSATHYAE 10 -0,32 0,002 
50 70 EIRSKSINSATHYAESVKGRF 10 -0,33 0,005 
51 62 IRSKSINSATHY 10 -0,31 0,003 
51 64 IRSKSINSATHYAE 10 -0,38 0,001 
51 64 IRSKSINSATHYAE 60 -0,37 0,001 
238 255 LGGPSVFLFPPKPKDTLM 1 -0,32 <0,001 
329 351 KALPAPIEKTISKAKGQPREPQV 10 -0,52 <0,001 
430 449 VMHEALHNHYTQKSLSLSPG 10 -0,46 0,006 
430 449 VMHEALHNHYTQKSLSLSPG 60 -0,37 0,006 
Light 
chain 
149 172 KVDNALQSGNSQESVTEQDSKD
ST 
60 -0,31 <0,001 
155 161 QSGNSQE 1 -0,45 0,003 
L
a
b
o
ra
to
ry
 2
 
Heavy 
chain 
60 70 THYAESVKGRF 10 -0,32 0,003 
60 70 THYAESVKGRF 60 -0,40 0,005 
427 449 SCSVMHEALHNHYTQKSLSLSPG 10 -0,36 0,002 
427 449 SCSVMHEALHNHYTQKSLSLSPG 60 -0,43 0,001 
Light 
chain 
136 161 LNNFYPREAKVQWKVDNALQSG
NSQE 
3 -0,29 <0,001 
136 161 LNNFYPREAKVQWKVDNALQSG
NSQE 
10 -0,29 0,003 
144 161 AKVQWKVDNALQSGNSQE 10 -0,28 <0,001 
162 172 SVTEQDSKDST 3 -0,28 0,001 
162 179 SVTEQDSKDSTYSLSSTL 1 -0,27 <0,001 
162 179 SVTEQDSKDSTYSLSSTL 60 -0,29 0,002 
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Table S2   SAXS - experimental details 
Instrument P12 BioSAXS beamline (PETRAIII) 
Date 12th July 2019 
Detector Pilatus6m 
Wavelength (nm) 1.23981 
Beam size (mm2) 0.2 × 0.12 
Detector distance (m) 4.0 
q-measurement range (nm-1) 0.017- 5.506 
Absolute scaling method Comparison with scattering from BSA 
Normalization To transmitted intensity by beam-stop counter  
Monitoring for radiation 
damage 
Frame-by-frame comparison 
Exposure time (s) 20 x 0.195 
Sample configuration Quartz glass capillary 
Sample temperature (ºC) 20 
c) Software employed for SAXS data reduction, analysis and interpretation 
SAS data reduction PRIMUSqt29 from ATSAS 2.8.330  
Basic analyses: Guinier, p(r), 
VP 
PRIMUSqt29  
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Chapter 5 Generation of mAb variants with less 
attractive self-interaction but preserved target 
binding by well-directed mutation 
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5.1 Abstract 
Strongly attractive self-interaction of therapeutic protein candidates can impose challenges 
for manufacturing, filling, stability and administration due to elevated viscosity or 
aggregation propensity. Suitable formulations can mitigate these issues to a certain extent. 
Understanding the self-interaction mechanism on a molecular basis and rational protein 
engineering provides a more fundamental approach, and it can save costs and efforts as 
well as alleviate risks at later stages of development. In this study, we used computational 
methods for identification of aggregation prone regions in a mAb and generated mutants 
based on these findings. We applied hydrogen-deuterium exchange mass spectrometry to 
identify distinct self-interaction hotspots. Ultimately, we generated mAb variants based on 
a combination of both approaches and identified mutants with low attractive self-interaction 
propensity, minimal off-target binding and even improved target binding. Our data show 
that the introduction of arginine in spatial proximity to hydrophobic patches is highly 
beneficial on all these levels. For our mAb, variants which contain more than one aspartate 
residue flanking to the hydrophobic HCDR3 show decreased attractive self-interaction at 
unaffected off-target and target binding. The combined engineering strategy described here 
underlines the high potential of understanding self-interaction in early stages of 
development to predict and reduce risk of failure in subsequent development. 
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5.2 Introduction 
By the end of 2019, more than 80 antibody therapeutics reached the biopharmaceutical 
market in US or EU.1 The design of suitable candidate molecules and their formulation play 
a pivotal role in every stage of discovery and development. In general, a formulation must 
ensure chemical, conformational and colloidal protein stability. The latter objective is 
strongly influenced by the self-interaction of the protein molecules. This challenge is 
enhanced in case of high concentration protein, specifically monoclonal antibody (mAb) 
formulations which are increasingly demanded for subcutaneous self-application by 
patients and for other convenience and safety reasons. Protein aggregation can arise from 
native oligomers as a result of strong attractive self-interaction.2 Self-interaction of mAbs 
can be associated with an extreme increase in viscosity at higher concentration3–5, a higher 
tendency for aggregation due to increased frequency of intermolecular collisions6 and filter 
clogging and fouling.7 
Several studies showed that self-interaction processes of mAbs are diverse and can be 
triggered by Fab-Fab, Fab-Fc or Fc-Fc interactions.4, 8–15 These interactions can be driven 
by both electrostatic and hydrophobic forces.12, 16, 17 Thus, formulation strategies can be 
applied to reduce the self-interaction propensity of a mAb. Ionic excipients like sodium 
chloride and arginine hydrochloride disrupt the self-interaction processes by either charge 
shielding or hydrophobic interactions and therefore reduce solutions viscosity.18–22 
Additionally, the solutions pH has a strong impact on the solvent accessible charges of a 
mAb and thus on self-interaction.10, 22-24 
Another approach to influence the propensity of a mAb to self-interact reversibly is rational 
mutagenesis. Data from in silico modeling or in vitro experiments can help to identify 
critical sites or residues in the protein, and thus set the basis for planning a rational 
engineering strategy.9,17,25,26 Applying computational methodologies for calculation of 
aggregation prone regions led to antibody variants with high solubility and lowered 
viscosity at high protein concentrations. However, these tools address the aggregation 
prone regions and not discrete sites for reversible self-interaction. Additionally, mutations 
addressing unequal charge distributions on the mAb surface improved the physicochemical 
properties of a less soluble mAb.17 
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Besides computational tools, emerging techniques for studying mAb self-interaction such 
as HDX-MS have driven rational engineering.9 Geoghegan et al. introduced mutations in 
protein regions, which were identified as self-interaction sites by HDX-MS.27 Some of the 
mAb variants showed improved solution properties, whereas others showed a decrease in 
target binding or conformational stability. The prediction of self-interaction sites based on 
crystal structures was also used for rational mutagenesis of mAbs.26, 28 The mAb CNTO607 
is a model mAb with low solubility and high self-interaction propensity.25, 29, 30 For this 
mAb, a hydrophobic triad within the HCDR3 was shown to mediate self-interaction. But 
mutations within this region compromised target binding affinity.25, 29, 30 
In addition to mAb low self-interaction propensity and high target affinity, minimized off-
target binding plays an important role for characterization and selection of drug candidates 
and needs to be considered upon mutation. As recently reviewed by Starr and Tessier, 
antibody specificity is a key property to optimize mAb therapeutics.30 In a study of 137 
antibodies, specificity measurements identified advantages of approved mAbs compared to 
mAbs currently under clinical investigations.31 
Here, we present a study on a mAb directed against Estradiol-decorated BSA as a model 
IgG protein which was derived from a fully human phage library.32 This mAb exhibits only 
one of the three desired features, namely high affine target binding, but shows several 
unwanted properties like precipitation in PBS during downstream processes, significantly 
higher retention time in SEC analysis compared to other mAbs and strong off-target 
binding.33 Goal of this study was to understand the mAbs aberrant behavior and to find 
solutions based on rational mutagenesis. To maintain the paratope and thus, the antigen 
binding capacity of the mAb, we first determined the target binding site by HDX-MS. We 
analyzed the self-interaction propensity of the mAb by self-interaction bio-layer 
interferometry (SI-BLI) and found significant effects for pH and ionic strength. We used 
this knowledge for protein surface analysis to identify hydrophobic patches and aggregation 
prone regions, which could be potentially involved in reversible self-interaction. HDX-MS 
was additionally applied to identify distinct self-interaction sites. After identification of 
potential self-interaction hot spots by in silico and in vitro experiments, mutations were 
introduced to experimentally verify these predictions and resolve the described issues. In 
total, 39 mAb variants were generated and subsequently characterized regarding self-
interaction, target binding and off-target binding. Thus we could gain a deeper 
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understanding of the self-interaction process of our model mAb and identify variants with 
improved specificity by combining both, in silico and in-vitro based rational engineering. 
5.3 Experimental section 
5.3.1 Materials 
Phosphate buffered saline (Thermo Fisher Scientific, MA), L-histidine (Merck KGaA, 
Germany), sodium chloride (Carl Roth GmbH + Co. KG, Germany), hydrochlorid acid 
(Merck KGaA, Germany), L-Arginine (Merck KGaA, Germany), trehalose dihydrate 
(Pfanstiehl Technologies, Waukegan, IL) were all of analytical grade. 
5.3.2 mAb Cloning 
DNA of variants containing mutations in the CH and VH variants with mutations next to 
restriction sites (HCDR1 or 3) were prepared via mutagenesis PCR. Other DNA strings 
were purchased (Thermo Fisher Scientific, MA). For Gibson assembly®, DNA strings 
were designed with a 21bp overlap next to restriction sites. 
The vectors were prepared via restriction digest followed by dephosphorylation with 
shrimp alkaline phosphatase and agarose gel purification prior to the Gibson cloning. After 
Gibson cloning, the DNA constructs were transformed in chemically competent DH5alpha 
competent E. coli cells and then checked via colony PCR sequencing. From the correct 
clones, Miniprep Plasmid DNA was prepared and sequenced. After consolidation via 50 pg 
retransformation, the final Plasmid Maxi prep DNA was transferred for transfection and 
expression of the constructs in HEK293 cells. 
5.3.3 mAb Production 
For large scale production, the wildtype mAb was expressed in HKB11 stable pool 
expression system for 6 days. Cell culture supernatant was applied to a MabSelect SuRe 
column with a column volume (CV) of 32 ml (Cytiva, MA) equilibrated with 0.1 M sodium 
phosphate pH 6.0 (NaPhos pH 6). Three washing steps were performed (wash 1: 5 CV 
NaPhos pH 6, wash 2: 5 CV NaPhos pH 6 + 1.5 M sodium chloride, wash 3: 5 CV NaPhos 
pH 6). Product was eluted with 0.1 M sodium acetate pH 3.0. Protein containing fractions 
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were pooled and adjusted to pH 5 with 2 M sodium acetate. The concentration was 
determined by UV absorbance at 280 nm (molar extinction coefficient 211580 M-1 cm-1, 
146.6 kDa) using Nanodrop 2000 (Thermo Fischer Scientific, MA). 
The protein containing pool was subjected to buffer exchange using Sephadex G-25 in PD-
10 desalting columns (Cytiva, MA) to the final formulation buffer (15 mM histidine 
hydrochloride pH 6.0). The concentration was determined by UV absorbance and adjusted 
to 20 mg/mL utilizing Amicon Ultra 15 centrifugal filter units (50 kDa cut-off, 
Merck KGaA, Germany). The final product was sterile filtered using a 50 mL Steriflip 
(Merck KGaA, Germany). 
The protein variants were expressed in small scale in HEK293 cells for 6 days after 
transfection. Cell culture supernatants were applied to HiTrap MabSelect SuRe columns 
(Cytiva, MA) installed on an Äkta Xpress system equilibrated with NaPhos pH 6. Three 
washing steps were performed (wash 1: 5 CV NaPhos pH 6, wash 2: 5 CV NaPhos pH 6 + 
1.5 M NaCl, wash 3: 5 CV NaPhos pH 6). Product was eluted with 0.1 M sodium acetate 
buffer pH 3 and protein containing fractions were pooled without pH adjustment. The 
protein containing pools were subjected to buffer exchange using Sephadex G-25 in PD-10 
desalting columns (Cytiva, MA) to the final formulation buffer (15 mM histidine 
hydrochloride pH 6.0). The concentration was determined by UV absorbance at 280 nm 
using an average molar extinction coefficient of 208356 M-1 cm-1 and an average molecular 
weight of 146.6 kDa using Nanodrop 2000 (Thermo Fischer Scientific, MA). The final 
products were sterile filtered using Microsep Advance Centrifugal Devices (PALL, NY). 
5.3.4 SI-BLI 
The SI-BLI method was performed as previously described.34 Anti-hIgG Fc capture (AHC) 
biosensors (FortèBio, CA) were used to assess antibody self-interaction on an Octet QK384 
or HTX system (FortéBio, CA). In the first assay step, a baseline was established in 15 mM 
histidine hydrochloride pH 6.0 for at least 60 s, followed by capture of the mAb of interest 
at 25 nM in 15 mM histidine hydrochloride until the BLI signal increased by approximately 
1 nm. Remaining binding capacity of the capture sensors was saturated for 300 s with 1 μM 
of human Fc in PBS. Subsequently, a second baseline was acquired in the formulation 
composition of interest for 500 s, followed by an association step with 2 μM mAb in the 
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same formulation of interest for at least 1200 s. The response at equilibrium was used for 
further calculations. To compensate for differences in the amount of captured mAb, the 
equilibrium binding signal obtained during self-interaction was normalized to the amount 
of captured mAb (Rrel, equation 1). 
𝑅𝑟𝑒𝑙 =
𝑅𝑒𝑠𝑝𝑜𝑛𝑠𝑒𝐴𝑠𝑠𝑜𝑐𝑖𝑎𝑡𝑖𝑜𝑛 𝑒𝑞𝑢𝑖𝑙𝑖𝑏𝑟𝑖𝑢𝑚 [𝑛𝑚]
𝑅𝑒𝑠𝑝𝑜𝑛𝑠𝑒𝑐𝑎𝑝𝑡𝑢𝑟𝑒 𝑠𝑡𝑒𝑝[𝑛𝑚]
 
(1) 
5.3.5 HDX-MS 
HDX-MS experiments were performed on a fully automated system equipped with a Leap 
robot (HTS PAL, Leap Technologies, NC), a Waters Acquity NanoUPLC, a HDX manager 
and the Synapt G2-Si mass spectrometer (Waters, MA).35 For ionization in positive mode 
(300-2000 m/z) a capillary voltage of 3.0 kV, a desolvation gas flow of 500 L/hr, a source 
temperature of 80°C and a desolvation temperature of 250°C was applied. Sampling cone 
and offset was set to 40.0 and 50.0, respectively. Peptide elution occurred using a gradient 
from 10-60% (B) within 8.5 min followed by a 1.5 min gradient from 60-95% (B) prior a 
reconditioning-step. Peptides were identified via MSE using a collision energy ramp from 
10-45 eV. 
5.3.6 Paratope mapping 
For determination of the antigen binding site of the mAb, HDX-MS analysis was performed 
for the antigen-antibody complex and for mAb only. 1:10 dilutions of complex (3.7 µM 
antigen and 6.8 µM mAb) and mAb only (6.8 µM) in 15 mM histidine DCl pH 5.0 were 
incubated for 1, 10, 60 and 240 min at 25°C. After incubation in D2O containing buffer, the 
labeling reaction was quenched by 1:1 dilution with quenching buffer (0.1 M potassium 
phosphate pH 2.6, 0.2 M TCEP, 4 M guanidine hydrochloride). For proper denaturation, 
the solution was incubated under quenching conditions for 1 min at 2.0 °C. Afterwards, 
50 µl of the solution were directed to a pepsin column for online digestion at 15°°C (Waters 
Enzymate 300 Å, 5 µm; 3 min, 0.1 ml/min 0.1 % formic acid in H2O). Peptides were 
trapped (Waters VanGuard C18) and subsequently separated on a Waters UPLC column at 
0 °C (Waters Acquity UPLC, BEH C18, 130 Å, 1.7 µm).36 Eluting peptides were directed 
Generation of mAb variants with less attractive self-interaction but preserved target binding 
by well-directed mutation 
 
102 
 
 
into a Synapt G2-Si TOF mass spectrometer by electrospray ionization (Waters, MA). 
Before fragmentation by MSE and mass detection in resolution mode, the peptide ions were 
additionally separated by drift time within the mobility cell. Data processing was performed 
using the Waters Protein Lynx Global Server PLGS (version 2.5.3) and DynamX 
(version 3.0). Each incubation time point was measured in triplicates. Statistical analysis 
of significant differences was performed using Hybrid Significance Testing as described.37  
5.3.7 Self-interaction sites mapping 
For determination of self-interaction sites, the protein stock solutions (180 mg/ml) were 
diluted 1:3 with 15 mM Histidine-DCl pH 7.0 to 60 mg/ml for high concentration condition 
and to 0.5 mg/ml for low concentration condition. After incubation for 0, 2 and 10 min, 
samples were analyzed and processed as described above. As control experiment, labeling 
was performed in 15 mM Histidine-DCl pH 5.0 because self-interaction propensity was 
low under these conditions.  
5.3.8 Protein surface analysis 
Homology models of the wildtype mAb were generated by using BioLuminate 
(Schrödinger Release 2018-2, Schrödinger LLC, NY, 2015). As template structure, an 
already published crystal structure derived from a HuCAL phage display library was used.38 
The knowledge based approach was used for model building. A further preparation of the 
structure was carried out by checking for missing side chains, overlapping H-bonds and 
false molecule geometry. A restrained minimization using the OPLS3e force field was 
performed. The Protein Surface Analyzer Tool in combination with AggScore calculation 
was used to identify aggregation prone regions and hydrophobic patches.39 
5.3.9 Protein panel profiling 
The method was essentially performed as described before.33 Briefly, off-target binding of 
IgG samples was assessed in a plate-based assay, using electrochemiluminescence readout. 
A panel of 32 proteins and controls was coated onto two MSD standard 384-well plates per 
assay, each row coated with one protein or control. Subsequently, the plate was blocked 
with 3 % (w/v) BSA in PBS. The coated proteins and samples included highly abundant 
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serum proteins, different cytokines and cell-surface receptors, proteins bearing different 
post-translational modifications (phosphorylation, glycosylation), representatives for 
different pI values (ranging from 2.8 to 10.7), and vesicles prepared from HKB11 cells and 
Baculovirus particles40. Additionally, Protein A, anti-human Fc and anti-human Fab 
antibodies, lysozyme and target proteins of the sample IgGs, as well as blank rows were 
included as controls. Each IgG sample was assessed at 10 and 100 nM. For referencing 
purposes, an anti-lysozyme antibody was included known to show negligible non-specific 
binding. ECL-labeled anti-human Fab antibody was added for detection, and ECL-signals 
detected using a Sector Imager S 600 instrument (Meso Scale Discovery, MD). Binding 
signals were divided by the signal of the reference mAb on the same protein. The sum of 
binding ratios on all off-target probes (i.e. excluding specific antigens and controls) were 
used as a metric for off-target binding of the respective IgG. 
5.3.10 BLI for target binding 
BLI assays were performed on an Octet HTX system (FortéBio, CA) using Streptavidin 
sensors (Fortébio, CA) loaded with 3 µg/ml biotinylated MabSelect SuRe Ligand (Cytiva, 
MA) for 600 s followed by quenching for 5 min with 20 µg/ml biocytin (Merck KGaA, 
Germany) in PBS. PBS containing 0.05 % polysorbate 20 and 1 % (w/v) BSA was used as 
assay buffer. 5 µg/mL IgG was captured on several sensors in parallel, until a capture level 
of 0.8 nm was achieved. Subsequently, association of a 3-fold serial dilution series of 
estradiol-BSA (0.2 – 150 nM) was monitored for 300 s; dissociation was recorded for 300 s. 
After each interaction, captured IgG including bound estradiol-BSA was removed from the 
sensor with an acidic regeneration (Glycine-HCl pH 1.5; 3 steps à 30 s). Signals recorded 
on sensors with captured IgG but without estradiol-BSA were used for reference 
subtraction.  
Each assay was performed in triplicates. Raw data were preprocessed using the Octet Data 
Analysis HT 10.0 software (FortéBio, CA), and evaluated using Xlfit software (IDBS, 
MA). Binding signals at the end of the association were plotted against analyte 
concentrations, and fitted to a steady state model. Due to the multivalent and unknown 
coupling ratio of estradiol-BSA, i.e. unknown valency of binding sites per molecule, only 
an apparent KD value could be obtained, i.e. an apparent affinity including avidity. 
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5.3.11 Viscosity determination 
Viscosity measurements were performed on a ViscoSizer TD system (Malvern, UK). The 
sample is automatically pumped through a capillary under constant pressure. Viscosity is 
calculated relative to a caffeine standard (1 mg/l in H2O) depending on the time needed to 
pass a set capillary length. Protein samples were detected by UV absorbance at 280 nm. 
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5.4 Results and Discussion 
5.4.1 Characterization of the self-interaction behavior of the wildtype 
mAb 
SI-BLI was performed to analyze the formulation dependent self-interaction propensity of 
the wildtype mAb, using a histidine buffered formulation covering the typical pH range of 
mAb formulation 5 and 7. An increase in pH from 5 to 7 led to a higher Rrel and thus, to an 
increase in attractive self-interaction propensity (Figure 1 A). This effect was further 
intensified by addition of the ionic excipients sodium chloride and arginine hydrochloride. 
We further evaluated the effect of buffer concentration (Figure 1 B). At pH 5.0 the SI-BLI 
response clearly increased with higher buffer concentration. This effect was also observed 
at pH 6.0 and pH 7.0 but less pronounced at neutral pH. These results underlined the strong 
pH effect on the self-interaction of the wildtype mAb and may explain the aberrant 
precipitation and poor recovery during downstream processing, where typically buffers are 
applied which contain e.g. sodium chloride and are close to neutral pH.  
Strong attractive self-interaction of mAbs can lead to a disproportionately high increase in 
viscosity at higher protein concentration. As shown in Figure 1 C, the viscosity increased 
extremely, starting at 50 mg/ml protein. At 100 mg/mL wildtype mAb the viscosities 
reached 300 mPa*s at pH 7.0, and 130 mPa*s at pH 5.0, respectively. We therefore decided 
to use formulations at pH 7.0 for in-depth characterization of the mAb self-interaction and 
at pH 5.0 as low self-interaction control condition for HDX-MS experiments. 
 
Figure 1 Self-interaction analysis of the wildtype mAb. A) SI-BLI in 15 mM His HCl at pH 5.0, 6.0 and 7.0 
with different excipients added; B) SI-BLI in dependence of buffer concentration and pH; C) Increase 
in solutions viscosity in 15 mM His-HCl at pH 5.0 and pH 7.0. 
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5.4.2 Paratope mapping of the wildtype mAb by HDX-MS 
HDX-MS was performed to detect the antibody-antigen interaction site comparing the 
deuterium uptake of the antibody-antigen complex to antibody alone by hybrid significance 
testing. For evaluation of significance, we calculated a ∆HX threshold of 0.41 Da (Table 
S1). Regions of the mAb that showed less uptake in the complex state were interpreted as 
antigen binding sites. In total, we analyzed 113 peptides of the heavy chain and 45 peptides 
of the light chain, which reflects a coverage of 85 % and 92 % respectively. In the Fc 
domain, peptides in proximity to the N-glycosylation region were not covered. However, 
antigen binding was expected to be mediated by the CDR regions of the mAb. We identified 
several peptides in the HCDR2 (W47MGGIIPIYGTAYYAQKFQG65) and the HCDR3 
(S95PRSYVTYRRYWFDY102) of the Fab domain as being involved in antigen binding 
(Figure 2). The H/D exchange of the CDRs of the light chain did not depend significantly 
on the presence of antigen, indicating that these segments did not contribute to the antigen 
binding. Thus, the introduction of mutations in only one of the two identified regions could 
weaken target binding but may not abolish it. 
 
Figure 2 Volcano plot of HDX-MS results of the paratope mapping of the wildtype mAb. Data points within 
the area of significance showed decreased uptake in the complex state compared to mAb alone. A 
peptide list and the calculation of ∆HX threshold can be found in the supplemental material in table 
S1. As ∆HX, the difference in uptake between mAb-antigen complex and mAb alone is shown.  
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5.4.3 Identification of self-interaction sites by in silico surface analysis 
We prepared a homology model of the wildtype Fab fragment to perform protein surface 
analysis at pH 7.0. Hydrophobic patches were identified in the HCDR2 and the HCDR3 
(Figure 3). The hydrophobic patch of the HCDR2 consisted of I52, I53, Y54 and Y58. The 
non-hydrophobic residues G55 and T56 were also located within the paratope region, and in 
close proximity to the hydrophobic patch In the HCDR3 the hydrophobicity was 
prominently driven by a surface exposed W100c. In addition to visual analysis of the 
hydrophobicity, aggregation scores were calculated for individual HCDR2 residues39. For 
rational mutagenesis, we introduced residues into the identified regions by in-silico 
mutagenesis to change the extent of hydrophobicity or to insert negative or positive charges 
(Table 1). Additionally, we mutated HCDR1 (G27) based on its spatial proximity to HCDR2 
and HCDR3. 
 
 
Figure 3  Homology model of the wildtype Fab fragment on crystal structure 5D7S (Light Green: Heavy chain, 
Blue: Light chain, Dark green: Surface exposed hydrophobic patches). 
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Table 1   Characterization of mAb variants based on in silico surface analysis: Experimental parameters were 
compared to wildtype (Self-interaction, Target binding: ↓↓ decreased >2SD, ↓ decreased >1SD, ≈ 
comparable, ↑ increased >1SD, ↑↑ increased >2SD; Off-target binding: ↓↓ < 50 %, ↓ < 75 %, ↑ > 
125 %). Absolute values can be found in the supplemental material in table S2. 
mAb variant Region 
Cumulative 
AggScore 
of HCDR2 
Self-
interaction 
Off-
target 
binding 
Target 
binding 
wildtype  43  
I52R 
HCDR2 
12 ↓ 
 
↑ 
I53R 16 ↓↓ ↑ 
Y54R 13 ↓↓ ≈ 
Y58R 30 ↓↓ ≈ 
G55R 34 ↓↓ ↑ ↑ 
G55D 25 ↓↓ 
 
≈ 
T56R 23 ↓ ↑↑ 
T56D 29 ↓↓ ↓↓ ↑ 
I52A I53A Y54A Y58A 7 ↑ ↓↓ ↓↓ 
I52A I53A Y54S Y58S 2 ≈ ↓↓ ↓↓ 
I52V I53V Y54A Y58A 12 ≈ ↓↓ ↓↓ 
I52V I53V Y54S Y58S 5 ↓↓ ↓↓ ↓↓ 
W100cV 
HCDR3 
44 ↑↑ ↓ ↑ 
W100cS 44 ↑ ↓ ≈ 
G27R HCDR1 43 ↓↓ ↑ ↑↑ 
G27R T56D HCDR1/HCDR2 29 ↓ ↓ ↑ 
5.4.4 Characterization of mAb variants engineered based on in silico 
surface analysis 
The mAb variants shown in Table 1 were characterized regarding the change in the 
cumulative Aggscore, self-interaction, target binding and off-target binding.  
For comparison of mutants, the scores of each residue of the patch were added up to a total 
AggScore. The cumulative AggScore was reduced for variants with single mutations in the 
HCDR2 (e.g. I52R, T56D) and further minimized for variants with multiple mutations (e.g. 
I52A I53A Y54S Y58S). Mutations introduced to HCDR3 or flanking to HCDR2 (G27R) did 
not influence the calculated AggScore of HCDR2. 
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All variants containing single point mutations in the HCDR2, which also introduced 
additional negative or positive charges, showed decreased self-interaction propensity. In 
case the hydrophobic patch in HCDR2 was resolved by replacing all positions with either 
Ser or Val, but no Ala, attractive self-interaction was reduced as well. Additionally, the 
introduction of a charged residue flanking HCDR2 (G27R) resulted in improved self-
interaction behavior. Variants of the HCDR3 showed unaffected or slightly increased 
attraction of the mAb molecules. Regarding target binding, single mutations in HCDR2 
influenced the behavior only slightly whereas multiple mutations reduced the apparent 
target binding affinity. This was expected as HCDR2 was shown to mediate target binding. 
Target binding of HCDR3 variants was not changed or slightly improved. Introduction of 
arginine in HCDR1 and HCDR2 improved target binding slightly but increased off-target 
binding. The most prominent decrease in off-target binding was observed for variants 
containing multiple mutations in HCDR2. Thus, this region was involved in target and off-
target binding. In summary, the introduction of charged residues into the hydrophobic patch 
of HCDR2 or in spatial proximity of the patch in HCDR1 of our mAb reduced self-
interaction significantly. A single mutation did not impair target binding behavior. Inserting 
a charged residue in proximity to hydrophobic hotspots, which were identified as target 
binding region, could reflect an approach to reduce the self-interaction propensity while 
maintaining the target binding properties.  
Additionally, we evaluated the combined effect of the most promising single mutations in 
reducing self-interaction propensity, T56D and G27R, by producing and characterizing a 
variant containing both mutations in HCDR1 and HCDR2 (Table 1). Interestingly, the 
effects of the single mutations contributed additively to the properties of the double 
mutation variant. We observed decreased self-interaction propensity, improved target 
binding and decreased off-target binding. As mentioned above, G27 was not located in a 
hydrophobic patch based on results from computational calculations. We hypothesize, that 
the reduction of attractive self-interaction is driven by electrostatic shielding of self-
interaction sites in HCDR2 and flanking to HCDR3. The interplay of CDRs for self-
interaction has also been reported for the mAb MEDI1912 with relevant motifs in HCDR1 
and HCDR2.11 Additionally, shielding of self-interaction sites by more hydrophilic 
moieties like N-glycans was described for CNT060726 with a reintroduced Fab-
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glycosylation shielding the hydrophobic triad, increasing the solubility and maintained high 
affine target binding. 
The calculation of AggScores was used to generate and evaluate variants in silico. The 
scores indicate that the aggregation propensity of the HCDR2 mutants might be reduced 
due to the reduction of overall hydrophobicity of the identified patches. Overall, the 
AggScore was not predictive for self-interaction. However, mutants with a lower AggScore 
showed reduced off-target binding, indicating that these hydrophobic patches contributed 
to non-specificity. Additionally, our results showed that the Fc region was also involved in 
self-interaction. The AggScore calculations do only include properties of the Fab domain. 
This may explain the limited predictive power for lowering self-interaction only by 
inserting mutations into the Fab. 
In summary, rational engineering of hydrophobic patches based on homology modeling 
and protein surface analysis led to mAb variants with reduced attractive self-interaction 
propensity. As shown by the 4-fold mutants, molecular modeling revealed insights into 
structural regions involved in off-target binding. Thus, this approach guided to 
“unspecificity” hot spots of the mAb. Additionally, we observed that mutations flanking 
this hydrophobic patch influenced the self-interaction behavior positively. 
5.4.5 Identification of self-interaction sites by HDX-MS 
HDX-MS experiments followed by Hybrid Significance Testing were performed to 
determine self-interaction sites of the wildtype mAb. At pH 7.0, we analyzed 92 peptides 
of the heavy chain and 51 peptides of the light chain, which corresponds to a total sequence 
coverage of 90 %. At pH 5.0, we identified 80 peptides of the heavy chain and 45 peptides 
of the light chain, resulting in a sequence coverage of 85 %. As shown in Figure 4 A, several 
peptides showed significant differences in deuterium uptake when comparing high and low 
concentration condition. Analyzing the H/D exchange of overlapping peptides and surface 
exposure at pH 7.0, three major hot spots of attractive self-interaction were defined: Hot 
spot 1 was located in spatial proximity to HCDR3 (W103 – L108), hot spot 2 was located in 
the Fc part of the mAb containing the PENNY loop (V379 – N384) and hot spot 3 was located 
in CL of the Fab fragment (S155 – T163). At pH 5.0 no significant differences of H/D 
exchange between high and low protein concentration were observed, confirming the 
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decreased attractive self-interaction at low pH seen in SI-BLI and viscosimetry (Figure 4 
B). We additionally studied the G27R mutant at pH 7.0 by HDX-MS and identified 96 heavy 
chain and 48 light chain peptides, which reflects 90 % sequence coverage. The deuterium 
uptake did not differ significantly between the low and high concentration conditions 
demonstrating decreased attractive self-interaction propensity compared to the wildtype 
mAb (Figure 4 C). 
 
Figure 4   Volcano plots of HDX-MS analysis of A) wildtype mAb at pH 7.0, ∆HX threshold = 0.61 Da; B) 
wildtype mAb at pH 5.0, ∆HX threshold = 0.64 Da; C) G27R variant at pH 7.0, ∆HX threshold = 
0.34 Da. A peptide list and the calculation of ∆HX threshold can be found in the supplemental material 
in table S4. As ∆HX, the difference between the uptake at low protein concentration (0.5 mg/ml) and 
high protein concentration (60 mg/ml) is shown. 
5.4.6 Characterization of mAb variants engineered based on HDX-MS 
Subsequently, we designed mAb variants with mutations in the identified hot spots 
introducing positive (R) or negative charges (D, E) or combinations thereof. The variants 
were analyzed regarding self-interaction, off-target binding and target binding (Table 2). 
Binding to the neonatal Fc receptor was not investigated, because the mutated regions were 
not in spatial proximity to the receptor binding site of our mAb.41, 42 Introduction of arginine 
residues in hot spot 1 resulted in decreased self-interaction propensity (Y102R, Q105R and 
L108R) while target binding remained unaffected or was slightly improved. As already 
shown for the G27R variants, the presence of arginine residues increased off-target binding. 
Introducing aspartate did not affect the self-interaction behavior, improved target binding 
and only marginally impacted off-target binding (Y102D, Q105D and L108D). Introduction of 
more than one aspartate in hot spot 1 led to a decrease in self-interaction combined with 
improved target binding and decreased off-target binding (Q105D-L108D and Y102D-Q105D-
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L108D). In addition, we identified residues R100 and R100a as residues within HCDR3 
contributing to target binding, which confirmed the results of the paratope mapping 
experiment (R100aD, R100aD-Y102D and R100D-R100aD). 
We further analyzed the change in self-interaction by mutations of hot spot 2 located in the 
heavy chain of the Fc fragment. Contrary to hot spot 1, the introduction of one negatively 
charged aspartate residue decreased self-interaction while maintaining or improving target 
binding properties (V379D). Mutations introducing arginine did not show significant 
changes in self-interaction (E380R and E382R). Interestingly, off-target binding was 
increased for all the variants of hot spot 2, indicating that the engineering of the Fc region 
increased unspecific binding processes, presumably mediated via this domain. 
Mutations introduced in the light chain of the mAb (hot spot 3) led to a reduction of self-
interaction in variants containing arginine in position 155 or aspartate in position 157 or 
159 (S155R, N157D and Q159D). As shown for hot spot 1, we saw a cumulative effect of more 
multiple negatively charged residues leading to a strongly reduced self-interaction 
propensity of the 4-fold mutant S155D N157D Q159D T163D, resulting in 74 % of the self-
interaction propensity of the wildtype (Table S3). Unexpectedly, all variants of the light 
chain showed an improved target binding behavior, indicating that not only the CDRs of a 
mAb contribute to target binding. Because this region did not light up in paratope mapping, 
we hypothesize that this segment of the light chain contributes to target binding by 
conformational effects. Similar effects were reported for the constant region of an 
immunoglobulin heavy chain.43 Another hypothesis is based on the introduction of charged 
and polar residues, which could mediate additional interactions with the antigen. 
Additionally, the four fold light chain variant showed decreased off-target binding behavior 
which was not observed by the single mutations. 
In summary, the variants which were engineered based on the HDX-MS results showed 
decreased self-interaction propensity if one positive charge was introduced in the hot spot 
1 or 3. Additionally, self-interaction was reduced for variants in which more than one 
negatively charged residue was introduced in the region flanking the HCDR3. But a 
reduction in self-interaction was not necessarily accompanied by a reduction in off-target 
binding. Thus, HDX-MS results guided towards engineered mutants with reduced self-
interaction, several of which additionally showed improved target binding or reduced off-
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target binding. Contrary to that, changes in the hydrophobic patch identified by homology 
modeling reduced self-interaction by reducing the overall off-target binding behavior of the 
protein. Both approaches guided to mAb variants with decreased self-interaction propensity 
independent of the engineering approach. The lab-extensive approach including HDX-MS 
method development and refinement helped to identify specific self-interaction sites 
outside of the CDRs and thus led to variants with maintained affinity. For rapid 
identification of unspecificity hot spots, homology modeling followed by protein surface 
analysis was a valuable tool which can save cost and effort in the laboratory. But 
engineering may compromise the target binding properties because the paratope is not 
specified in silico. Further, homology modeling includes only the Fab region and cannot 
take Fab-Fc interactions or conformational effects into account. 
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Table 2   Characterization of mAb variants engineered based on HDX-MS analysis: Experimental parameters 
were compared to wildtype: (Self-interaction, Target binding: ↓↓ decreased >2SD, ↓ decreased 
>1SD, ≈ comparable, ↑ increased >1SD, ↑↑ increased >2SD; Off-target binding: ↓↓ < 50 %, ↓ < 
75 %, ≈ comparable, ↑ > 125 %; ↑↑ > 150 %). Absolute values can be found in the supplemental 
material in table S3. 
Hot 
spot 
mAb variant 
Domain 
/ 
Chain 
Self-
interaction 
Off-
target 
binding 
Target 
binding 
1 
Y102D 
Fab/HC 
≈ ↓ ↑↑ 
Q105D ≈ ≈ ↑↑ 
L108D ≈ ≈ ↑↑ 
Q105D L108D ↓↓ ≈ ↑ 
Y102D Q105D L108D ↓ ↓↓ ↑↑ 
Y102R ↓ ↑↑ ↑ 
Q105R ↓↓ ≈ ≈ 
L108R ↓↓ ↑↑ ↑ 
R100aD ↓ ↓↓ ↓ 
R100aD Y102D ≈ ↓↓ ↓↓ 
R100D R100aD ↓ ↓↓ ↓↓ 
2 
V379D 
Fc/HC 
↓↓ ↑ ↑↑ 
E380R ≈ ↑↑ ↑ 
E382R ≈ ↑↑ ≈ 
N384D ↓ ↑ ≈ 
3 
S155D 
Fab/LC 
≈ ↑ ↑↑ 
S155R ↓↓ ↑ ↑↑ 
N157D ↓ ↑↑ ↑↑ 
Q159D ↓ ↑ ↑↑ 
Q159E ≈ ↑ ↑↑ 
T163D ≈ ↑ ↑↑ 
T163R ≈ ↑↑ ↑↑ 
S155D N157D Q159D T163D ↓ ≈ ↑↑ 
 
5.4.7 Engineering of mAb variants based on results of HDX-MS and in 
silico surface analysis 
Because both, the in silico approach and the in vitro HDX-MS approach resulted in mAb 
variants with improved properties regarding self-interaction, off-target binding and 
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apparent target binding affinity, we additionally generated and analyzed variants 
combining input from both methodologies. Based on the low self-interaction propensity, 
we selected the G27R and T56D variants from the in-silico approach and combined them 
with Q105D, L108D and N384D from the HDX-MS approach, where these variants showed 
improved self-interaction behavior. Additionally, we chose N384D to generate a variant with 
mutations in both, Fab and Fc region. The analyzed combinations are shown in Figure 5. 
The pedigree visualizes how these new combined mAb mutants compare to the single 
mutants. All variants containing either G27R or T56D showed a decreased attractive self-
interaction propensity. For Q105D and L108D, a reduction of self-interaction was only 
observed if both mutations were introduced. The triple mutant G27R Q105D L108D showed 
the lowest self-interaction propensity. Additionally, target binding was improved. As 
shown for G27R, introduction of arginine at this position increased off-target binding also 
for the triple mutant. 
Based on the HDX-MS results a Fab-Fc interaction was hypothesized as a plausible self-
interaction mechanism, because both sites were identified within Fab and Fc domain of the 
wildtype mAb. For further evaluation, a mutation in the Fab domain (G27R) was combined 
with a mutation in the Fc domain (N384D). Interestingly, self-interaction was not further 
improved compared to the wildtype mAb and the G27R mutant. 
 
Figure 5  Pedigree of combination mutants containing heavy chain mutations G27R, T56D, Q105D, L108D and 
N384D. * - variants originate from in-silico approach, # - variants originate from HDX-MS approach. 
Self-interaction, target binding and off-target binding are shown in relation to the wildtype properties. 
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5.4.8 The effect of arginine and aspartate residues on mAb self-
interaction 
As shown in Tables 1 and 2, we generated variants containing either arginine or aspartate 
at distinct positions identified by surface analysis or HDX-MS. In total, we evaluated six 
pairs of this combination. Depending on the position, in 4 out of 6 cases the introduction 
of arginine decreased self-interaction more pronounced than the corresponding aspartate 
variant. In particular, this effect was observed for the region flanking HCDR3. Whereas the 
introduction of aspartate did not influence self-interaction at all, arginine drastically 
reduced attractive self-interaction. In two cases (G55 and T56), both mutations showed the 
same extent in reduction of self-interaction indicating that the addition of a charged residue 
itself influenced interaction propensity. As both mutations affected the HCDR2 region of 
the mAb reflecting the hot spot of off-target binding, this effect could be associated with 
the overall decrease in off-target binding. 
5.4.9 The effect of arginine residues on off-target binding 
Within our set of mAb variants, the introduction of arginine residues in HCDR1, HCDR2 
or in spatial proximity to HCDR3 increased off-target binding. Corresponding mutations 
to aspartate residues decreased this propensity. Thus our results confirmed former results 
by Tiller et al., who demonstrated that the enrichment of arginine residues in the CDRs of 
scFv contributed to non-specificity while target binding affinity was improved for variants 
containing arginine in the CDR.44 In particular, the introduction of arginine in HCDR1 
(G27R) led to more affine target binding but impaired off-target binding. However, self-
interaction propensity of this variant was significantly reduced. This finding demonstrates 
that self-interaction propensity is not necessarily connected to non-specificity. The 
increased off-target binding coming with G27R was also observed for variants containing 
this mutation in combination. Whereas off-target binding was not affected by the 
combination of Q105D and L105D, the addition of G27R increased off-target binding 
(Figure 5). Adding the G27R variation to the HCDR2 hydrophobic patch variant (T56D), 
which show substantially reduced off-target binding, did not lead to an increase 
highlighting the impact of this mutation on off-target binding. 
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5.5 Conclusions 
Here, we presented different, complementary approaches to study self-interaction of a mAb 
as input for a rational mutagenesis to reduce attractive self-interaction. We applied 
computational methods such as homology modeling and protein surface analysis of the Fab 
fragment to identify aggregation prone regions. This strategy enabled us to generate 
variants with decreased self-interaction by parallel maintaining target binding properties 
upon a single mutation. Additionally, we identified a hydrophobic patch in the HCDR2 
responsible for the increased off-target binding. As an alternative approach, we determined 
self-interaction sites via HDX-MS by comparing the H/D exchange at high and low protein 
concentration. The introduction of mutations in the identified self-interaction hot spots 
reduced the self-interaction propensity of the variants compared to the wildtype mAb. Only 
for a subset of the generated variants the decrease in self-interaction was accompanied by 
a reduction in off-target binding. Except for variants with modifications in HCDR3, all 
variants showed comparable or improved target binding. 
For our model system, in silico methodologies allowed us to identify residues within and 
close to the CDRs which could be addressed to reduce self-interaction. A hydrophobic 
patch in HCDR2 turned out to be additionally a hot spot for off-target binding. HDX-MS 
gave independent information on self-interaction sites even outside of the CDRs. This input 
helped to generate variants with in most cases reduced self-interaction, but concomitantly 
also affected target and off-target binding. For our mAb the introduction of one additional 
positive charge in form of an arginine in HCDR1 or HCDR2 reduced self-interaction, 
similar to the effect of introducing two negative charges (aspartates) flanking the HCDR3. 
In addition, the introduction of acidic residues also decreased off-target binding. If 
mutagenesis was guided by both, computational and in vitro experiments, we generated 
variants with properties improved in all investigated aspects, i.e. stronger target binding, 
lower attractive self-interaction propensity and reduced off-target binding, compared to the 
wildtype mAb. Thus, both approaches can be successfully applied to guide engineering 
with the aim to reduce self-interaction, and potentially influence additional parameters. In 
silico modeling provided information on CDR structures, exposed hydrophobic patches and 
suitable flanking residues amenable to engineering. Self-interaction sites were more 
specifically identified by HDX-MS experiments. As both approaches gave complementary 
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input for engineering, also combinatorial variants were generated, which mostly behaved 
as expected from the individual results obtained with the parental variants. Thus the most 
effective strategy for similar engineering campaigns should be to apply the combination of 
both approaches. 
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Supplementary data 
Table S1  Peptide list of paratope mapping 
Chain start end Sequence time ΔHX p-value 
Heavy Chain 46 58 EWMGGIIPIYGTA 1 -1.08 0.001 
46 58 EWMGGIIPIYGTA 10 -0.90 0.000 
46 58 EWMGGIIPIYGTA 60 -0.75 0.000 
46 58 EWMGGIIPIYGTA 240 -0.66 0.000 
48 59 MGGIIPIYGTAY 1 -1.08 0.001 
48 59 MGGIIPIYGTAY 10 -0.77 0.003 
48 59 MGGIIPIYGTAY 60 -0.81 0.000 
48 59 MGGIIPIYGTAY 240 -0.92 0.001 
50 59 GIIPIYGTAY 1 -1.09 0.001 
50 59 GIIPIYGTAY 60 -0.52 0.000 
50 59 GIIPIYGTAY 240 -0.53 0.001 
103 111 YVTYRRYWF 1 -0.85 0.001 
103 111 YVTYRRYWF 10 -0.80 0.009 
103 111 YVTYRRYWF 60 -1.18 0.000 
103 111 YVTYRRYWF 240 -1.33 0.000 
103 112 YVTYRRYWFD 1 -0.81 0.001 
103 112 YVTYRRYWFD 10 -0.79 0.009 
103 112 YVTYRRYWFD 60 -1.18 0.000 
103 112 YVTYRRYWFD 240 -1.43 0.000 
103 113 YVTYRRYWFDY 1 -1.11 0.000 
103 113 YVTYRRYWFDY 10 -0.68 0.000 
103 113 YVTYRRYWFDY 60 -1.59 0.000 
103 113 YVTYRRYWFDY 240 -1.70 0.000 
104 113 VTYRRYWFDY 1 -0.80 0.000 
104 113 VTYRRYWFDY 10 -0.71 0.010 
104 113 VTYRRYWFDY 60 -1.35 0.000 
104 113 VTYRRYWFDY 240 -1.64 0.000 
106 113 YRRYWFDY 1 -0.45 0.000 
106 113 YRRYWFDY 60 -1.09 0.000 
106 113 YRRYWFDY 240 -1.35 0.000 
Criteria for significant differences of ΔHX: 
Pooled standard deviation sp = 0.135, standard error of the mean SEM = 0.11, Confidence criteria 
for ΔHX values were calculated by following equation: |Δ𝐻𝑋|>𝑘×𝑆𝐸𝑀 using k = -3.75 according 
to Student’s t-distribution (One-tailed, α = 0.01, df = 4) 
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Table S2  Characterization of mAb variants generated based on in silico surface analysis -  Absolute values 
mAb variant Region 
Self-interaction 
[%] 
Off-
target 
binding 
[%] 
Target binding 
KDapp [nM] 
Average SD Average SD 
Wildtype --- 100.0 13.9 100 7.7 1.0 
I52R 
HCDR2 
83.0 4.0 
 
5.9 0.8 
I53R 70.6 2.0 6.6 0.2 
Y54R 67.6 2.0 7.4 0.4 
Y58R 67.9 3.0 7.3 0.4 
G55R 50.0 2.0 180 6.0 0.2 
G55D 66.0 8.0 
 
6.8 0.6 
T56R 75.4 2.0 5.7 0.4 
T56D 50.4 2.0 25 5.9 0.6 
I52A I53A Y54A Y58A 127.8 3.0 8 9.7 0.5 
I52A I53A Y54S Y58S 110.0 3.0 16 11.1 0.4 
I52V I53V Y54A Y58A 86.2 3.0 18 9.8 0.6 
I52V I53V Y54S Y58S 63.4 3.0 12 9.7 0.6 
W100cV 
HCDR3 
135.5 2.0 67 5.8 0.2 
W100cS 124.8 1.0 67 7.7 0.4 
G27R HCDR1 48.8 2.0 161 5.4 0.7 
G27R T56D HCDR1/HCDR2 85.7 7.4 61 6.3 0.8 
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Table S3   Characterization of mAb variants engineered based on HDX-MS analysis – Absolute values 
Hot 
spot 
mAb variant 
Domain 
/ 
Chain 
Self-interaction 
[%] 
Off-
target 
binding 
[%] 
Target binding 
[nM] 
Average SD Average SD 
--- Wildtype --- 100.0 13.9 100 7.7 1.0 
1 
Y102D 
Fab/HC 
100.0 7.7 64 5.3 0.5 
Q105D 96.0 8.0 120 5.3 0.7 
L108D 88.0 5.0 118 5.3 0.5 
Q105D L108D 58.6 2.3 99 6.0 0.5 
Y102D Q105D L108D 81.4 1.9 38 5.6 0.6 
Y102R 73.2 2.0 180 5.8 0.8 
Q105R 65.7 2.5 119 7.0 0.9 
L108R 69.2 3.7 171 6.6 0.5 
R100aD 76.4 1.2 1 9.6 0.6 
R100aD Y102D 90.7 4.5 1 11.1 0.4 
R100aD R100 77.8 2.3 1 22.1 1.0 
2 
V379D 
Fc/HC 
53.5 0.8 140 4.5 0.9 
E380R 96.1 5.0 176 6.6 0.7 
E382R 90.9 4.4 183 7.2 0.8 
N384D 8.9 0.1 144 7.2 0.7 
3 
S155D 
Fab/LC 
95.2 8.8 144 4.0 0.7 
S155R 71.6 2.8 135 5.5 0.9 
N157D 82.4 1.5 160 4.7 0.8 
Q159D 85.3 3.7 139 4.7 0.6 
Q159E 95.8 1.5 140 4.7 0.6 
T163D 90.9 4.7 144 5.1 0.7 
T163R 93.0 3.9 151 4.7 0.6 
S155D N157D Q159D 
T163D 
74.1 1.8 119 5.4 0.8 
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Table S4. Peptide list of self-interaction sites mapping 
Chain start end Sequence time ΔHX p-value 
Heavy Chain 103 112 YVTYRRYWFD 10 -0.925 0.000 
103 113 YVTYRRYWFDY 10 -0.595 0.000 
104 119 VTYRRYWFDYWGQGTL 2 -0.761 0.001 
104 119 VTYRRYWFDYWGQGTL 10 -0.806 0.000 
106 119 YRRYWFDYWGQGTL 2 -0.589 0.002 
106 119 YRRYWFDYWGQGTL 10 -0.653 0.000 
107 119 RRYWFDYWGQGTL 10 -0.592 0.000 
363 387 EEMTKNQVSLTCLVKGFYPSDIAVE 10 -0.627 0.008 
387 405 EWESNGQPENNYKTTPPVL 2 -0.692 0.000 
388 405 WESNGQPENNYKTTPPVL 2 -0.620 0.001 
Light Chain 150 173 KVDNALQSGNSQESVTEQDSKDST 2 -1.069 0.001 
150 173 KVDNALQSGNSQESVTEQDSKDST 10 -1.101 0.000 
156 173 QSGNSQESVTEQDSKDST 2 -0.560 0.007 
163 179 SVTEQDSKDSTYSLSST 2 -0.576 0.003 
163 179 SVTEQDSKDSTYSLSST 10 -0.580 0.003 
163 180 SVTEQDSKDSTYSLSSTL 2 -0.584 0.000 
163 180 SVTEQDSKDSTYSLSSTL 10 -0.637 0.000 
168 193 DSKDSTYSLSSTLTLSKADYEKHKVY 10 -0.652 0.005 
168 195 DSKDSTYSLSSTLTLSKADYEKHKVYAC 10 -0.782 0.000 
Criteria for significant differences of ΔHX: 
Wildtype mAb at pH 7.0 
Pooled standard deviation sp = 0.183, standard error of the mean SEM = 0.15, Confidence 
criteria for ΔHX values were calculated by following equation: |Δ𝐻𝑋|>𝑘×𝑆𝐸𝑀 using k = -
3.75 according to Student’s t-distribution (One-tailed, α = 0.01, df = 4) 
Wildtype mAb at pH 5.0 
Pooled standard deviation sp = 0.208, standard error of the mean SEM = 0.17, Confidence 
criteria for ΔHX values were calculated by following equation: |Δ𝐻𝑋|>𝑘×𝑆𝐸𝑀 using k = -
3.75 according to Student’s t-distribution (One-tailed, α = 0.01, df = 4) 
G27R variant at pH 7.0 
Pooled standard deviation sp = 0.107, standard error of the mean SEM = 0.09, Confidence 
criteria for ΔHX values were calculated by following equation: |Δ𝐻𝑋|>𝑘×𝑆𝐸𝑀 using k = -
3.75 according to Student’s t-distribution (One-tailed, α = 0.01, df = 4) 
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6.1 Abstract 
Strong attractive self-interaction of monoclonal antibodies (mAbs) poses the risk for 
limited solubility, increased aggregation propensity, and high viscosity at elevated protein 
concentration. We describe the improvement of two strongly self-interacting wildtype 
mAbs which are related, have the same target and show these adverse properties. Based on 
homology modeling and calculation of aggregation scores we designed and generated 26 
variants. Self-interaction as well as target and off-target binding were characterized. 
Hydrophobic patches affected both self-interaction, as well as target binding. The LCDR3 
hosts a self-interaction hot spot whereas a hydrophobic patch in the HCDR3 mediated target 
binding. Variants based on rational mutagenesis within the LCDR3 showed improved self-
interaction behavior at a maintained highly affine target binding. The experimental results 
were compared to the mAbs’ biophysical properties predicted by the algorithm of protein-
sol. Protein-sol was able to distinguish between the model systems but showed limitations 
in its capability to predict the self-interaction behavior of the variants. Thus the approach 
of in silico identification of aggregation hot spots and subsequent generation and 
experimental characterization for mAb variants proved to be most suitable to achieve leads 
with low self-interaction and off-target binding as well as high target affinity during 
candidate selection. 
6.2 Introduction 
Attractive self-interaction processes of mAbs can be key driver for native oligomerization.1 
These oligomers can form clusters which entail a tremendous increase in viscosity2–4, an 
enhanced tendency for aggregation5 as well as downstream processing challenges.6 Each 
domain of a mAb molecule can be involved in the self-interaction processes 3, 7–14 which 
are driven by both, electrostatic and hydrophobic forces.11, 15, 16 Formulation factors such 
as pH and excipients influence the properties of the molecule and consequently impact 
aggregation propensity and solution viscosity.9, 17–23 However, formulation development is 
usually initiated after lead candidate selection. At earlier project stages, during the selection 
process itself, changes within the protein sequence are still possible to address an enhanced 
self-interaction propensity. 
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Mutations can be introduced based on rationales derived from molecular modelling or 
experimental data.8, 16, 24, 25 In silico methodologies have been developed to predict 
biophysical properties based on primary sequence alone, or in combination with structural 
information of homology models. Recently, Hebditch and Warwicker published a machine 
learning approach trained with the biophysical properties of 137 clinical stage or approved 
antibodies.26, 27 This tool, called protein-sol, is available as web application and provides 
predictions based on the primary sequence of the variable fragment. Prediction of 
aggregation prone regions (APRs) is also possible with AggScore which is based on 3D 
homology models.28 The input structure is used to calculate the energetic contribution of 
each residue to surface patches which can be hydrophobic or electrostatic in nature. Sankar 
et al. applied the AggScore algorithm on selected biophysical parameters of the dataset 
published by Jain et al. and observed correlations between hydrophobic interaction 
chromatography, cross interaction chromatography and standup monolayer adsorption 
chromatography with AggScore.27, 28 Mutations based on computational methodologies 
were successfully applied to improve solubility and reduce viscosity at high concentration 
for mAbs. This can be achieved by disruption of a hydrophobic patch and neutralization of 
a negatively charged surface by single mutation16 or by introduction of asparagine and 
positively charged residues such as arginine or lysine without negatively affecting target 
binding.29 
The mAb CNTO607 has been used in various studies as an example for a mAb with low 
solubility and high self-interaction propensity.24, 30, 31 A hydrophobic triad within the 
HCDR3 (F99H100W100a) was shown to mediate aggregation of CNTO607.
25 Engineering of 
the hydrophobic patches increased solubility but diminished target binding, e.g. variants 
including W100aA 
24 and F99A H100AW100aA, also called mAbVI. 
25 The precursor of 
CNTO607, a phage display derived mAb against hIL-13 from the Human Combinatory 
Antibody Library HuCAL GOLD32 is used in the present study and is referred to as mAb1. 
The second mAb, mAb2, targets the same antigen.The two mAbs show a sequence 
similarity of 99.5 % and exhibited precipitation in typical platform formulations like PBS 
and phase separation after storage at 2-8°C during downstream processing. 
Previous studies showed the generation of variants of CNTO607, which include mutations 
within the HCDR3 as the most striking hydrophobic patch of this mAb. By mutagenesis of 
this target binding region, the variants showed impaired antigen affinity. Therefore, in this 
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study we applied homology modelling and computational tools to understand the structure 
of the molecules and identify critical residues as a starting point for engineering. Variants 
of the two mAbs were generated with the aim of improving self-interaction behavior while 
maintaining the high affinity for the target, and the low off-target binding propensity. In 
addition to the hydrophobic patch of the HCDR3, we identified an additional hydrophobic 
patch in the LCDR3 which was not involved in target binding but in self-interaction 
processes. The aggregation propensity calculated based on AggScore corresponded with 
self-interaction determined by SI-BLI. The introduction of either positively or negatively 
charged residues in spatial proximity of the hydrophobic patches reduced self-interaction. 
By using computational techniques, lab and cost extensive techniques to identify self-
interaction hot spots such as hydrogen deuterium exchange mass spectrometry were 
avoided, and distinct sequences for rational mutagenesis were defined faster. Our data 
extend the already published data set for CNTO607 and help to understand self-interaction 
processes for challenging mAbs based on structural analysis. Furthermore, we challenged 
our approach of experimentally generating and characterizing mAb variants by comparing 
our results with physico-chemical properties predicted by the machine learning tool 
protein-sol, which would have been a faster way to find superior variants. 
6.3 Material and Methods 
6.3.1 mAb cloning 
Genestrings of mutated VL and VH were purchased from Thermo Fisher Scientific (MA). 
The DNA fragments were designed with a 21 bp overlap next to restriction enzyme sites. 
After Gibson cloning, the constructs were transformed in chemically competent DH5alpha 
cells. From resulting single colonies, Miniprep Plasmid DNA was prepared and sequenced. 
After consolidation via 50 pg retransformation the final plasmid Maxiprep DNA was used 
for transfection and expression of the constructs. 
6.3.2 mAb production 
The wildtype mAb was expressed in HKB11 stable pool expression system for 6 days. Cell 
culture supernatant was applied to a MabSelect SuRe column of 32 ml column volume 
(CV) (Cytiva, MA) equilibrated with 0.1 M sodium phosphate buffer pH 6.0 (NaPhos pH 
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6). After washing with 5 CV NaPhos pH 6, product was eluted with 0.1 M sodium acetate 
buffer pH 3.0. Protein containing fractions were pooled and adjusted to pH 5 with 2 M 
sodium acetate solution. The concentration was determined by UV absorbance at 280 nm 
(molar extinction coefficient 211580 M-1 cm-1, 146.6 kDa) using Nanodrop 2000 (Thermo 
Fischer Scientific, MA). 
The protein containing pool was subjected to buffer exchange using Sephadex G-25 in PD-
10 desalting columns (Cytiva, MA) to the final formulation buffer (15 mM histidine 
hydrochloride pH 6.0). The concentration was determined by UV absorbance and adjusted 
to 20 mg/mL utilizing Amicon Ultra 15 centrifugal filter units (50 kDa cut-off, Merck 
KGaA, Germany). The final product was sterile filtered using a 50 mL Steriflip (Merck 
KGaA, Germany). 
The protein variants were expressed in HEK293 cells for 6 days after transfection. Cell 
culture supernatants were applied to HiTrap MabSelect SuRe columns (Cytiva, MA) 
installed on an Äkta Xpress system equilibrated with NaPhos pH 6. Three washing steps 
were performed (wash 1: 5 CV NaPhos pH 6, wash 2: 5 CV NaPhos pH 6 + 1.5 M NaCl, 
wash 3: 5 CV NaPhos pH 6). Product was eluted with 0.1 M sodium acetate buffer pH 3 
and protein containing fractions were pooled without pH adjustment. The protein 
containing pools were subjected to buffer exchange using Sephadex G-25 in PD-10 
desalting columns (Cytiva, MA) to the final formulation buffer (15 mM histidine 
hydrochloride pH 6.0). The concentration was determined by UV absorbance at 280 nm 
using an average molar extinction coefficient of 208356 M-1 cm-1 and an average molecular 
weight of 146.6 kDa using Nanodrop 2000 (Thermo Fischer Scientific, MA). The final 
products were sterile filtered using Microsep Advance Centrifugal Devices (PALL, NY) 
and analyzed for monomer content by SEC-MALS. All variants contained a monomer 
portion of > 90 %. 
6.3.3 Self-interaction Bio layer interferometry (SI-BLI) 
SI-BLI was performed as described previously.33 Briefly, anti-hIgG Fc capture biosensors 
were used on an Octet HTX system (Sartorius AG, FortéBio, CA) in a 384 well plate 
format. A baseline was established in PBS (Gibco), followed by capture of the mAb of 
interest at 25 nM in PBS until the BLI signal increased by approximately 1 nm followed 
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by saturation of the sensor with 1 μM human Fc in PBS. Subsequently, a second baseline 
was acquired in the formulation composition, followed by an association step with 2 μM 
mAb in the same formulation. The response at equilibrium normalized to the amount of 
captured mAb (Rrel) was used for further calculations. As control, sensors saturated with 
human Fc without IgG capture were used. 
6.3.4 Homology Modelling and Protein Surface Analysis 
Homology models of the wildtype mAb were generated with BioLuminate (Schrödinger 
Release 2019-4, Schrödinger LLC, NY). Homology modelling of the Fab fragment was 
based on the published crystal structure of CNTO607 (PDB: 3G6D) achieving a composite 
score of 0.99 for mAb1 and 0.97 for mAb2. A restrained minimization using the OPLS3e 
force field was performed. For both mAbs, loops of the LCDR1 to the HCDR2 were 
modelled by automated cluster selection and the HCDR3 by a built-in PRIME module for 
H3 prediction. The AggScore was calculated with the Protein Surface Analysis module. In 
silico mutations were generated with the residue-scanning module followed by backbone 
minimization and calculation of the solvent exposed surface area (SASA). Residue specific 
AggScores within the regions were added up for each model. 
6.3.5 Protein-sol Analysis 
Based on the protein-sol algorithm, regression values of 12 biophysical properties were 
calculated for our data set (https://protein-sol.manchester.ac.uk/abpred).26 The variants 
were ranked regarding self-interaction, off-target binding and apparent temperature of 
unfolding. Afterwards, we ranked the mAbs of our data set based on our own experimental 
SI-BLI, protein panel profiling (3P) and nanoDSF results. Spearman correlation 
coefficients were calculated by PRISM 5 (GraphPad, CA). Raw data for apparent unfolding 
temperature and results from protein panel profiling can be found as supplemental material 
(Table S1). 
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6.3.6 Protein Panel Profiling (3P) 
The method was performed as described before.34 Briefly, off target binding of MAb 
samples was assessed in a plate-based assay, using electrochemiluminescence readout. A 
panel of 32 proteins and controls including highly abundant serum proteins, different 
cytokines and cell-surface receptors, proteins bearing different post-translational 
modifications (phosphorylation, glycosylation), representatives for different pI values 
(ranging from 2.8 to 10.7), and vesicles prepared from HKB11 cells and Baculovirus 
particles35 as well as protein A, anti-human Fc and anti-human Fab antibodies, lysozyme 
and target proteins of the sample MAbs as controls was coated onto two MSD standard 
384-well plates (Meso Scale Discovery, MD) per assay, each row coated with one protein 
or control. Subsequently, the plate was blocked with 3 % (w/v) BSA in PBS. Each mAb 
sample was assessed at 10 nM and 100 nM. For referencing purposes, an anti-lysozyme 
mAb was included known to show negligible non-specific binding. ECL-labeled anti-
human Fab antibody was added for detection, and ECL-signals acquired using a Sector 
Imager S 600 instrument (Meso Scale Discovery, MD). For evaluation, binding signals of 
the mAb of interest were divided by the signal of the anti-lysozyme mAb on the same 
protein, resulting in a binding ratio. The sum of binding ratios on all off target probes (i.e. 
excluding specific antigens and controls) at 10 nM and 100 nM mAb were used as a metric 
for off target binding of the respective mAb. 
6.3.7 Target Binding Analysis by SPR 
Affinities were determined in kinetic experiments using a Biacore 8K+ instrument (Cytiva, 
MA). 0.01 M HEPES pH 7.4 with 0.15 M NaCl, 3 mM EDTA, and 0.05% (v/v) polysorbate 
20 was used as assay buffer. Human IL-13 was produced and purified at MorphoSys and 
contained at 93% monomer by SEC-MALS. A high-capacity, high–affinity capture surface 
was prepared by covalently immobilizing MabSelect SuRe ligand (Cytiva, MA) at high 
density onto all flowcells and channels of a CM5 SPR chip (BR-1005-30; approx. 3700 
RU). With each mAb (approx. 70 RU) captured onto one channel of the sensor, serial 
dilutions of hIL-13 (up to seven concentrations; highest concentration between 100 nM and 
900 nM, depending on the KD of the individual interaction) were analyzed in separate 
cycles for 240 s at 30 µL/min with subsequent 1200 s dissociation phase (multi-cycle 
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kinetics). At the end of each cycle, mAb and remaining bound antigen were completely 
removed from the sensor by two 30 s injections of Glycine / HCl pH 1.5. The sensorgrams 
were fitted to a monovalent binding model with both rate constants (kon, koff) fitted globally 
and bulk RI fixed at 0 RU. Sensorgrams not contributing to the kinetics (insignificant or no 
signal) were excluded from evaluation. All interactions were characterized at least in 
duplicate (n=2 to n=4). 
6.3.8 Nano Differential Scanning Fluorimetry (nanoDSF) 
1 mg/ml mAb samples were filled in standard nanoDSF glass capillaries and measurements 
were performed using a Prometheus NT.48 (NanoTemper Technologies, Germany). 
Intrinsic fluorescence at 330 nm and 350 nm was evaluated during a temperature ramp from 
20 °C to 90 °C at 1 K/min. Transition onset and inflection points were determined from the 
first derivative using the PR.Control software (NanoTemper, Germany). 
6.4 Results 
6.4.1 Identification of self-interaction sites by in silico surface analysis 
We generated homology models of mAb1 and mAb2 using the published crystal structure 
of CNTO607.36 After model refinement, surface analysis was performed to calculate 
AggScores and SASA of residues in the CDRs (Table 1). 
For mAb1, aggregation prone regions were identified in the LCDR3 and the HCDR3 
(Figure 1A and B). The identification of the hydrophobic triad containing phenylalanine, 
histidine and tryptophan (F99HW100a) in the HCDR3 as aggregation hot spot confirmed 
previously published data for CNTO607.24, 25 The SASA of W100a was the highest in this 
patch pointing towards hydrophobic interactions mediated by this residue as the potential 
driver for aggregation. A patch consisting of methionine (M93) and valine (V94) in the 
LCDR3 was identified as second hydrophobic, aggregation prone region with M93 showing 
the highest solvent accessibility. Consequently, we selected M93 in the LCDR3 and the 
hydrophobic triad of the HCDR3 containing W100a for structure guided engineering. 
Additionally, we generated the mAb formerly published as CNTO607 and its variants 
mAbVI and W100aA in order to compare our data set to literature. The variants which 
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include alanine mutations in the HCDR3 were shown to have an improved solubility but 
diminished target binding. 24, 25 
For mAb2, two major aggregation prone regions were identified in the LCDR3 and the 
HCDR3 (Figure 1C and D). In the LCDR3, valine (V94) and tyrosine (Y95) showed the 
highest AggScores and highest surface accessibility. In the HCDR3, the patch 
F99VYLFF100d contributed most to the surface exposed hydrophobicity. In addition to these 
two major hot spots, hydrophobic residues phenylalanine and tyrosine in the LCDR1 
(F31Y32) contributed to an aggregation prone region but the AggScores were lower than in 
LCDR3 and HCDR3. To this end, F99VY100 in the HCDR3 and V94 and Y95 in the LCDR3 
were mutated and additionally, aspartate (D27) in the LCDR1, which is in spatial proximity 
to its hydrophobic residues. As shown by Teplyakov et al., the HCDR1 plays a subordinate 
role in IL-13 binding. Thus, we chose phenylalanine (F27) as the most solvent accessible 
residue of the HCDR1 for further engineering to improve target binding affinity by 
introducing tryptophan as a more hydrophobic amino acid to enhance the interaction with 
IL-13. The generated and characterized mAb variants are shown in Table 2. 
 
Figure 1  Homology models of Fab fragments of mAb1 and mAb2. Grey: Light Chain; Blue: Heavy Chain; Red: 
Aggregation prone residues (high AggScore). A) Homology model and surface analysis of mAb1; B) 
Aggregation hot spot of mAb1 in HCDR3 (F99HW100a) and LCDR3 (M93V94); C) Homology model and 
surface analysis of mAb2; D) Aggregation hot spot of mAb2 in HCDR3 (F99VY100a) and LCDR3 
(V94Y95). 
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Table 1   AggScores and SASA of residues located in hydrophobic patches of mAb1 and mAb2.  
Protein Area Residue SASA [Å2] AggScore 
m
A
b
1
 
L
C
D
R
3
 
W91 50.5 4 
D92 20.5 8 
M93 165.5 9 
V94 91.0 6 
T95 45.6 0 
D95a 8.6 0 
H
C
D
R
3
 
A98 14.0 12 
F99 85.9 17 
H100 58.2 18 
W100a 146.5 7 
D100b 38.8 2 
M100c 0.0 0 
Q100d 7.7 0 
P100e 2.3 0 
D101 11.0 0 
Y102 112.1 0 
m
A
b
2
 
L
C
D
R
1
 
S24 40.7 0 
G25 17.6 0 
D26 116.3 0 
N27 7.9 0 
L28 1.1 0 
G29 56.8 0 
T30 117.7 6 
F31 47.8 8 
Y32 83.8 8 
L
C
D
R
3
 
S90 0.0 0 
F91 0.2 0 
D92 10.2 1 
T93 5.2 5 
V94 87.4 9 
Y95 173.1 10 
H
C
D
R
1
 
G26 45.3 0 
F27 109.8 0 
T28 82.3 0 
F29 7.6 0 
S30 56.6 0 
S31 57.2 0 
Y32 13.3 0 
H
C
D
R
3
 
F97 86.3 4 
G98 12.8 0 
F99 69.0 12 
V100 0.0 0 
Y100a 128.8 18 
L100b 49.1 21 
F100c 105.5 21 
F100d 45.2 17 
D101 3.6 0 
Y102 43.9 4 
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6.4.2 AggScore analysis of variants of mAb1 and mAb2 
AggScores of mAb variants were calculated by surface analysis of homology models 
(Table 3). For mAb1, AggScores were decreased for the LCDR3 variants mAb1-6 (M93A) 
and mAb1-7 (M93R) as well as for the HCDR3 variants W100aA, mAbVI (A99AA100a), 
mAb1-4 (F99HE100a) and mAb1-5 (Y99HH100a).  
LCDR3 mutants of mAb2, V94Y95 to A94A95 (mAb2-5 and mAb2-12) and Y95 to T95 
(mAb2-15) showed a markedly decreased AggScore compared to the wildtype and 
complete removal of hydrophobic residues as embodied by e.g. mAb2-6 (V94Y95 to E94S95) 
reduced the AggScore more than the introduction of a less hydrophobic residue e.g. in 
mAb2-7 (V94Y95 to E94L95). Also the HCDR3 mutation of mAb2 in case of mAb2-1 to 
mAb2-4, mAb2-8 to mAb2-10 and mAb2-15 led to lower AggScore. As observed for 
LCDR3, the complete removal of the hydrophobic residues in the HCDR3 represented by 
mAb2-1 (A99A100A100a) had a more significant impact than a decrease in hydrophobicity by 
introducing less hydrophobic residues as reflected in mAb2-9 (V99A100T100a). 
6.4.3 Conformational properties of mAb1, mAb2 and variants thereof 
To evaluate correlations of the change in AggScores with experimental data, we produced 
all variants of mAb1 and mAb2 and performed nanoDSF for determination of unfolding 
temperatures, protein panel profiling for off-target binding analysis, SI-BLI for the 
determination of self-interaction and SPR to evaluate target binding kinetics and affinity 
(Table S1 and Table 3). The wildtype proteins mAb2 and mAb3 differed in their unfolding 
temperatures by approximately 10 K. The Tm values of the mAb1 and mAb2 variants were 
in a range of ± 5 K and 3 K respectively of the wildtype Tm (see supplemental material 
Table S1). Thus, all variants showed a similar conformational stability as the wildtype 
proteins.  
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Table 2:  Overview of the sequences of mAb1 and mAb2 as well as the generated variants thereof. 
mAb Variant LC 1-4 LCDR1 LC 76-81 LCDR3 HCDR1 HCDR2 HCDR3 Rationale 
mAb1 DIEL SGDNIGGTFVS GTQAE GTWDMVTNN GFTFNSYWIN WVSGIAYNSSNTLYADSVKG GLGAFHWDMQPDY  
CNTO607 SYEL     …DSSN…  Wu et al. (2010)25 
W100aA SYEL     …DSSN… AFHADM Bethea et al. (2012)24 
mAbVI SYEL  RVEAG   …DSSN… …AAAADM… Wu et al. (2010)25 
mAb1-1      …DSSN…  Removal of N-Glyc site 
mAb1-2       …AFVYDM… 
Change of hydrophobicity in 
HCDR3 
mAb1-3      …DSSN… …AFHLDM… 
mAb1-4      …DSSN… …AFHEDM… 
mAb1-5      …DSSN… …AYHHDM… 
mAb1-6    …DAVT…  …DSSN…  Change of hydrophobicity in 
LCDR3 mAb1-7    …DRVT…  …DSSN…  
mAb1-8  …TEVS    …DSSN…  Insertion of a charged residue 
mAb2 DIEL SGDNLGTFYVD GTQAE QSFDTVYPGI GFTFSSYGLS WVSSIVYSGSSTSYADSVGR EKFGFVYLFFDY  
mAb2-1       …GAAALF… 
Change in hydrophobicity in 
HCDR3 
mAb2-2       …GAASLF… 
mAb2-3       …GVESLF… 
mAb2-4       …GFHWLF… 
mAb2-5    …DTAA…    
Change in hydrophobicity in 
LCDR3 
mAb2-6    …DTES…    
mAb2-7    …DTEL…    
mAb2-8    …DTAA…   …GAAALF… 
Combination of HCDR3 and 
LCDR3 variants 
mAb2-9    …DTAA…   …GVATLF… 
mAb2-10    …DTES…   …GVESLF… 
mAb2-11    …DTAA… GWTF…   
Change in hydrophobicity of 
HCDR1 
mAb2-12  SGANL…  …DTAA…    
Change in hydrophobicity in 
LCDR3 and removal of 
potential salt bridge in LCDR1 
mAb2-13 DDEL       
Insertion of a charged residue 
mAb2-14 DDEL SGLDL…      
mAb2-15 DDEL SGLDL…  …DTVT…   …GAAALF… 
Change in hydrophobicity of 
LCDR3 and HCDR3 and 
insertion of charges in LCDR1 
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Table 3:  AggScore and experimental characteristics of mAb1, mAb2 and variants thereof. 
n.b. – no binding observed; HB – heterogeneous binding, best approximation of monovalent model applied; n.d. – not determined 
 AggScore Experimental data 
mAb Variant LCDR1 LCDR3 HCDR1 HCDR2 HCDR3 Rrel 
kon [1/M*s]  
( ±SE ) 
koff [1/s]  
( ±SE ) 
KD [nM] 
( ±SE ) 
Off-target binding 
mAb1 0 28 0 0 57 3.4 ± 0.5 1.08E+6 ( 8.02E+4 ) 1.68E-4 ( 5.61E-5 ) 0.15 ( 0.06 ) 55 
CNTO607 0 41 0 0 57 3.1 ± 0.2 1.34E+6 ( 1.79E+5 ) 8.95E-5 ( 9.23E-6 ) 0.07 ( 0.01 ) 68 
W100aA 0 28 0 0 37 2.7 ± 0.2 1.31E+6 ( 2.22E+5 ) 8.70E-3 ( 1.50E-4 ) 6.9 ( 1.1 ) 59 
mAbVI 0 43 0 0 0 1.8 ± 0.1 n.b. 70 
mAb1-1 0 28 0 0 57 3.9 ± 0.2 1.27E+6 ( 1.11E+5 ) 1.11E-4 ( 2.01E-5 ) 0.09 ( 0.02 ) 54 
mAb1-2 0 28 0 0 47 3.8 ± 0.2 1.10E+6 ( 1.11E+4 ) 3.85E-3 ( 2.73E-4 ) 3.5 ( 0.2 ) 59 
mAb1-3 0 29 0 0 55 3.1 ± 0.1 4.74E+6 ( 9.92E+5 ) 4.98E-3 ( 5.26E-4 ) 1.1 ( 0.1 ) 64 
mAb1-4 0 28 0 0 29 4.0 ± 0.1 5.46E+6 ( 7.76E+5 ) 3.43E-3 ( 1.56E-4 ) 0.65 ( 0.05 ) 55 
mAb1-5 0 28 0 0 28 2.3 ± 0.1 2.28E+6 ( 3.79E+5 ) 8.65E-3 ( 3.86E-4 ) 3.9 ( 0.5 ) 67 
mAb1-6 0 0 0 0 60 3.2 ± 0.1 1.54E+6 ( 9.57E+4 ) 1.39E-4 ( 4.57E-6 ) 0.09 ( 0.01 ) 57 
mAb1-7 0 0 0 0 60 2.3 ± 0.2 1.08E+6 ( 9.23E+4 ) 1.16E-4 ( 1.63E-5 ) 0.11 ( 0.02 ) 60 
mAb1-8 0 26 0 0 56 4.0 ± 0.1 1.71E+6 ( 1.73E+5 ) 6.43E-2 ( 9.13E-3 ) 37.2 ( 1.8 ) HB 56 
mAb2 51 65 0 29 175 3.0 ± 0.6 3.54E+4 ( 3.47E+3 ) 1.05E-4 ( 8.84E-6 ) 3.0 ( 0.3 ) 102 
mAb2-1 59 82 0 28 113 1.6 ± 0.1 n.b. 53 
mAb2-2 59 82 0 28 103 1.7 ± 0.1 n.b. 53 
mAb2-3 45 84 0 28 118 2.4 ± 0.2 n.b. 52 
mAb2-4 52 78 0 29 221 1.5 ± 0.1 9.59E+3 ( 1.62E+3 ) 8.96E-3 ( 7.55E-4 ) 978 ( 110 ) 57 
mAb2-5 64 1 0 28 181 1.5 ± 0.1 3.69E+4 ( 5.90E+3 ) 5.18E-4 ( 9.33E-6 ) 14.5 ( 2.5 ) 67 
mAb2-6 62 1 0 21 169 2.2 ± 0.1 3.75E+4 ( 5.50E+3 ) 5.04E-4 ( 1.18E-5 ) 14.0 ( 2.7 ) 55 
mAb2-7 65 10 0 26 169 1.6 ± 0.1 3.23E+4 ( 2.75E+3 ) 9.91E-4 ( 7.14E-5 ) 31.0 ( 2.7 ) 59 
mAb2-8 66 1 0 28 113 1.6 ± 0.1 n.b. 57 
mAb2-9 68 1 0 28 131 1.6 ± 0.2 n.b. 52 
mAb2-10 48 1 0 23 112 2.5 ± 0.1 n.b. 56 
mAb2-11 64 1 0 28 181 1.6 ± 0.1 2.64E+4 ( 7.63E+3 ) 4.59E-4 ( 2.32E-5 ) 13.5 ( 2.0 ) 61 
mAb2-12 57 1 0 28 181 0.9 ± 0.1 2.54E+4 ( 3.23E+3 ) 5.14E-4 ( 6.15E-5 ) 21.0 ( 5.5 ) 59 
mAb2-13 45 54 0 28 180 1.4 ± 0.1 2.09E+4 ( 2.01E+3 ) 2.58E-4 ( 1.01E-4 ) 11.8 ( 3.6 ) n.d. 
mAb2-14 49 54 0 28 180 1.8 ± 0.2 3.33E+4 ( 8.62E+3 ) 2.80E-4 ( 1.04E-4 ) 8.5 ( 2.7 ) 67 
mAb2-15 60 7 0 28 111 2.1 ± 0.3 n.b. 52 
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6.4.4 Evaluation of off-target binding by protein panel profiling (3P) 
We determined the proteins propensity to interact with a variety of proteins which differ in 
size, charge and origin.34 The sum of ratios of all variants were determined in a range of 52 
to 102 (Table S1), which is well below the value of >5000 for the positive control. Thus, 
all variants were regarded as non-critical in terms of off-target binding. 
6.4.5 Influence of the HCDR3 hydrophobic patch on self-interaction and 
target binding affinity of mAb1 
In order to enable a comparison with previous publications on the behavior of CNTO607, 
we generated the mAb variants mAbVI and W100aA which had shown an increased 
solubility in these studies.24, 25 Variant W100aA was shown to bind the target molecule with 
a 10-fold lower affinity.24 Target binding of variant mAbVI, which contains a triple alanine 
mutant in the HCDR3 (F99A H100A W100aA) was further reduced compared to CNTO607 
and W100aA.
25 We analyzed self-interaction by SI-BLI and observed a lower self-interaction 
propensity for both variants of CNTO607 which correlated with published solubility data.  
We tried to maintain target binding by exchanging the hydrophobic residues phenylalanine 
and tryptophan by tyrosine, leucine, and histidine (mAb1-3, mAb1-5). Additionally, we 
added glutamic acid as negatively charged residue (mAb1-4). We observed slightly 
decreased target binding for all variants. The reduction in hydrophobicity of this patch led 
to less attractive self-interaction for mAb1-3 and mAb1-5. Because self-interaction 
propensity of mAb2 was less pronounced compared to mAb1, we generated variant mAb1-
2 containing the hydrophobic triad F99VY100a of mAb2 in the mAb1 backbone HCDR3. 
Self-interaction was not decreased for these variant but we observed a target affinity 
comparable to mAb2. Thus, we hypothesize that the HCDR3 is involved in target binding 
of both mAb1 and mAb2.  
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6.4.6 Influence of the LCDR1 and the LCDR3 hydrophobic patch on self-
interaction and target binding affinity of mAb1 
The LCDR1 showed a slightly hydrophobic surface element comprising phenylalanine 
(F31) and valine. We generated a mutant containing glutamic acid instead of phenylalanine 
to switch from a hydrophobic to a negatively charged surface (mAb1-8). This variant 
showed no significant changes in self-interaction behavior but a drastically decreased target 
binding. To evaluate the impact of the LCDR3 hydrophobic patch, we introduced alanine 
and arginine at position 93 instead of methionine (mAb1-6. mAb1-7). Both variants showed 
comparable target affinity, indicating that M93 was not involved in target binding. Self-
interaction was only slightly influenced for the alanine variant but decreased by the 
introduction of arginine. Based on these findings, a change in the hydrophobic patch in the 
LCDR3 reduces self-interaction of the mAb at maintained high target affinity. 
6.4.7 Influence of the HCDR3 hydrophobic patch on self-interaction and 
target binding affinity of mAb2 
mAb1 and mAb2 show a sequence similarity of 99.5 % but differ in their CDR 
composition. For mAb2, two major hydrophobic patches were determined in silico. Our 
targeted mutagenesis comprised the exchange of residues F99VY100a in the HCDR3 to less 
hydrophobic amino acid such as alanine (mAb2-1, mAb2-2) or valine (mAb2-3). To 
maintain the polar hydroxyl group of Y100a, serine containing mutants were generated 
(mAb2-2, mAb2-3). In addition, we introduced the hydrophobic triad of mAb1 in the mAb2 
HCDR3 (mAb2-4). 
With stronger depletion of the HCDR3 hydrophobicity the self-interaction propensity was 
significantly reduced for mAb2-1 and mAb2-2 whereas a less pronounced decrease of 
hydrophobicity (mAb2-3) led to little reduction of self-interaction (Table 3). All these 
variants with a reduced HCDR3 hydrophobicity lost affinity to the target molecule 
(exemplarily shown for mAb2-2 in Figure 2). Target binding of mAb2 appears to be 
mediated by the HCDR3, which indicates a comparable target binding mechanism to 
mAb1. Variant mAb2-4 contained the hydrophobic triad of mAb1 and CNTO607 and 
showed less self-interaction compared to the wildtype but reduced target binding affinity. 
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Based on AggScore calculation a higher self-interaction propensity could be expected. 
However, the lower target affinity of mAb2-4 may be due to conformational changes in the 
hydrophobic surface region which are not covered by AggScore calculations. 
 
Figure 2  SPR sensorgram overlays and applied monovalent fits of the interaction of human IL-13 with mAb2 
(A), the HDCR3 variant mAb2-2 (B), and the LCDR3 variant mAb2-5 (C). SPR sensorgram overlays 
of all mAbs are depicted in figure S1 and S2 in the supplementary data. 
6.4.8 Influence of the LCDR3 hydrophobic patch on self-interaction and 
target binding affinity of mAb2 
The variants mAb2-5, mAb2-6 and mAb2-7 were generated to illuminate the influence of 
the second hydrophobic patch identified for mAb2 in the LCDR3 on self-interaction 
propensity. The variants contained either alanine residues (A94A95, mAb2-5), charged and 
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polar residues glutamic acid and serine (E94S95, mAb2-6) or charged and hydrophobic 
residues glutamic acid and leucine (E94L95, mAb2-7) instead of the surface exposed 
hydrophobic residues V94Y95. All variants showed a decreased self-interaction propensity 
(Table 3). Target binding was reduced, especially for mAb2-7 (Figure 2C), but the effect 
was less drastic compared to mutations in the HCDR3. For further understanding, we 
generated a mAb2 variant that contained a double alanine mutation in the LCDR3 and a 
mutation to increase the HCDR1 hydrophobicity (F27W V94A Y95A, mAb2-11). Compared 
to the variant mAb2-5, which only contains the double alanine mutation, self-interaction 
and target binding affinity were not further influenced by the introduction of the tryptophan 
residue (Table 3), indicating that the phenylalanine F27 as the most surface exposed 
hydrophobic residue of the HCDR1 was neither directly involved in self-interaction nor in 
target binding processes. Because changes in both, HCDR3 and LCDR3 influenced self-
interaction propensity, we generated variants engineered in both hydrophobic patches 
(mAb2-8, mAb2-9 and mAb2-10). Self-interaction was not further reduced compared to 
single patch mutations, but all variants lost target binding affinity, which confirmed the 
involvement of the HCDR3 in hIL-13 binding. 
Next, we engineered variants with modified hydrogen acceptor and modified potential for 
electrostatic interactions (mAb2-12 to mAb2-15). In mAb2-12, an aspartate to alanine 
mutation (D27A) was introduced in addition to the LCDR3 mutations V94A Y95A. Self-
interaction was further reduced compared to mAb2-5, indicating that electrostatics are 
involved in self-interaction. Variants mAb2-13 to mAb2-15 contained a modified N-
terminal sequence of the light chain. We determined a spatial proximity of this area to the 
hydrophobic patch in the LCDR3 in silico and hypothesized that the introduction of a 
negative charge may influence self-interaction. As shown for mAb2-13, self-interaction 
was drastically decreased compared to wildtype mAb2 and target affinity was slightly 
reduced. Adding further mutations did not decrease self-interaction, but affected hIL-13 
binding, which was lost for mAb2-15. 
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6.4.9 Can machine learning approaches predict results of our 
engineering data set? 
Protein-sol is a machine learning approach to predict the biophysical properties of 
antibodies based on the sequence of their variable fragments.26, 27 Using tools for predicting 
the effect of distinct mutations can save costs and time compared to experimental 
mutagenesis. Thus, to challenge our approach, we compared our experimental results of the 
mAb variants generated based on homology modeling and AggScore evaluation with 
predictions of protein-sol. We focused on most similar methods and parameters with the 
highest impact in context of our engineering approach: i) self-interaction, the main focus 
of this engineering campaign, was experimentally determined by SI-BLI which is very 
similar to CSI included in protein-sol; additionally, we included AC-SINS (AC in protein-
sol) in our analysis, ii) off-target binding experimentally evaluated by protein panel 
profiling (3P) was compared with CIC integrated in protein-sol. A major handicap of 
protein-sol is that it cannot predict target binding which was important aspect of the mAb 
optimization. Although we did not observe major effects of the mutations on Tm in our 
dataset by nanoDSF, we included comparison with Tm from DSF as included in protein-sol 
as indicator for conformational stability.  
With regard to self-interaction, the correlation graph for CSI indicated a clustering of the 
two model systems (Figure 3A). We determined correlation coefficients cluster wise and 
found significant correlation for mAb2. In particular, the low measured self-interaction 
propensity of mAb2-12, where the LCDR3 hydrophobicity was depleted by a double 
alanine mutation, was predicted by protein-sol (Figure 3A). For mAb1, no significant 
correlation between the protein-sol prediction and the experimental results was obtained 
(Table 4). For the whole data set, we found a significant correlation between the predictions 
based on AC and the experimental results (Table 4). A low self-interaction propensity of 
mAb2-12 was also predicted based on AC (Figure 3B). The algorithm indicated clustering, 
predicting higher self-interaction propensity for the mAb1 variants compared to the mAb2 
variants, which is opposite to the predicted self-interaction based on CSI. Therefore, cluster 
wise correlation analysis was performed, but no significant correlation was obtained. 
Surprisingly, engineering of the mAbs did not influence the off-target binding as shown 
experimentally in the 3P assay. A similar outcome was predicted by protein-sol considering 
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CIC. Therefore, only a weak correlation could be found between experiment and prediction 
applying the whole data set (Table 4). 
Finally, we looked for correlation between the Tm values measured and predicted as 
indicator for conformational stability. Using the whole data set, we found significant 
correlation indicating that the algorithm was able to predict the higher Tm
app of mAb2 and 
variants thereof. Clustering was observed for the two mAbs (Figure 3C and Table 4), but 
no significant correlations were given within the individual mAb clusters. Although the 
experimentally determined Tm
app values differed by 5 K for the mAb1 and 3 K for the mAb2 
variants, the in silico approach was not able to predict the effect of the mutations. A detailed 
overview of the correlation matrices can be found in the supplemental material Table S2, 
S3 and S4. 
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Figure 3 Correlation plots of CSI (A) and AC-SINS (B) and Rrel obtained by SI-BLI; DSF and Tmapp obtained 
by nanoDSF (C). Circles indicate clustering of data prior to cluster wise correlation analyses. Open 
symbols reflect values of the wildtype proteins mAb1 and mAb2. 
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Table 4 Correlation matrix of experimental results and selected values from protein-sol. The complete 
correlation matrix can be found in the supplemental material Table S2 and S3. 
 
SI-BLI 
Spearmans ρ (p-value) 
3P 
Spearmans ρ (p-value) 
nanoDSF 
Spearmans ρ (p-value) 
 
Total 
(n=28) 
mAb1 
(n=12) 
mAb2 
(n=16) 
Total 
(n=28) 
mAb1 
(n=12) 
mAb2 
(n=16) 
Total 
(n=28) 
mAb1 
(n=12) 
mAb2 
(n=16) 
CSI 
-0.48 
(<0.05) 
0.40 
(0.20) 
0.61 
(<0.05) 
 
 
AC-
SINS 
0.69 
(<0.01) 
0.24 
(0.44) 
0.40 
(0.12) 
CIC 
 
0.41 
(<0.05) 
0.39 
(0.21) 
0.41 
(0.12 
DSF  
0.70 
(<0.01) 
0.06 
(0.86) 
0.10 
(0.71) 
 
6.5 Discussion 
6.5.1 The role of the HCDR3 in target binding and self-interaction 
In our study, we focused on improving self-interaction while maintaining or as well 
improving other properties of our initial mAbs which are critical for developability and 
functionality: the Tm
app was included as an indicator for conformational integrity and 
stability, the 3P assay as a measure for off-target binding, SI-BLI for the determination of 
self-interaction, and ultimately affinity for the target molecule analyzed by SPR as a central 
factor for mAb functionality. Several algorithms are published to predict at least one part 
of developability such as spatial aggregation propensity and net charge37 or hydrophobicity 
analyzed by HIC.38 We used AggScore to identify regions with high aggregation propensity 
that trigger self-interaction.28 
The HCDR3 of both wildtype proteins contain a hydrophobic region. By introducing more 
hydrophilic residues into these patches (e.g. triple alanine in mAbVI and mAb2-1), target 
binding was diminished. Thus, we identified the HCDR3 as paratope of both wildtype 
proteins. The target binding processes of mAb1 and mAb2 were comparable and showed 
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similarities to the published data for CNTO607.36Although self-interaction was decreased 
for many of the HCDR3 variants, a reduction in target binding affinity is not acceptable as 
trade off. Therefore, we focused on the second hydrophobic patch identified in the LCDR3.  
6.5.2 The role of the LCDR3 in target binding and self-interaction 
For mAb1 we focused on M93 as the most surface exposed residue of the patch. Mutations 
to alanine and arginine reduced the AggScore and the self-interaction propensity, especially 
for the arginine variant (mAb1-7) but did not affect binding to hIL-13. Despite slight 
differences in the primary sequence, mAb2 showed a similar hydrophobic patch in the 
LCDR3. Variants of mAb2 with LCDR3 mutations (mAb2-5 and mAb2-6) showed target 
affinities similar to the wildtype protein. However, self-interaction propensity was 
significantly reduced for these variants. To our knowledge, these are the first mAbs shown 
to undergo self-interaction mediated by the LCDR3. In previous studies, Fab-Fc interaction 
via the HCDR3, the LCDR2 and the Fc domain as well as Fab-Fab interaction between the 
HCDR2 and the LCDR2 were demonstrated.7, 39 For Infliximab, a chimeric IgG1 from 
hybridoma, interacting regions outside of the CDRs were identified by X-ray 
crystallography.12, 40 Furthermore, Fc-Fc-interactions were identified for a humanized 
IgG1.14 mAbs derived from phage display, such as our model systems, show an overall 
increased prevalence of aliphatic residues which might have contributed to the generation 
of the hydrophobic LCDR3.41 Our results show that rational mutagenesis of the CDRs of 
our model mAbs improved the physico-chemical behavior while maintaining a high affinity 
for the target hIL-13. Thus, CDRs can be addressed in engineering to resolve certain 
unwanted properties such as enhanced self-interaction, but knowledge of the paratope is a 
prerequisite for this approach. 
Additionally, we introduced a shielding negatively charged aspartate at the N terminus of 
the light chain of mAb2 (mAb2-13) due to the spatial proximity to the hydrophobic patch 
in the LCDR3 and since positively charged residues are correlated to non-specific 
binding.30 Compared to the wildtype, this variant showed a decreased self-interaction 
behavior and maintained high affinity to hIL-13. Thus, not directly mutating hydrophobic 
sites but changing the charge distribution in their vicinity appears another attractive 
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approach, especially in the context of the high conformational flexibility of the N terminal 
region. 
For CNTO607, the reintroduction of the N-linked carbohydrate moiety in the HCDR2 
increased the solubility, most probably due to shielding of the hydrophobic triad by the N-
glycan.25 Comparing mAb1 which contains the N-glycosylation consensus sequence and 
variant mAb1-1 containing N53D mutation shows that removal of the consensus sequence 
only slightly increases the self-interaction and that the carbohydrate attachment may simply 
increase solubility because of its hydrophilic nature.42  
The conformational properties and stability was not influenced by the introduced 
mutations. With Tm
app values of 59 °C for mAb1 and 72 °C for mAb2, both mAbs can be 
regarded as conformationally stable. However, minor structural changes in secondary or 
tertiary structure of the mAbs cannot be resolved by nanoDSF experiments. Whereas self-
interaction was significantly reduced for many variants, their off-target binding and 
unspecificity resp. were low compared to a non-specific positive control, and similar to the 
wildtype mAbs. 
In summary, the CDRs of the model mAbs were shown to mediate both, target binding 
(HCDR3) and self-interaction processes (LCDR3). Engineering approaches of the LCDR3 
led to variants with improved self-interaction behavior without negatively impacting target-
binding. Additionally, negatively charged residues in the N-terminal region of the light 
chain decreased self-interaction, which reflects a new attractive approach to influence the 
physico-chemical behavior of a mAb. All variants showed comparable Tm
app and off-target 
binding behavior. 
6.5.3 The use of in silico tools to predict the outcome of mutagenesis 
Applying protein-sol, a machine learning approach to predict biophysical parameters of 
mAbs, followed by targeted mutagenesis of the predicted best variants has the potential to 
be a more efficient approach compared to lab and cost extensive engineering approaches. 
To challenge our combination of homology modeling, AggScore analysis and experimental 
engineering, we applied protein-sol to predict the properties of our mAb variants in terms 
of self-interaction, off-target binding and Tm and compared these predictions with the 
experimental data. 
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For self-interaction of mAb2, we found significant correlation of CSI and SI-BLI. Both 
methods highlighted mAb2-12 (D27AV94AY95A) as the mAb with the lowest self-
interaction propensity compared to other mAb2 variants. For this distinct variant, the 
prediction and the work extensive engineering approach led to similar results. 
We did not observe correlations for mAb1. This may be due to the fact that SI-BLI was 
performed in 15 mM histidine hydrochloride pH 6.0 as formulation buffer, whereas the CSI 
data, which were used to train the algorithm, were acquired in PBS. Self-interaction 
strongly depends on formulation composition and pH-value.15, 19, 22, 43–46 In addition, mAb1 
contains unusual carbohydrate moieties and therefore its self-interaction behavior may 
differ from that of the mAbs used to train the machine learning tool. 
Both the CIC predictions as well as the experimental 3P results indicated no remarkable 
effect of the mutations on off-target binding. This resulted in a weak correlation, but overall 
the protein-sol prediction was in agreement with the experimental results. Regarding the 
conformational stability, protein-sol predicted a higher Tm for mAb2, which was confirmed 
by our experimental data, but within the two groups, the mAb1 variants and the mAb2 
variants, the algorithm could not predict the effects seen in the measurements. 
In summary, for our data set, in silico predictions of protein-sol were not suitable to guide 
rational engineering by predicting residue specific effects to reduce self-interaction. Target 
binding affinity is an essential factor which is however not included in protein-sol. 
Applying homology modeling, AggScore evaluation to guide targeted mutagenesis, 
generating these mutants and analyzing self-interaction, target binding and off-target 
binding the mutagenesis was well directed and led to in-depth understanding of the 
contributions of the different CDRs, and effects of the individual mutations. The affinity 
measurements highlight which mutated regions are involved in the target binding process, 
in our case the HCDR3. Using the in silico approach based on protein-sol to design the 
variants, where target binding is not addressed, would have allowed to come up with mAb 
variants with reduced self-interaction propensity. But the scientist would be in the dark 
what the effect of the mutations on target binding would be and still needs to generate the 
variants and analyze their target affinity. 
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6.6 Conclusions 
This study illustrates the application of structure guided engineering to reduce self-
interaction of therapeutic mAbs. After homology modeling of wildtype proteins, the 
algorithm AggScore was used to identify aggregation prone surface patches. These were 
subsequently modified by targeted mutagenesis. In total, 26 variants of 2 wildtype proteins 
were generated and characterized. All variants showed comparable apparent Tm as indicator 
for conformational integrity, and unchanged off-target binding behavior. The results 
demonstrate the impact of mutations in hydrophobic patches on mAb self-interaction and 
target binding properties. For our model systems, HCDR3 mutations led to a decrease in 
self-interaction propensity but diminished target binding. Mutations in the LCDR3 resulted 
in reduced self-interaction but did not affect antigen affinity. In particular, a variant of 
mAb1 containing arginine in the LCDR3 showed improved self-interaction behavior. 
Comparable findings were shown for a double alanine variants of the LCDR3 of mAb2. 
Based on our observations, self-interaction of mAb1 and mAb2 are mediated by the 
LCDR3. In addition, introduction of a negatively charged residue at the N terminus of the 
light chain minimized self-interaction propensity indicating that a charge shielding of 
surface exposed hydrophobicity of the CDRs is a possibility to improve the developability 
of a mAb without compromising antigen affinity. Further, we used protein-sol as a machine 
learning approach to predict the effect of the mutations on the self-interaction, off-target 
binding and melting temperature for the variants. Protein-sol does not include the 
prediction of target affinity. The algorithm could be useful to come up with protein 
sequences which show reduced self-interaction, but its applicability for directing targeted 
engineering is limited. 
Ultimately, deeper understanding of the self-interaction process as well as of the target 
binding is a prerequisite for successful engineering of therapeutic mAbs to improve their 
physico-chemical behavior while maintaining the antigen affinity. Homology modeling and 
identification of hydrophobic surface exposed region followed by generation and analysis 
of designed variants is well suited to resolve effects and ultimately find mAb variants with 
improved properties. 
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Supplementary data 
 
 
Figure S1 SPR sensorgram overlays and applied monovalent fits of the interaction of human IL-13 with mAb1 
and variants thereof 
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Figure S2 SPR sensorgram overlays and applied monovalent fits of the interaction of human IL-13 with mAb2 
and variants thereof 
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Table S1  Additional characterization of mAb2, mAb3 and variants thereof 
 
 
 
 
 
   
mAb Variant Tm
app [°C] Sum of off-target binding 
mAb1 58.9 55 
CNTO607 63.7 69 
W100aA 61.0 59 
mAbVI 65.4 70 
mAb1-1 61.3 54 
mAb1-2 59.3 59 
mAb1-3 59.6 64 
mAb1-4 60.9 55 
mAb1-5 63.3 67 
mAb1-6 63.6 57 
mAb1-7 64.0 60 
mAb1-8 62.5 56 
mAb2 72.2 54 
mAb2-1 71.7 53 
mAb2-2 71.7 53 
mAb2-3 71.0 52 
mAb2-4 74.1 57 
mAb2-5 73.2 67 
mAb2-6 72.7 55 
mAb2-7 72.6 59 
mAb2-8 72.9 57 
mAb2-9 72.3 52 
mAb2-10 71.9 56 
mAb2-11 69.5 61 
mAb2-12 73.4 59 
mAb2-13 70.5 n.d. 
mAb2-14 70.2 67 
mAb2-15 70.1 52 
Positive control (3P)  5041 ± 1565 
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Table S2  Spearman correlation matrix. The whole data set (n=28) was used for correlation analysis. 
  
n=28                               
Spearman ρ HIC SMAC SGAC CIC CSI AC HEK PSR ELISA BVP DSF SI-BLI Tm 3P HEK 
HIC 1.000 0.968 0.832 -0.145 0.602 -0.760 0.565 -0.932 -0.194 -0.841 0.837 -0.775 0.794 0.107 -0.527 
SMAC 0.968 1.000 0.746 -0.031 0.444 -0.733 0.475 -0.919 -0.291 -0.791 0.774 -0.779 0.732 0.192 -0.456 
SGAC 0.832 0.746 1.000 -0.176 0.565 -0.749 0.467 -0.796 -0.117 -0.776 0.848 -0.649 0.770 0.018 -0.430 
CIC -0.145 -0.031 -0.176 1.000 -0.626 0.430 -0.681 0.259 -0.430 0.248 -0.320 0.237 -0.405 0.418 -0.082 
CSI 0.602 0.444 0.565 -0.626 1.000 -0.427 0.631 -0.533 0.438 -0.539 0.666 -0.476 0.637 -0.295 -0.238 
AC -0.760 -0.733 -0.749 0.430 -0.427 1.000 -0.729 0.880 0.303 0.881 -0.633 0.686 -0.794 0.179 0.199 
HEK 0.565 0.475 0.467 -0.681 0.631 -0.729 1.000 -0.627 0.099 -0.678 0.529 -0.499 0.659 -0.422 -0.093 
PSR -0.932 -0.919 -0.796 0.259 -0.533 0.880 -0.627 1.000 0.285 0.913 -0.793 0.830 -0.864 -0.040 0.432 
ELISA -0.194 -0.291 -0.117 -0.430 0.438 0.303 0.099 0.285 1.000 0.413 0.051 0.212 -0.129 -0.298 0.273 
BVP -0.841 -0.791 -0.776 0.248 -0.539 0.881 -0.678 0.913 0.413 1.000 -0.660 0.758 -0.855 0.117 0.376 
DSF 0.837 0.774 0.848 -0.320 0.666 -0.633 0.529 -0.793 0.051 -0.660 1.000 -0.717 0.696 0.046 -0.415 
AS 0.827 0.699 0.783 -0.545 0.868 -0.781 0.788 -0.830 0.108 -0.842 0.781 -0.705 0.827 -0.269 -0.334 
SI-BLI -0.775 -0.779 -0.649 0.237 -0.476 0.686 -0.499 0.830 0.212 0.758 -0.717 1.000 -0.778 -0.067 0.427 
Tm 0.794 0.732 0.770 -0.405 0.637 -0.794 0.659 -0.864 -0.129 -0.855 0.696 -0.778 1.000 -0.042 -0.304 
3P 0.107 0.192 0.018 0.418 -0.295 0.179 -0.422 -0.040 -0.298 0.117 0.046 -0.067 -0.042 1.000 -0.279 
HEK -0.527 -0.456 -0.430 -0.082 -0.238 0.199 -0.093 0.432 0.273 0.376 -0.415 0.427 -0.304 -0.279 1.000 
  
               
p-value HIC SMAC SGAC CIC CSI AC HEK PSR ELISA BVP DSF SI-BLI Tm 3P HEK 
HIC 0.000 0.000 0.000 0.460 0.001 0.000 0.002 0.000 0.322 0.000 0.000 0.000 0.000 0.596 0.006 
SMAC 0.000 0.000 0.000 0.875 0.018 0.000 0.011 0.000 0.133 0.000 0.000 0.000 0.000 0.336 0.019 
SGAC 0.000 0.000 0.000 0.370 0.002 0.000 0.012 0.000 0.554 0.000 0.000 0.000 0.000 0.930 0.028 
CIC 0.460 0.875 0.370 0.000 0.000 0.022 0.000 0.184 0.022 0.204 0.097 0.225 0.032 0.030 0.691 
CSI 0.001 0.018 0.002 0.000 0.000 0.023 0.000 0.004 0.020 0.003 0.000 0.010 0.000 0.136 0.242 
AC 0.000 0.000 0.000 0.022 0.023 0.000 0.000 0.000 0.117 0.000 0.000 0.000 0.000 0.370 0.330 
HEK 0.002 0.011 0.012 0.000 0.000 0.000 0.000 0.000 0.618 0.000 0.004 0.007 0.000 0.028 0.651 
PSR 0.000 0.000 0.000 0.184 0.004 0.000 0.000 0.000 0.141 0.000 0.000 0.000 0.000 0.842 0.027 
ELISA 0.322 0.133 0.554 0.022 0.020 0.117 0.618 0.141 0.000 0.029 0.797 0.278 0.514 0.131 0.177 
BVP 0.000 0.000 0.000 0.204 0.003 0.000 0.000 0.000 0.029 0.000 0.000 0.000 0.000 0.562 0.058 
DSF 0.000 0.000 0.000 0.097 0.000 0.000 0.004 0.000 0.797 0.000 0.000 0.000 0.000 0.819 0.035 
AS 0.000 0.000 0.000 0.003 0.000 0.000 0.000 0.000 0.585 0.000 0.000 0.000 0.000 0.176 0.095 
SI-BLI 0.000 0.000 0.000 0.225 0.010 0.000 0.007 0.000 0.278 0.000 0.000 0.000 0.000 0.742 0.030 
Tm 0.000 0.000 0.000 0.032 0.000 0.000 0.000 0.000 0.514 0.000 0.000 0.000 0.000 0.837 0.131 
3P 0.596 0.336 0.930 0.030 0.136 0.370 0.028 0.842 0.131 0.562 0.819 0.742 0.837 0.000 0.176 
HEK 0.006 0.019 0.028 0.691 0.242 0.330 0.651 0.027 0.177 0.058 0.035 0.030 0.131 0.176 0.000 
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Table S3  Spearman correlation matrix. Cluster wise correlation analysis (mAb1. n=12) 
mAb1 (n=12)                
Spearman ρ HIC SMAC SGAC CIC CSI AC HEK PSR ELISA BVP DSF SI-BLI Tm 3P HEK 
HIC 1.000 0.979 0.130 0.676 -0.780 -0.361 -0.515 -0.646 -0.742 -0.623 0.105 -0.340 0.088 0.497 -0.210 
SMAC 0.979 1.000 0.165 0.613 -0.780 -0.452 -0.522 -0.646 -0.732 -0.587 0.147 -0.389 0.025 0.581 -0.155 
SGAC 0.130 0.165 1.000 0.112 -0.338 -0.399 -0.455 -0.186 -0.172 -0.423 0.406 -0.308 -0.070 0.203 -0.273 
CIC 0.676 0.613 0.112 1.000 -0.517 0.070 -0.706 -0.369 -0.525 -0.536 -0.343 -0.133 0.357 0.392 0.064 
CSI -0.780 -0.780 -0.338 -0.517 1.000 0.739 0.502 0.892 0.879 0.884 -0.160 0.397 0.022 -0.375 0.206 
AC -0.361 -0.452 -0.399 0.070 0.739 1.000 0.140 0.642 0.543 0.558 -0.238 0.245 0.469 -0.154 0.118 
HEK -0.515 -0.522 -0.455 -0.706 0.502 0.140 1.000 0.523 0.634 0.657 0.147 0.503 -0.483 -0.531 0.318 
PSR -0.646 -0.646 -0.186 -0.369 0.892 0.642 0.523 1.000 0.948 0.900 -0.183 0.574 -0.290 -0.484 0.368 
ELISA -0.742 -0.732 -0.172 -0.525 0.879 0.543 0.634 0.948 1.000 0.927 0.007 0.480 -0.305 -0.476 0.501 
BVP -0.623 -0.587 -0.423 -0.536 0.884 0.558 0.657 0.900 0.927 1.000 -0.021 0.401 -0.274 -0.341 0.516 
DSF 0.105 0.147 0.406 -0.343 -0.160 -0.238 0.147 -0.183 0.007 -0.021 1.000 -0.594 0.056 0.385 0.136 
AS -0.481 -0.481 0.480 -0.393 0.318 -0.044 0.393 0.493 0.481 0.222 0.044 0.480 -0.480 -0.480 -0.100 
SI-BLI -0.340 -0.389 -0.308 -0.133 0.397 0.245 0.503 0.574 0.480 0.401 -0.594 1.000 -0.538 -0.783 -0.018 
Tm 0.088 0.025 -0.070 0.357 0.022 0.469 -0.483 -0.290 -0.305 -0.274 0.056 -0.538 1.000 0.531 -0.245 
3P 0.497 0.581 0.203 0.392 -0.375 -0.154 -0.531 -0.484 -0.476 -0.341 0.385 -0.783 0.531 1.000 0.055 
HEK -0.210 -0.155 -0.273 0.064 0.206 0.118 0.318 0.368 0.501 0.516 0.136 -0.018 -0.245 0.055 1.000 
  
               
p-value HIC SMAC SGAC CIC CSI AC HEK PSR ELISA BVP DSF SI-BLI Tm 3P HEK 
HIC 0.000 0.000 0.688 0.016 0.003 0.249 0.087 0.023 0.006 0.031 0.745 0.280 0.787 0.100 0.536 
SMAC 0.000 0.000 0.609 0.034 0.003 0.140 0.082 0.023 0.007 0.045 0.648 0.212 0.940 0.047 0.649 
SGAC 0.688 0.609 0.000 0.729 0.282 0.199 0.138 0.562 0.594 0.171 0.191 0.331 0.829 0.527 0.417 
CIC 0.016 0.034 0.729 0.000 0.085 0.829 0.010 0.237 0.079 0.072 0.276 0.681 0.255 0.208 0.853 
CSI 0.003 0.003 0.282 0.085 0.000 0.006 0.096 0.000 0.000 0.000 0.619 0.202 0.946 0.230 0.543 
AC 0.249 0.140 0.199 0.829 0.006 0.000 0.665 0.024 0.068 0.059 0.457 0.443 0.124 0.633 0.729 
HEK 0.087 0.082 0.138 0.010 0.096 0.665 0.000 0.081 0.027 0.020 0.649 0.095 0.112 0.075 0.340 
PSR 0.023 0.023 0.562 0.237 0.000 0.024 0.081 0.000 0.000 0.000 0.569 0.051 0.360 0.111 0.265 
ELISA 0.006 0.007 0.594 0.079 0.000 0.068 0.027 0.000 0.000 0.000 0.983 0.114 0.336 0.117 0.116 
BVP 0.031 0.045 0.171 0.072 0.000 0.059 0.020 0.000 0.000 0.000 0.948 0.196 0.390 0.278 0.104 
DSF 0.745 0.648 0.191 0.276 0.619 0.457 0.649 0.569 0.983 0.948 0.000 0.042 0.863 0.217 0.689 
AS 0.113 0.113 0.114 0.206 0.313 0.893 0.206 0.104 0.113 0.488 0.893 0.114 0.114 0.114 0.770 
SI-BLI 0.280 0.212 0.331 0.681 0.202 0.443 0.095 0.051 0.114 0.196 0.042 0.000 0.071 0.003 0.958 
Tm 0.787 0.940 0.829 0.255 0.946 0.124 0.112 0.360 0.336 0.390 0.863 0.071 0.000 0.075 0.467 
3P 0.100 0.047 0.527 0.208 0.230 0.633 0.075 0.111 0.117 0.278 0.217 0.003 0.075 0.000 0.873 
HEK 0.536 0.649 0.417 0.853 0.543 0.729 0.340 0.265 0.116 0.104 0.689 0.958 0.467 0.873 0.000 
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Table S4  Spearman correlation matrix. Cluster wise correlation analysis (mAb2. n=16) 
mAb2 (n=16)                
Spearman ρ HIC SMAC SGAC CIC CSI AC HEK PSR ELISA BVP DSF SI-BLI Tm 3P HEK 
HIC 1.000 0.971 0.674 0.753 -0.442 -0.318 -0.212 -0.781 -0.419 -0.295 0.673 -0.453 0.276 0.689 -0.749 
SMAC 0.971 1.000 0.629 0.738 -0.593 -0.444 -0.126 -0.879 -0.444 -0.358 0.612 -0.529 0.315 0.611 -0.627 
SGAC 0.674 0.629 1.000 0.515 -0.322 -0.468 -0.124 -0.541 -0.374 -0.344 0.681 -0.144 0.559 0.314 -0.254 
CIC 0.753 0.738 0.515 1.000 -0.364 -0.059 -0.338 -0.494 -0.484 -0.406 0.409 -0.379 -0.015 0.425 -0.552 
CSI -0.442 -0.593 -0.322 -0.364 1.000 0.876 -0.508 0.805 0.700 0.776 0.056 0.609 -0.584 -0.129 0.093 
AC -0.318 -0.444 -0.468 -0.059 0.876 1.000 -0.582 0.733 0.593 0.681 -0.010 0.403 -0.776 -0.021 -0.129 
HEK -0.212 -0.126 -0.124 -0.338 -0.508 -0.582 1.000 -0.129 -0.368 -0.452 -0.389 -0.059 0.338 -0.364 0.308 
PSR -0.781 -0.879 -0.541 -0.494 0.805 0.733 -0.129 1.000 0.572 0.562 -0.433 0.584 -0.558 -0.497 0.355 
ELISA -0.419 -0.444 -0.374 -0.484 0.700 0.593 -0.368 0.572 1.000 0.956 0.060 0.319 -0.456 -0.250 0.186 
BVP -0.295 -0.358 -0.344 -0.406 0.776 0.681 -0.452 0.562 0.956 1.000 0.130 0.370 -0.515 -0.106 0.083 
DSF 0.673 0.612 0.681 0.409 0.056 -0.010 -0.389 -0.433 0.060 0.130 1.000 -0.159 0.096 0.418 -0.457 
AS 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 
SI-BLI -0.453 -0.529 -0.144 -0.379 0.609 0.403 -0.059 0.584 0.319 0.370 -0.159 1.000 -0.326 -0.200 0.534 
Tm 0.276 0.315 0.559 -0.015 -0.584 -0.776 0.338 -0.558 -0.456 -0.515 0.096 -0.326 1.000 0.221 0.054 
3P 0.689 0.611 0.314 0.425 -0.129 -0.021 -0.364 -0.497 -0.250 -0.106 0.418 -0.200 0.221 1.000 -0.827 
HEK -0.749 -0.627 -0.254 -0.552 0.093 -0.129 0.308 0.355 0.186 0.083 -0.457 0.534 0.054 -0.827 1.000 
  
               
p-value HIC SMAC SGAC CIC CSI AC HEK PSR ELISA BVP DSF SI-BLI Tm 3P HEK 
HIC 0.000 0.000 0.004 0.001 0.087 0.231 0.431 0.000 0.106 0.267 0.004 0.078 0.300 0.004 0.001 
SMAC 0.000 0.000 0.009 0.001 0.016 0.085 0.641 0.000 0.085 0.174 0.012 0.035 0.235 0.016 0.012 
SGAC 0.004 0.009 0.000 0.041 0.224 0.068 0.649 0.030 0.154 0.192 0.004 0.594 0.024 0.254 0.360 
CIC 0.001 0.001 0.041 0.000 0.165 0.829 0.200 0.052 0.057 0.119 0.116 0.147 0.957 0.114 0.033 
CSI 0.087 0.016 0.224 0.165 0.000 0.000 0.044 0.000 0.003 0.000 0.837 0.012 0.018 0.646 0.742 
AC 0.231 0.085 0.068 0.829 0.000 0.000 0.018 0.001 0.015 0.004 0.970 0.122 0.000 0.940 0.647 
HEK 0.431 0.641 0.649 0.200 0.044 0.018 0.000 0.633 0.161 0.079 0.137 0.829 0.200 0.182 0.264 
PSR 0.000 0.000 0.030 0.052 0.000 0.001 0.633 0.000 0.021 0.023 0.094 0.017 0.025 0.059 0.194 
ELISA 0.106 0.085 0.154 0.057 0.003 0.015 0.161 0.021 0.000 0.000 0.824 0.228 0.076 0.368 0.506 
BVP 0.267 0.174 0.192 0.119 0.000 0.004 0.079 0.023 0.000 0.000 0.630 0.159 0.041 0.708 0.767 
DSF 0.004 0.012 0.004 0.116 0.837 0.970 0.137 0.094 0.824 0.630 0.000 0.557 0.725 0.121 0.086 
AS 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SI-BLI 0.078 0.035 0.594 0.147 0.012 0.122 0.829 0.017 0.228 0.159 0.557 0.000 0.217 0.475 0.040 
Tm 0.300 0.235 0.024 0.957 0.018 0.000 0.200 0.025 0.076 0.041 0.725 0.217 0.000 0.428 0.849 
3P 0.004 0.016 0.254 0.114 0.646 0.940 0.182 0.059 0.368 0.708 0.121 0.475 0.428 0.000 0.000 
HEK 0.001 0.012 0.360 0.033 0.742 0.647 0.264 0.194 0.506 0.767 0.086 0.040 0.849 0.000 0.000 
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Chapter 7 Summary 
Self-Interaction processes of monoclonal antibodies are linked to the intrinsic molecular 
properties as well as to the composition of the formulation environment. Considering both 
factors in combination helps the pharmaceutical scientist to understand the process itself 
and to master challenges arising from high self-interaction propensity during development, 
manufacturing and application. 
Chapter 1 describes the current understanding of self-interaction of mAbs as a process as 
well as of the impact of protein structure and formulation. Additionally, the link between 
self-interaction and developability of mAbs is introduced. In silico approaches are 
highlighted which can be used to predict physicochemical parameters based on the proteins 
primary structure. 
At first, a high-throughput assay was established for determining formulation dependent 
self-interaction based on bio layer interferometry (SI-BLI) (Chapter 2). Due to minimal 
sample consumption and high throughput, this assay enables the differentiation between 
several candidate molecules in parallel to a formulation screening. The assay results 
correlated significantly with kD from DLS, a parameter well-established for describing 
protein self-interaction. Whereas kD analysis requires the preparation and measurement of 
various protein solutions at different protein concentration, SI-BLI requires only one low 
protein concentration (2 µM) and a single measurement of an association reaction. The 
assay can be implemented in early stages of developability assessments, when the available 
protein amount is low and the number of potential candidates is high. Subsequently the 
assay was utilized in a developability assessment for ranking potential lead candidates in 
combination with a preformulation screening (Chapter 3). With SI-BLI, specific ion 
effects on mAb self-interaction were detected and further studied. In particular, bivalent 
magnesium ions reduce the self-interaction propensity of the mAbs more than sodium ions. 
Moreover, the SI-BLI results correlated with viscosimetry data. This case study confirmed 
the applicability of the assay for both, high-throughput studies and in-depth self-interaction 
characterization.  
Chapter 4 describes a multi-method approach to analyze the self-interaction process of 
Infliximab as a model system. Within this study, established analytical techniques were 
combined with emerging techniques for analyzing self-interaction. Thus, AUC, 
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Viscosimetry, DLS, SAXS and SI-BLI were used for analysis on a protein resolution level. 
Additionally, SI-BLI and AUC investigations were carried out to describe the self-
interaction process on a fragment level after digestion. Finally, HDX-MS, which comprises 
online pepsin digestion, led to high resolution results of peptides involved in the interaction. 
Based on the results, we hypothesize a self-interaction mechanism for Infliximab that 
differs from a previously published mechanism of Infliximab identified by X-ray 
crystallography of the Fab fragment. This study underlines the importance of a multi 
method approach on different level to analyze and understand mAb self-interaction in a 
pharmaceutically relevant formulation. 
Ultimately we demonstrated the application of different approaches to modify mAb 
interactions by targeted mutation based on an understanding of loci involved in self-
interaction (Chapter 5 and 6).  
At first, the self-interaction of a model mAb was analyzed, which showed striking 
disadvantageous properties, namely precipitation at low protein concentration during 
downstream processes, high retention time in size exclusion chromatography and strong 
off-target binding (Chapter 5). The high self-interaction propensity of the mAb at neutral 
pH and high ionic strength was associated with an increase in viscosity at elevated protein 
concentration. Distinct self-interaction sites in the HCDR2, the HCDR3 as well as in the 
constant regions of the Fab and Fc domains were identified by HDX-MS and in silico. 
Based on the finding, 39 mAb variants were generated and characterized. The introduction 
of a positively charged residue in spatial proximity to the self-interaction hot spot in the 
HCDR2, which was identified in silico reduced self-interaction but increased off-target 
binding. Placing more than one negative charged residues in spatial proximity to the 
hydrophobic patch of the HCDR3, which was identified by HDX-MS, decreased self-
interaction and off-target binding while maintaining high affine target binding.  
Secondly, two closely related mAbs directed against the same target were mutated in 
hydrophobic hot spots in the HCDR3 and the LCDR3 regions identified based on homology 
modeling and calculation of the residue specific aggregation propensity (Chapter 6). In 
total, 26 variants were generated and characterized. The HCDR3 was identified as essential 
paratope locus, whereas the introduction of alanine and aspartate residues in the LCDR3 
decreased hydrophobicity and the self-interaction propensity without affecting target 
binding. The data set was used to challenge a recently published machine learning approach 
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(protein-sol). This approach was able to differentiate between the different parental mAbs 
and their variants, but the capability of rankings within the mAb family was limited.  
In summary, the combination of in silico and experimental techniques is key to understand 
and improve the self-interaction propensity of mAbs. Fast screening methods with minimal 
material consumption and effort should be used in early stages of discovery, whereas 
methods with lower throughput but high resolution should be applied later. By that, the risk 
of failure due to developability issues arising from pronounced self-interaction propensity 
of a mAb can be reduced by engineering and formulation development. In particular, the 
use of HDX-MS to identify loci involved in self-interaction sites enables rational 
engineering without the loss of functionality.  
 
